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Abstract
In eukaryotic cells, degradation of many mRNAs is initiated by removal of the polyA tail
followed by decapping and 5’ to 3’ exonucleolytic decay. Although the order of these events is
well established, we are still lacking a mechanistic understanding of how deadenylation and
decapping are linked. During my PhD studies, I characterized the human Pat1b protein and
showed that Pat1b links the deadenylation complex to the decapping complex both physically
and functionally. Pat1b is tightly associated with the Ccr4-NOT deadenylation complex as
well as with the Dcp1-Dcp2 decapping complex. In addition, Pat1b overexpression increases
the association of the deadenylation complex with the decapping complex. When tethered to a
reporter mRNA, Pat1b induces its rapid degradation. Pat1b-mediated mRNA decay depends
on the deadenylase Caf1a and the decapping enzyme Dcp2, indicating that these interactions
are functionally important. Moreover, Pat1b interacts with the decapping enhancers Rck,
the Lsm1-7 complex, Hedls and Edc3. Pat1b interacts with the deadenylation complex, the
decapping complex and the decapping enhancers via at least three different domains, suggesting
that Pat1b serves as a scaffolding protein. Together, the data provide evidence that human
Pat1b is a central component of the mRNA decay machinery that connects deadenylation
with decapping.
Most enzymes of the 5’ to 3’ mRNA decay pathway, including the Ccr4-NOT deadenylation
complex, are localized in cytoplasmic foci called processing (P) bodies. I could show that
Pat1b is required for P-body formation, and that it strongly induces P-body numbers when
overexpressed. My data indicate that an amino-terminal region within Pat1b serves as an
aggregation-prone domain that nucleates P-bodies, whereas an acidic domain controls the
size of P-bodies. Although Rck specifically interacts with the acidic domain of Pat1b, point
mutations in Pat1b that abolish the Rck interaction did not alter P-body size. On the other
hand, I also identified point mutations in Rck that abolish Pat1b binding, and found that
Rck needs to associate with PAt1b in order to promote P-body formation. Furthermore, I
purified Pat1b and identified additional binding partners via mass spectrometry. Further
characterization of these interactions may help to understand how Pat1b controls P-body
numbers and size, and what additional functions Pat1b may have.

Zusammenfassung
In eukaryontischen Zellen wird der Abbau vieler mRNAs mit der Entfernung des Poly(A)-
Schwanzes initiiert, wonach das Cap am 5’ Ende entfernt und anschließend der Rest der
mRNA exonukleolytisch vom 5’ zum 3’ Ende abgebaut wird. Obwohl die Reihenfolge dieser
Vorgänge sehr gut beschrieben ist, ist bis heute wenig bekannt über den genauen Mechanis-
mus, der Deadenylierung und Decapping verbindet. In meiner Doktorarbeit habe ich das
humane Protein Pat1b charakterisiert und konnte zeigen, dass Pat1b den Deadenylierungs-
Komplex sowohl physisch als auch funktionell mit dem Decapping-Komplex verbindet. Pat1b
ist zum einen stark mit dem Ccr4-NOT Deadenylierungs-Komplex, zum anderen aber auch
mit dem Dcp1-Dcp2 Decapping-Komplex assoziiert. Zudem verstärkt die Überexpression von
Pat1b die Kopplung von Deadenylierung und Decapping. Wenn Pat1b experimentell an eine
Reporter-mRNA gebunden wird, induziert Pat1b den schnellen Abbau dieser mRNA. Pat1b-
vermittelter mRNA-Abbau hängt von der Deadenylase Caf1a und dem Decapping-Enzym
Dcp2 ab, was darauf hindeutet, dass die Interaktion mit Pat1b wichtig ist für deren Funktion.
Darüber hinaus interagiert Pat1b mit den Proteinen Rck, Hedls, Edc3 und dem Lsm1-7
Komplex, die den Decapping-Prozess fördern. Pat1b assoziiert mit dem Deadenylierungs-
Komplex, dem Decapping-Komplex und weiteren Decapping-Proteinen über mindestens drei
verschiedene Domänen, was darauf schließen lässt, dass Pat1b eine Plattform-Funktion ein-
nimmt. Zusammenfassend liefern diese Daten Hinweise darauf, dass das humane Pat1b eine
zentrale Komponente der mRNA-Abbaumaschinerie ist, die Deadenylierung mit Decapping
verbindet.
Die meisten Enzyme, die beim mRNA Abbau vom 3’ zum 5’ Ende beteiligt sind, einschließlich
dem Ccr4-NOT-Komplex, lokalisieren in zytoplasmatischen Foci, sogenannten Processing
Bodies (PBs). Ich konnte zeigen, dass Pat1b notwendig ist für die Bildung von PBs, und dass
die Überexpression von Pat1b die Anzahl an PBs erhöht. Meine Daten weisen darauf hin, dass
ein Bereich am aminoterminalen Ende von Pat1b als aggregationsfördernde Domäne dient, die
zur PB-Bildung führt, während ein anderer Bereich, der mehrere saure Aminosäuren enthält,
die Größe der PBs kontrolliert. Obwohl Rck spezifisch mit eben dieser sauren Domäne in
Pat1b interagiert, zeigten Punktmutationen in Pat1b, die die Interaktion mit Rck verhindern,
keinen Einfluss auf die PB-Größe. Andererseits konnte ich durch Punktmutationen in Rck,
die die Assoziation mit Pat1b verhindern, zeigen, dass die Interaktion von Rck und Pat1b
für die Bildung von PBs benötigt wird. Außerdem konnte ich Pat1b aufreinigen und mittels
Massenspektrometrie weitere Proteine identifizieren, die mit Pat1b interagieren. Die genauere
Charakterisierung dieser Interaktionen könnte helfen zu verstehen, wie Pat1b die Anzahl und
Größe von PBs kontrolliert, und welche zusätzlichen Funktionen Pat1b noch haben könnte.
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1 Introduction
All of the cells in an organism have the same sequence of DNA, yet not all cells express
every gene encoded in the genome. Moreover, expression of most genes needs to be tightly
regulated according to internal and external stimuli. During evolution, several mechanisms
have emerged to control gene expression and to thereby achieve such tight regulation. One
efficient way to enable rapid responses to internal and environmental stimuli is to control
the levels of messenger RNAs (mRNAs) in the cell and the availability of mRNAs to the
translation machinery. Keeping the amount of mRNA stable but blocking its translation gives
the cell capacity to generate high amounts of the corresponding protein in a short time once the
translation inhibition is removed. Moreover, restricting the levels of the mRNA by degradation
ensures the suppression of protein levels which can be deleterious to the cell unless tightly
controlled. To achieve this, the 5’ and 3’ untranslated regions (UTRs) of certain mRNAs
contain regulatory sequences that control the translation or degradation rate of that particular
mRNA without affecting other transcripts in the cell. These sequences mostly function as
binding sites for regulatory proteins or small regulatory RNAs such as microRNAs (miRNAs)
and small interfering RNAs (siRNAs).
Despite different regulatory elements which give the initial trigger to degrade mRNAs, there
are common steps in different mRNA decay pathways (see Figure 1.1). The first and rate
limiting step in cytoplasmic mRNA degradation is the removal of the poly adenosine (polyA)
tail [1, 2]. Exceptions to this rule are histone mRNAs, which do not have polyA tails,
and mRNA decay initiated by endonucleolytic cleavage. After removal of the polyA tail,
degradation of the mRNA body can follow two routes. First, it can be degraded from its 3’
end by a large ribonuclease complex termed the exosome. At the end of this decay pathway 5’
cap will be metabolized by the scavenger decapping enzyme DcpS. Alternatively, following
deadenylation, mRNA can be decapped by the Dcp1/Dcp2 decapping complex and degraded
in the 5’ to 3’ direction by the exoribonuclease Xrn1 [1, 3, 4, 5].
Deadenylation is reversible and highly utilized to control translation during vertebrate oocyte
maturation and early embryogenesis. On the other hand, decapping and exoribonucleolytic
degradation either by the exosome or Xrn1 are irreversible steps that lead to degradation of
mRNA body. The 5’ to 3’ decay pathway was suggested to be the primary mode of degradation
both for stable and labile mRNAs in Saccharomyces cerevisiae [1, 4, 2]. Nevertheless, the 3’
to 5’ decay and decapping followed by the 5’ to 3’ decay appear to be redundant pathways in
mRNA decay. Knocking out components of either pathway in S. cerevisiae has only minimal
effects on the transcriptome [5].
Since my PhD project aimed to characterize human Pat1, whose yeast homolog was suggested
to be a decapping enhancer, in the following I will focus on deadenylation and the 5’ to 3’
mRNA decay pathway.
5
1 Introduction
Figure 1.1. Deadenylation-dependent mRNA degradation and the enzymes and protein complexes
involved. Figure was reproduced from Garneau et al. [5].
1.1 mRNA-Specific Decay Pathways
Before going into details of deadenylation and decapping I will briefly introduce two mRNA-
specific degradation pathways.
1.1.1 ARE-Mediated mRNA Decay (AMD)
AU-rich elements (AREs) are 3’ UTR sequence elements characteristic for many short-lived
mRNAs. ARE-containing mRNAs usually code for the proteins with functions in cell growth
(e.g. c-fos, c-myc), inflammatory response (e.g. cytokines IL2, TNFa, GM-CSF) and response
to other environmental stimuli (e.g. iNOS, VEGF, cyclin b1). Precise temporal regulation
required for the translation of these mRNAs is achieved by the help of AREs [6, 7, 8].
AREs are 50-150 nt long, uridine-rich sequences with frequently overlapping AUUUA
pentamers. Presence of this pentamer alone is not enough to trigger rapid mRNA degradation,
but 2-4 copies of the UUAUUUA(U/A)(U/A) nanomer are required for efficient enhancement of
mRNA turnover. The stability of these ARE-containing mRNAs is regulated by ARE-binding
proteins (ARE-BPs). Most of the ARE-BPs that have been identified so far activate mRNA
decay (e.g. tristetraprolin (TTP), BRF1/2, KSRP), some stabilize the bound mRNA (e.g.
HuR, HuD), and some regulate translation (e.g. TIA-1). The functions of these proteins were
reported to be cell type-specific [6, 9, 10, 8]. This implies the interplay of other regulatory
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factors in ARE-mediated mRNA decay (AMD) and/or dependency of the mRNA half life
on the relative abundance of the stabilizing and destabilizing proteins. AMD was shown
to be deadenylation-dependent [9, 8]. Moreover, TTP and KSRP are known to stimulate
the deadenylases polyA-specific ribonuclease (PARN) and Caf1. TTP interacts with the
mammalian Ccr4-NOT deadenylase complex, the decapping enzyme Dcp2, and the decapping
enhancer Edc3 [7, 9, 11]. Both 3’ to 5’ degradation by the exosome and 5’ to 3’ degradation by
Xrn1 participate in AMD [12]. In support of both pathways, KSRP, BRF1 and TTP interact
with the exosome, and the latter two also with the decapping complex [6]. Several ARE-BPs
including TTP and TIA-1 are associated with stress granules and Processing bodies (P-bodies),
where 5’ to 3’ degradation enzymes are concentrated. Nevertheless, depletion of Xrn1 and
Lsm1 (an activator of decapping) blocks AMD to a larger extend than depletion of exosome
components [12]. Furthermore, tethering of TTP or BRF1 to an mRNA that does not contain
an ARE is sufficient to target the mRNA to P-bodies and to induce decay [13, 9]. These
observations suggest that the 5’ to 3’ degradation pathway is predominant in AMD.
1.1.2 RNAi-Mediated mRNA Decay
siRNAs and miRNAs are 20-25 nucleotide (nt) long RNA species that originate from extra-
cellular sources or from the genomic transcripts. After being processed in the nucleus by
the protein factors Drosha and Pasha, miRNA precursors are exported to the cytoplasm
where they share the same pathway with siRNAs for maturation. The evolutionary conserved,
cytoplasmic protein Dicer (DCR) cleaves the siRNA and miRNA precursors into 20-25 nt long
double stranded RNA (dsRNA) species. While being loaded onto the RNA-induced silencing
complex (RISC), which contains Angonaute (Ago) and GW182 proteins, the dsRNAs are
unwound. One strand serves to target mRNAs in RISC whereas the other strand is usually
degraded [14, 15, 16]. Recently, miRNAs that do not follow these canonical maturation steps
have also been identified [17]. In the RISC, the function of the miRNA or the siRNA is deter-
mined partially by the identity of the interacting Ago proteins. Ago proteins are a large family
of conserved proteins. The N-terminal PAZ domain mediates sequence-independent single
stranded RNA (ssRNA)-binding. The C-terminal PIWI domain has an ribonuclease (RNase)-H
like fold which mediates endonucleolytic cleavage of the siRNA and its target mRNA. In fact,
the PIWI domain is not catalytically active in all Ago proteins; only Ago2 associated RISC
having cleavage activity in humans [18, 5].
After intensive research on the mechanism of RNAi-mediated gene silencing, it is now clear
that miRNAs or siRNAs target the RISC to mRNAs via sequence-specific interactions, and
GW182 mediates silencing [19, 20, 21, 22]. RNA interference (RNAi)-mediated gene silencing
can result in translational suppression and/or degradation of the target mRNA [23, 24, 5].
What determines this decision remains to be resolved. A possible answer to this question
can include interacting proteins. Ago proteins are, indeed, known to interact with several
proteins that have roles in translational regulation or mRNA decay, either directly or in an
RNA-dependent manner. In Drosophila, miRNA-mediated mRNA decay was reported to
require the decapping complex Dcp1/Dcp2, the decapping enhancer Edc3, the deadenylase
Ccr4-NOT complex [16, 23].
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1.2 Deadeylation
In the cytoplasm, the polyA tail together with the polyA-binding protein (PABP) supports
translation and protects the 3’ end of the mRNA from exoribonucleases. Therefore, removal
of the polyA tail is a prerequisite for degradation, and the rate of deadenylation is the
major determinant of mRNA half life [1]. There are three main eukaryotic deadenylases:
(1) the polyA-specific ribonuclease, PARN, (2) the PAN2-PAN3 deadenylase and (3) the
Ccr4-NOT deadenylation complex. While PARN has important roles in control of polyA tail
length in embryogenesis, the PAN2-PAN3 and Ccr4-NOT complexes are the main cytoplasmic
deadenylases [5, 25]. Deadenylation was shown to be biphasic in mammalian cells: First, PAN2-
PAN3, stimulated by PABP, shortens the polyA tail down to 100-110 nt. This deadenylation
step is slow and synchronous. In the second phase, the Ccr4-NOT complex takes over and
deadenylates the mRNA rapidly. This phase of deadenylation is asynchronous, and decapping
and degradation of the mRNA body already start to take place [25, 26]. Zheng et al. [27]
showed that the PAN2-PAN3 and Ccr4-NOT complexes interact with each other, and that
overexpression of a Caf1 dominant negative mutant impairs not only the second phase of
deadenylation but also the first one. These data indicate that the two complexes communicate
with each other to coordinate deadenylation.
1.2.1 The PARN Deadenylase
PolyA-specific ribonuclease, PARN, also known as deadenylating nuclease, DAN, is a single
polypeptide, which functions as homooligomer. PARN is a magnesium (Mg2+)-dependent
enzyme and belongs to the DEDD family of nucleases. It has a distributive deadenylation
activity that requires a free 3’-hydroxyl group and releases solely 5’-AMP [28]. In contrast
to the PAN2-PAN3 and Ccr4-NOT deadenylases, PARN interacts with the 7-methylated
guanosine cap (m7G). Its in vitro activity is stimulated by the presence of the cap but
inhibited by the cap-binding protein 80 (CBP80) and the eukaryotic translation initiation
factor 4E (eIF4E), which also binds to the cap [29, 30]. At the 3’ end of the mRNA, PABP
was shown to inhibit the activity of PARN [28, 31, 32].
PARN is a nucleo-cytoplasmic shuttling protein, mainly localized to the nucleus [25]. It
is essential for embryogenesis in plants, catalyzes the deadenylation of maternal mRNAs in
Xenopus laevis oocytes during maturation [5], and represents the main deadenylase in HeLa
S100 extracts [30]. Despite these early data, Yamashita et al. [25] demonstrated that PARN
does not play a major role in mammalian mRNA degradation. Lack of homologs of PARN in
S. cerevisiae or in Drosophila melanogaster also indicates that PARN is not required in all
eukaryotes [25, 5].
1.2.2 The PAN2-PAN3 Deadeylation Complex
PolyA nuclease (PAN), is a heterodimeric complex, largely localized to the cytoplasm. PAN2
is the catalytic and PAN3 the regulatory subunit of the complex [33, 34]. Like PARN, PAN2-
PAN3 is a distributive exonuclease dependent on Mg2+. It also requires a free 3’-OH group
and releases 5’-AMP as a product. PAN shortens the mammalian polyA tails down to 110 nt
from their normal length of 200-250 nt, and the yeast polyA tails to 50 nt from 70-90 nt [35].
This implies the need for a second complex to take over the PAN activity after the first step of
deadenylation is catalyzed by PAN [25]. On the other hand, deletion of PAN2 in S. cerevisiae
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or siRNA knockdown in mammalian cells has only subtle effects on mRNA degradation. This
suggests that PAN2-PAN3 is not the main deadenylase in the cell [25, 34, 36]
In contrast to the PARN and Ccr4-NOT deadenylases, which are both inhibited by PABP,
PAN activity is stimulated by PABP [35, 33, 34]. PAN3 interacts with the C-terminus of PABP
[37]. This interaction is needed for the stimulatory effect of PABP on the enzymatic activity of
PAN as overexpression of PABP can suppress the deadenylation defect of a pan mutant yeast
strain. Moreover, interaction of PAN with PABP together with the observation that PAN does
not degrade the polyA tail completely suggests that PAN has the ability to sense the number
of PABP proteins on the polyA tail. This would eventually lead PAN to lose its affinity for
the polyA tail as the number of PABP decreases in the course of deadenylation, explaining
why PAN mediates only the first step of deadenylation [36, 25]. Besides its stimulatory role,
PABP interaction also increases the substrate specificity of the human PAN2-PAN3 complex
[38]. On the other hand, Lowell et al. [35] provided evidence that the activity of PAN can also
be regulated by cis-acting sequences within an mRNA, like AREs in the 3’ UTR.
In addition to its role in cytoplasmic deadenylation and mRNA degradation, PAN is also
implicated in the final step of mRNA biogenesis in the nucleus. It is responsible for the
trimming of the newly synthesized polyA tail to its mature length, in an mRNA-specific
manner [36]. Retention of mRNAs at the site of transcription is observed in yeast cells lacking
PAN [39]. This finding points towards the idea of coupling of polyA tail maturation to mRNA
export [8].
1.2.3 The Ccr4-NOT Deadenylation Complex
The Ccr4-NOT complex is a global regulator of gene expression, involved not only in mRNA
deadenylation but also transcription. As the focus of my thesis is cytoplasmic mRNA decay, I
will only mention functions of the Ccr4-NOT complex that are related to mRNA deadenylation.
I will first summarize what is known about the composition of the complex, and then focus on
the deadenylase subunits Ccr4 and Caf1.
The Ccr4-NOT complex is an evolutionary conserved, multi-subunit complex (see Table 1.1
for comparison of the yeast and human complexes). In gel filtration experiments, Ccr4-NOT is
found in two major complexes, ∼1.0 MDa and ∼1.9 MDa in size [40]. The ∼1.0 MDa complex
is the core complex while the ∼1.9 MDa complex includes associated proteins. Thus, the
Ccr4-NOT core complex is thought to be a platform that recruits different interactors via its
individual subunits to mediate its diverse functions in the cell [41, 42].
Together with PAN2-PAN3, the Ccr4-NOT complex represents the major deadenylases in
the cell. While deletion of CCR4 or CAF1 slows down deadenylation, double deletion of CCR4
and PAN2 completely blocks deadenylation [43]. In contrast to PAN2–PAN3, Ccr4–NOT
activity is inhibited by PABP [25]. In addition to the role of Ccr4-NOT in bulk mRNA
degradation, the complex can also be recruited to mRNAs via adaptor proteins that recognize
sequence motifs in 3’ UTRs. For example, Sandler et al. [11] showed that human TTP recruits
the Ccr4-NOT complex via its interaction with CNOT1 to ARE-containing mRNAs. Moreover,
Behm-Ansmant et al. [20] and Fabian et al. [22] provided evidence that miRNAs interact with
the Ccr4-NOT complex, and that this interaction is necessary for mRNA degradation.
In S. cerevisiae, the ∼1.0 MDa complex was shown to contain Not1p-5p, Ccr4p, Caf1p,
Caf40p and Caf130p [40]. The largest subunit Not1p is the only essential protein for yeast
viability while mutations in Not2p, Not4p and Not5p lead to growth defects. These in vivo
observations can be explained by the finding that Not2p, Not3p and Not5p contribute to the
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Yeast core Aliases for Human core Aliases for
subunit yeast subunits subunit (HGNC) human subunits
Not1 CDC39 CNOT1 hNOT1
ROS1
SMD6
Not2 CDC36 CNOT2 hNOT2
DNA19
Not3 CNOT3S hNOT3
Not5 CNOT3L
Not4 MOT2 CNOT4N hNOT4
SIG1 CNOT4S
CNOT4L
Ccr4 FUN27 CNOT6 hCCR4, Ccr4a
NUT21
CNOT6L Ccr4b
Caf1 POP2 CNOT7 hCAF1, Caf1a
CNOT8 hPOP2, CALIF, Caf1b
Caf40 CNOT9 hRcd1, Rqcd1, hCAF40
Caf130 CNOT10
TAB182
C2ORF29
Table 1.1. Comparison of yeast and human Ccr4-NOT complex components. Table reproduced from
Collart and Timmers [42].
stability of Ccr4-NOT complex. Not1p is suggested to be the scaffold of the complex, and the
C-terminal 800 amino acids (aas) of the protein appear to be sufficient for this function. The
other Not proteins interact with this C-terminal part of Not1p, while the Ccr4p and Caf1p
bind with a more N-terminal region in the middle of the protein. Ccr4p is associated with the
complex via Caf1p, and is the major deadenylase in the yeast complex. In cells lacking any of
the Not proteins, both Ccr4p and Caf1p become essential. This points towards a role of Ccr4p
and Caf1p in integrity of the Ccr4-NOT complex, or alternatively, their deadenylation activity
becoming more important when other functions of the complex are impaired. Interestingly,
Caf130p, interacts with both the N- and C-terminal parts of Not1p. Caf40p behaves like
Caf130p, though its interaction site on Not1p has not been determined. These two proteins
appear to interact with Not1p on site(s) separate from other Ccr4-NOT proteins, since they
do not depend on any other component for Not1p interaction and their deletion does not
impair association of other components with Not1p [40, 42].
Recently, Temme et al. [44] published a detailed analysis of the Ccr4-NOT complex in
Drosophila melanogaster. First of all, the authors found that in the Drosophila genome there is
one ortholog for yeast Not3p and Not5p, called NOT3. They further showed that the Ccr4-NOT
complex has a stable core formed of NOT1, NOT2, NOT3, CAF40, CCR4 and CAF1, while
NOT4 is excluded from the core. Surprisingly, RNAi-mediated depletion of individual subunits
results in co-depletion of other subunits. This indicates that the subcomplex formation is
required for the stability of the Ccr4-NOT complex itself. CCR4 and CAF1 are expressed
10
1.2 Deadeylation
throughout the lifetime of the fly, from oogenesis to the adult with a punctuate staining
in the cytoplasm [45]. CAF1, NOT1, NOT2 and NOT3 are required for the deadenylation
activity of the Drosophila Ccr4-NOT complex. In contrast to yeast, CCR4 is dispensable for
deadenylation and CAF1 appears to be the main deadenylase [44].
In humans, the Ccr4-NOT complex is conserved with some differences to the yeast complex.
Like Drosophila, humans have only one ortholog of Not3p and Not5p. The human protein,
CNOT3, is expressed as a short and a long isoform: CNOT3S and CNOT3L. In yeast, Not2p
and Not5p interact with each other via their Not-Box motifs. CNOT3S lacking the Not-Box
motif, does not interact with the human Ccr4-NOT complex. CNOT3L associates with the
complex via the Not-Box-mediated interaction with CNOT2 [42, 46]. On the other hand,
similar to the situation in Drosophila, CNOT4, which can complement yeast Not4p [47], is
not an integral subunit of the human Ccr4-NOT complex. Indeed, CNOT4 was detected in a
separate 200 kDa complex and its association with the Ccr4-NOT complex may be regulated
[46]. Not4 is the only Not protein that has catalytic activity. Both yeast and human Not4
proteins have a RING finger domain at their N-terminus and were shown to have E3 ubiquitin
ligase activity [48, 49]. Dimitrova et al. [50] showed that Not4p, in conjunction with the
Ubc4p/Ubc5p E2 enzyme, ubiquitinates and leads to proteasomal degradation of translationally
arrested nascent polypeptites containing polylysine or polyarginine. Nevertheless, degradation
of protein products of mRNAs lacking a stop codon (non-stop mRNAs) was not dependent on
Not4p. Deletion of other Not proteins did not affect degradation of the polylysine-containing
peptides raising the question if it is Ccr4-NOT associated or free Not4p that mediates this
activity.
Lau et al. [46] identified two additional proteins, TAB182 and C2ORF29, being involved in
the human Ccr4-NOT complex. In addition, there are two orthologs of both yeast Caf1p and
Ccr4p in humans: Caf1a (CNOT7) and Caf1b (CNOT8), and Ccr4a (CNOT6) and Ccr4b
(CNOT6L), respectively. The human Ccr4-NOT complex exists in 4 different forms specified by
the associated Caf1 and Ccr4 proteins [46]. Moreover, Ccr4a and Ccr4b interact more tightly
with Caf1a than with Caf1b. Gene Ontology analysis of the interactors of these complexes
indicates that the Caf1a-containing complexes may be involved in mRNA splicing, transport
and localization, while the Caf1b-containing complexes may be associated only with splicing
[46].
Ccr4 Ccr4, like PARN and PAN2, is a Mg2+-dependent 3’ to 5’ exoribonuclease. Chen
et al. [51] showed that yeast Ccr4p can use both ssDNA and RNA as substrate in vitro,
with preference for RNA with a 3’ polyA tail. Ccr4p processivity depends on the length of
the substrate RNA. With substrates longer than 45 nt, it is processive while with shorter
substrates it shows distributive activity. Unlike PARN, Ccr4 activity is not enhanced by the
5’ cap [52]. In contrast to PAN2-PAN3, Ccr4 is inhibited by PABP [53]. Ccr4 has three main
domains: N-terminal activation domain, a central leucine-rich repeat (LRR) with five tandem
repeats, and a C-terminal exonuclease III-like domain. The LRR domain binds to Caf1. The
activity of the exonuclase domain was confirmed via mutational analysis [51, 52].
Ccr4 is connected to the Ccr4-NOT complex via Caf1, which is also an exoribonuclease.
Presence of two deadenylases in the same complex resulted in questioning the contribution of
the individual enzymes to deadenylation. In S. cerevisiae, deletion of either CCR4 or CAF1
leads to slower deadenylation and mRNA degradation rates [43]. Tucker et al. [53] showed
that Caf1p is dispensable for Ccr4p catalytic activity in vitro, and overexpression of Ccr4p
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in CAF1 deletion strains could rescue the deadenylation defect. These data suggest that
Ccr4p is the major deadenylase in yeast, and that Caf1p may contribute to the affinity of the
Ccr4p/Caf1p complex to the substrate mRNA.
Despite its proven role in deadenylation in yeast, the importance of Ccr4 in higher eukaryotes
has been challenged by several findings. In Trypanosoma brucei no homolog of Ccr4 was
found, while orthologs of Caf1, Not1, Not2, Not5 and Caf130 form the Ccr4-NOT complex
[54]. Temme et al. [45] showed that in Drosophila S2 cells, knockdown of CCR4 does not
have a detectable effect on either steady-state polyA tail length or the rate of Hsp70 mRNA
deadenylation. In mouse, which has two homologs of Ccr4, Ccr4a and Ccr4b, overexpression
of wild type (wt) Ccr4 accelerates decay of stable β-globin mRNA. Moreover, knockdown of
both Ccr4 homologs in mouse NIH3T3 cells impairs the second phase of mRNA degradation
[25]. Nevertheless, further studies in the same cell line showed that overexpression of Caf1 does
also increase the decay rate of β-globin mRNA, and Caf1 knockdown stabilizes the reporter
mRNA to a greater extend than the Ccr4 knockdown [27]. Thus, in mouse, Ccr4 is not the
major deadenylase but has complementary roles to Caf1 activity. As in mouse, there are
two homologs of Ccr4 in humans: Ccr4a (CNOT6) and Ccr4b (CNOT6L). Morita et al. [55]
found that both homologs associate with the Ccr4-NOT complex. The authors also provided
evidence that the deadenylase activity of Ccr4b, but not Ccr4a, is necessary for proper cell
cycle control. Schwede et al. [54] compared the importance of human Ccr4 and Caf1. The
results did not show a statistically significant effect of Ccr4a and Ccr4b knockdown on average
polyA lengths.
Caf1 Caf1 is a member of the DEDDh family of exonucleases. Some in vitro deadenylase
activity was detected for yeast Caf1p. Nevertheless, it lacks residues that are thought to be
critical for enzymatic activity in the RNase domain [53]. Speaking against the deadenylase
activity of yeast Caf1p, Caf1p purified from strains lacking Ccr4p does not possess nuclease
activity [43]. Interestingly, employing Caf1p mutants Ohn et al. [56] showed that Caf1p can
affect deadenylation independently of its interaction with Ccr4p. This idea is supported by
the synthetic lethality of CAF1 deletion, but not of CCR4 deletion, with defects in PABP or
DHH1, whose protein products are involved in translation. These data indicate that yeast
Caf1p contributes to deadenylation both via its interaction with Ccr4p and by an undetermined
mechanism independently of Ccr4p.
In contrast to yeast, Caf1 homologs in higher eukaryotes have functional exoribonuclease
domains and appear to be the major deadenylase. In Trypanosomes, which lack detectable
Ccr4 othologs, Caf1 is an active deadenylase. It is essential for cell survival and reducing
its levels increases the average polyA tail length [54]. In Drosophila cells, overexpression of
a catalytically dead CAF1 mutant inhibits mRNA decay in a dominant-negative manner,
whereas, overexpression of inactive CCR4 does not have any effect [44]. This suggests that
CAF1 is the major deadenylase also in Drosophila. Viswanathan et al. [57] showed that
mouse Caf1 is a 3’ to 5’ exoribonuclease whose processivity is positively affected by the longer
substrates. PolyA substrates are preferred by mouse Caf1 and its activity is not influenced
by the 5’ cap or PABP on mRNA. In human cells, simultaneous depletion of both Caf1
homologs, Caf1a and Caf1b, inhibits deadenylation of bulk mRNA leading to longer polyA
tails in average. In addition, knockdown of both Caf1a and Caf1b stabilized a labile reporter
mRNA containing an ARE in its 3’ UTR [54].
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1.3 Decapping and 5’ to 3’ mRNA Decay
Even though deadenylation is the first and rate limiting step in mRNA degradation, it is
not the ultimate death sentence for the mRNA. Deadenylated mRNAs can be stored as
translationally silenced species in P-bodies (see Section 1.4). These mRNAs can become
readenylated and regain translational ability [58, 59]. On the other hand, removal of the
5’ m7G structure leaves the mRNA body accessible to degradation, which is an irreversible
decision in the life of an mRNA. Once decapped, the mRNA body becomes a substrate for
the 5’ to 3’ exoribonuclease Xrn1 and is quickly degraded [4]. Decapping is catalyzed by
the evolutionary conserved Dcp1/Dcp2 decapping complex and several decapping enhancer
proteins that stimulate its activity have been identified [60, 61, 62, 63, 64, 13].
The first indications for the presence of decapping and 5’ to 3’ decay were published by
Decker and Parker [1] in 1993. The authors were able to visualize decay intermediates of
mRNAs by inserting a poly guanosine (polyG) sequence in the mRNA 3’ UTR sequence.
polyG forms a strong secondary structure that hinders the yeast exoribonucleases. mRNA
fragments lacking the 5’ portion were detected from reporters both with short and long half
lives, suggesting that degradation of mRNA from its 5’ is a general pathway. In parallel, Xrn1
was identified as a processive exoribonuclease, whose deletion led to accumulation of full length
but deadenylated mRNAs, that also lacked the cap structure. Furthermore, polyadenylated
and capped mRNAs were resistant to hydrolysis by Xrn1 [3, 4]. A detailed analysis of both
stable PGK1 mRNA [2] and labile MFA2 mRNA [4] indicated that decapping followed by 5’ to
3’ decay is the major mode of mRNA degradation in yeast. These studies also put decapping
as a potentially regulated step in addition to deadenylation, because 5’ to 3’ exoribonucleolytic
degradation was estimated to be much faster than either of the two previous steps.
1.3.1 The Dcp1/Dcp2 Decapping Complex
The Dcp1/Dcp2 complex responsible for decapping was identified in S. cerevisiae and termed
mRNA decapping enzyme (Dcp). Initially, Dcp1p was thought to be the active enzyme of the
decapping complex [60]. But later on, Dcp2p was shown to be the catalytically active protein,
and Dcp1p enhances Dcp2 decapping activity [65]. The reason for this confusion appears to be
the selection of the divalent cation in the reaction [66]. Dcp2 has a low level, rather unspecific
activity in the presence of Mg2+. Both the substrate specificity and the processivity of Dcp2
is enhanced significantly by manganese (Mn2+).
Deletion of either DCP1 or DCP2 causes accumulation of deadenylated but capped MFA2
mRNA in addition to several transcripts with slowed turnover rates. Furthermore, both in
DCP1 and in DCP2 deletion strains there was no detectable decapping activity, as judged by
pull-down of reporter mRNA with anti-cap antisera [60, 67]. Moreover, neither Dcp1p purified
from a dcp2∆ strain nor Dcp2p purified from a dcp1∆ strain showed decapping activity.
These data strongly indicated that Dcp1p and Dcp2p function as a complex. Supporting this
idea, Dcp2p and Dcp1p interact with each other both in vitro and in vivo [67].
Dcp2p contains a Nucleotide diphosphate linked to an X moiety (NudiX) pyrophosphatase
motif. The N-terminal region of Dcp2 containing this motif is necessary and sufficient for
decapping of both yeast and human mRNAs [67, 68]. Characterization of the decapping
complex showed that 7-methyl group on the cap and 5’ of the mRNA body are important for
substrate recognition, and longer substrates (>25 nt) are preferred [69]. The cap is cleaved
at the 5’-triphosphate linkage, and the decapping reaction releases 7-methylated guanosine
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diphosphate (m7GDP) and 5’-monophosphate mRNA [60]. Importantly, cap structure alone
or cap analogs are not utilized by the decapping enzyme [69].
Via in silico searches two homologs of yeast Dcp1p, termed Dcp1a and Dcp1b, and one
homolog of Dcp2p were identified in humans by several groups [61, 70, 68]. The N termini of
the human Dcp1 proteins show homology to both the N- (which is important for decapping)
and the C-termini of the yeast protein. Both of the human Dcp1 proteins include ∼450 aa
long C-terminal extensions compared to the yeast Dcp1p. Likewise, Dcp2 proteins share high
homology at their N-termini, where the NudiX motif responsible for decapping activity is
located, however human Dcp2 lacks the central region of the yeast protein. Human Dcp1
and Dcp2 interact independently of RNA, implying complex formation as shown for the
yeast proteins. Nevertheless, human Dcp1 and Dcp2 depend on Hedls, a metazoan-specific
decapping enhancer, for their interaction [13]. Recombinant hDcp2 purified from E. coli
exhibits in vitro decapping activity while no activity is detectable with recombinant hDcp1.
Recombinant hDcp1 also failed to stimulate the activity of recombinant hDcp2, probably
due to the requirement for additional protein(s) to mediate the hDcp1-hDcp2 interaction.
Mutations in the NudiX motif of hDcp2 (either glutamic acid 147 (E147) alone or together
with E148) abolishes its activity, supporting the notion that hDcp2 is the decapping enzyme in
humans [61, 70]. The functional properties of human Dcp2 are similar to the yeast decapping
complex. hDcp2 recognizes the methylated cap in context of the mRNA body, with increasing
processivity on longer mRNAs. Substrate hydrolysis releases m7GDP [68, 71]. It was shown
that the activity of human Dcp2 is minimal unless Mn2+ is present in the reaction [66].
Dcp2 binds RNA Dcp2 substrate recognition and activity depend on the mRNA body,
raising the question whether Dcp2 binds to RNA. This was proved to be the case by Piccirillo
et al. [66] and Deshmukh et al. [72]. Cap recognition by Dcp2 requires RNA binding, which
is independent of cap itself. The N-terminal NudiX fold and conserved sequences flanking it
were shown to be important for RNA binding [66]. In addition to these data, the structure
of the NudiX domain of Dcp2p (aa 100-245) proved that Dcp2p is an RNA-binding protein
[72]. RNA binding is predicted to occur at a basic channel that runs along the dorsal surface
of the NudiX domain. Deshmukh et al. [72] also provided evidence that cap recognition by
the Nudix domain is weak, but specific, and requires the cap to be bound to a longer RNA.
Moreover, the authors showed that RNA binding by Dcp2p is sequence-independent and
stronger than binding to the cap. RNA binding was, therefore, suggested to increase the local
cap concentration, thereby accelerating the slow, rate limiting step of cap hydrolysis.
Substrate specificity of the Dcp1/Dcp2 decapping complex The ability of Dcp2 to bind
RNA then raised another question: Is Dcp2 a canonical enzyme, or does it have preference for
a subset of mRNAs? Li et al. [73] addressed this question by analyzing mRNAs associated
with human Dcp2 protein. In addition to several hundreds of mRNAs identified to interact
with Dcp2, the mRNA encoding Rrp41 was enriched >6-fold compared to control. Rrp41
is a component of the core exosome, the machinery that degrades mRNAs from the 3’ end
[74]. Rrp41 mRNA being a high affinity substrate for Dcp2 indicates a potential interplay
between the 5’ to 3’ and 3’ to 5’ mRNA degradation complexes. A 60 nt GC rich sequence
at the 5’ end of the Rrp41 mRNA is able to trigger faster degradation of a chimeric reporter
mRNA in a position-dependent manner. Hence, the GC rich sequence is important for higher
association with Dcp2 and the enhanced rate of decapping. Li et al. [75] analyzed this 60 nt
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sequence further and showed that the first 33 nt form a stem-loop structure. The stem-loop
structure and not the primary sequence is important for Dcp2 binding. Using bioinformatics,
the authors were able to identify 239 potential transcripts with similar stem-loops in their 5’
UTR. 3 examples chosen from this set of mRNAs were confirmed to have higher decapping
rates [75]. Moreover, phosphorylation of yeast Dcp2p upon stress was shown to interfere with
only a small subset of mRNAs. The group of mRNAs up-regulated more than 2-fold in the
phosphomimetic Dcp2p strain included several mRNAs coding for ribosomal proteins [76].
Therefore, although Dcp2 is believed to catalyze decapping of all cellular mRNAs, it does have
a preference for certain mRNAs and exhibits different rates of decapping on its substrates.
Recent data indicates that Dcp1a also contributes to the selective targeting of some substrates
by Dcp2 [77]. It was shown that phosphorylation of Dcp1 by the c-Jun N-terminal kinase (JNK)
pathway (see paragraph Regulation of decapping via phosphorylation) can lead to stabilization
of some mRNAs while increasing the turnover rate of others. Nevertheless, the observation
that small amounts of Dcp1a localize in the nucleus raises the possibility of transcriptional
regulation by Dcp1a. This puts into question the differential decapping hypothesis, at least
the contribution by Dcp1. Importantly, phosphorylation of Dcp1a did not affect the decapping
activity of Dcp2 on a given substrate [77].
Role of Dcp1 in Dcp2 activation Dcp1 and Dcp2 work as a complex with Dcp2 being the
catalytic subunit. Dcp1p is required for activation of Dcp2p as its deletion leads to complete
loss of decapping in yeast [60, 67]. Nevertheless, it remained elusive how Dcp1p enhances
Dcp2p activity. The decapping complex was shown to possess low basal catalytic activity, and
several proteins were identified to interact with the complex and to stimulate the decapping
activity (see Subsection 1.3.2). Therefore, it is proposed that Dcp1p is the critical factor that
mediates interactions of the complex with these decapping enhancers [62].
The crystal structure of Dcp1p revealed its resemblance to the Enabled/VASP homology
1 (EVH1) family of proteins, which share proline-rich sequence (PRS)-binding sites [78]. There
are two apparent conserved sequence patches on the surface of Dcp1p and an additional
conserved hydrophobic patch. All three patches are located at the N-terminal half of the
protein. The first patch corresponds to the EVH1 PRS-binding site and was proposed to
be the interaction site for the decapping enhancers. Mutations in this patch do not affect
the decapping activity of recombinant Dcp2p in vitro. The second patch is important for
the activity of Dcp1p/Dcp2p, but not for the interaction of Dcp1p with Dcp2p. Dcp1p
mutated in the second patch inhibits decapping both in vivo and in vitro. Similar to patch
2, the hydrophobic patch is also required for decapping activity, but dispensable for Dcp1p-
Dcp2p interaction. The hydrophobic patch is located C-terminal to patch 2. Their close
proximity suggests that they can regulate Dcp2 activity together, possibly via ligand binding
[78]. Deshmukh et al. [72] determined the structure of yeast Dcp1p together with the NudiX
domain of Dcp2p by nuclear magnetic resonance (NMR). The data showed that Dcp1p
promotes the catalytic step of decapping by roughly 1000-fold, but does not affect RNA
binding. In conclusion, Dcp1p enhances the rate limiting catalytic step of decapping by Dcp2p,
but not substrate recognition.
The structure of Schizosaccharomyces pombe Dcp1p in complex with Dcp2p by She et al.
[79] revealed that Dcp2p exists in an open and a closed conformation (see Figure 1.2). Residues
N-terminal to Dcp2p NudiX domain (NTD), which interact with Dcp1p, form a separate
globular lobe together with Dcp1p. In the open conformation, this lobe does not contact the
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NudiX domain. The closed conformation is defined by the presence of the Dcp2p NTD and
Dcp1p in close proximity of the NudiX domain, thereby putting the two lobes of the complex
together. The closed conformation is catalytically active, and the protein cycles between open
and closed states. Introducing prolines in the interdomain linker that connects the two lobes
disables the closed state and inhibits decapping [80]. Both the NTD and the catalytic domain
of S. pombe Dcp2p specifically interact with the cap with almost identical affinities. These
data imply that the active site of Dcp2p is formed by contribution of both domains and needs
closure to occur. Therefore, the closed conformation is stimulated by substrate binding and is
stabilized by binding of Dcp1p and decapping enhancers. Alternatively, Dcp1p can also exert
its enhancing effect by increasing the rate of closure [80, 79]. The PRS-binding site of Dcp1p
does not overlap with its Dcp2p interaction site, allowing Dcp1p to interact with Dcp2p and
decapping enhancers simultaneously. This gives Dcp1p the ability to enhance Dcp2p activity
even further [79, 81].
Figure 1.2. Model explaining the regulation of Dcp1p/Dcp2p decapping activity by open and closed
conformations. Cartoon represents yeast Dcp1p (yellow) in complex with Nudix domain (aa 100-245) of
Dcp2p (blue: N-terminal part preceding Nudix domain (NTD), green: Dcp2p NudiX domain, purple:
mRNA with cap depicted as a hexagon). Please refer to text for details. (NMD factors Upf2 and Upf3
are also known to interact with, and stimulate decapping activity of the Dcp1/Dcp2 complex. As NMD
is out of scope of this thesis I did not mention them in the text.) Figure was taken from Floor et al.
[82].
The structure of Dcp1 from human and Drosophila revealed that the protein forms a trimeric
complex [83]. Dcp1 proteins from metazoa, except for Caenorhabditis elegans, and plants
share a conserved C-terminal proline rich extension that is missing in yeast proteins. This
domain adopts a kinked α-helix and mediates trimerization of the protein in an asymmetrical
antiparallel assembly. The two human Dcp1 homologs, Dcp1a and Dcp1b, can also form
heteromers via trimerization. Indeed, trimerization is a requirement for formation of an active
decapping complex and decapping activity in vivo. Trimerization is also important for the
interaction of human Dcp1a with Dcp2 and human enhancer of decapping large subunit (Hedls),
but not with other decapping activators. In line with its requirement for active decapping
complex formation, trimerization is also needed for Dcp1a to localize to P-bodies [83].
Role of PABP and eIF4E in decapping Decapping is preceded by deadenylation. This
implies an inhibitory effect of the polyA tail or PABP on the decapping complex. In S.
cerevisiae, deletion of the PAB1 gene, which encodes for yeast PABPp, abolishes the need
for deadenylation, i.e. in this strain mRNA decapping takes place prior to deadenylation [84].
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In addition, decapping of a polyadenylated reporter mRNA can be enhanced by introducing
a polyA RNA as a competitor in an in vitro assay [85]. Therefore, PABP appears to be a
factor that blocks Dcp1p/Dcp2p activity. Negative regulation of decapping by the polyA tail
and PABP is also conserved in humans [70]. Looking for the mechanism behind the PABP-
mediated inhibition of decapping Khanna and Kiledjian [71] showed that this inhibition cannot
be competed out by a cap analog. This implies an eIF4E-independent mechanism. Indeed,
the authors provided evidence that PABP itself, via its second RNA-recognition motif (RRM),
binds the m7G cap, with simultaneous polyA binding. The PABP-cap interaction is proposed
to protect the cap from the Dcp1/Dcp2 complex. This function of PABP seems to be specific
to the mammalian cytoplasmic PABP, as neither yeast PABP nor human nuclear PABP,
PABPN1, can protect the cap from Dcp1/Dcp2.
The decapping complex is also inhibited by the cap-binding protein eIF4E. In yeast, eIF4Ep
competes with Dcp1p/Dcp2p for cap binding [86]. Addition of recombinant eIF4Ep to an
in vitro decapping reaction inhibits decapping activity. On the other hand, addition of cap
analog to cell extracts increases decapping [85]. Moreover, a temperature sensitive eIF4E
mutant rescues both the decapping defect and the slow mRNA decay in a dcp1 mutant strain.
In contrast to yeast, Wang et al. [70] failed to detect enhancement of decapping activity by
cap analog in mammalian cell extracts.
3’ uridine tracts (U-tracts) stimulate decapping in mammalian cell extracts In addition
to the 5’ cap and 3’ polyA tail, Song and Kiledjian [87] demonstrated that a 3’ U-tract also
influences the decapping rate. Addition of up to 15 uridines at the 3’ end of the reporter mRNA
stimulated decapping by Dcp2 and prevented degradation from the 3’ end, in a position-
dependent manner. Nevertheless, recombinant Dcp2 fails to recognize U-tract-containing
mRNA. This points towards the requirement of additional factors to signal the 3’ U-tract to
Dcp2. In fact, several proteins known to enhance decapping (see Subsection 1.3.2) were found
to bind U-tract-containing mRNAs [63, 88].
Regulation of decapping via phosphorylation Dcp1p is known to be a phosphoprotein since
1998 [69] but the role of this phosphorylation on decapping remained unaddressed. Recently,
Rzeczkowski et al. [77] identified serine 15 (S315) in human Dcp1a to be phosphorylated
by JNK. JNK co-immunoprecipitates with Dcp1a and co-localizes with Dcp1a in P-bodies.
Explanation of the role of this phosphorylation is not straightforward. Continuous activation
of JNK leads to delocalization of Dcp1a from P-bodies while IL-1 induced transient activation
of JNK increases Dcp1a positive P-body numbers. Nonetheless, S315 is not included in the
regions that are important for stimulating decapping or binding of Dcp1a interaction partners.
Although differential stabilization of some transcripts has been reported, the exact role of
Dcp1a S315 phosphorylation on decapping or the activity of Dcp1a remains obscure.
Dcp2 is also a phosphoprotein. In S. cerevisiae, Ste20p, a MAPKKKK, phosphorylates
Dcp2p at S137 both in vivo and in vitro under several stress conditions [76]. Although S137 is
located adjacent to the catalytic site, neither the S137A nor the S137E mutations alter the
in vitro decapping activity. Consequently, Dcp2p phosphorylation is unlikely to affect global
mRNA decay. Indeed, only a small subset of mRNAs were identified to be up-regulated more
than 2-fold in a S137E mutant strain. Phosphorylation of Dcp2 under stress appears to be
more important for interactions and localization of the protein rather than the decapping
activity itself. In fact, Dcp2p phosphorylation is necessary to maintain localization of Dcp2p
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to P-bodies, optimal formation of stress granules, and for its interaction with the decapping
enhancer Dhh1p (see Subsection 1.3.2) [76].
Localization of the decapping complex Similar to the deadenylation complexes PAN2-
PAN3 and Ccr4-NOT, the decapping complex Dcp1/Dcp2 localizes to the cytoplasm [70, 68].
Interestingly, the decapping complex shows punctuate localization in the cytoplasm. These foci
were shown to contain many proteins involved in mRNA degradation and termed ‘Processing
bodies’(see below Section 1.4).
1.3.2 Decapping Enhancers
Decapping enhancers are a group of proteins that stimulate the activity of the Dcp1/Dcp2
decapping complex. They associate with the decapping complex mostly via Dcp1. On Dcp1,
the EVH1 PRS-binding site is a conserved patch where the decapping enhancers are suggested
to bind [78]. Comparing sequences of 20 proteins that interact with Dcp1p, Borja et al. [81]
were able to identify FPRP[S/T][F/W] as a preferred proline rich motif that Dcp1p binds to.
Tritschler et al. [83] observed that Dcp1 trimerization mutants fail to interact with Hedls and
Dcp2, but the interactions with Edc3 (enhancer of mRNA decapping (Edc)) and Rck are not
affected. Therefore, it is possible that Dcp1 forms different subcomplexes, one including Hedls
and Dcp2, a second one with Edc3 and Rck, and a third combining both subcomplexes [83].
The general idea is that the decapping enhancers have roles in different steps of messenger
ribonucleoprotein (mRNP) assembly and/or rearrangement leading to a decapping compatible
mRNP [82]. In addition, the decapping enhancers can be divided into two groups: (1) Proteins
that are not rate limiting, but can affect the process of decapping. These include Edc1p,
Edc2p and Edc3. (2) Regulatory proteins, whose deletion blocks decapping partially. These
proteins are thought to be general activators of decapping and include Lsm1-7, Pat1, Rck and
Hedls [64].
Edc1p and Edc2p Edc1p and Edc2p are yeast-specific proteins as their homologs in higher
eukaryotes have not been identified yet. In yeast, single or double deletion of EDC1 and EDC2
do not show any phenotype. Nevertheless, double deletion of both EDC1 and EDC2 genes in
a dcp1 mutant strain abolishes decapping to the levels observed in a DCP1 deletion strain
[62]. Moreover, recombinant Edc1p and Edc2p were shown to stimulate the Dcp1p/Dcp2p
decapping complex individually in in vitro reactions [65]. Therefore, Edc1p and Edc2p appear
to stimulate decapping activity, with Dcp1p being more sensitive to Edc1p and Dcp2p to
Edc2p [62].
Edc1p and Edc2p interact with Dcp1p [62, 81]. Edc1p was shown to interact with the Dcp1
PRS-binding site via its C-terminus. Deletion of the Edc1 C-terminus eliminates the ability
of the protein to enhance decapping, both in vitro and in vivo [89]. For both proteins the
decapping activation and the Dcp1p binding sites are separate from each other. Nevertheless,
mutating residues either on Dcp1p or on Edc proteins that would hinder their interaction,
reduces the ability of Edc1p and Edc2p to activate decapping [81]. On the other hand, Dcp1p
binding itself is not sufficient for stimulation of decapping. Edc1p and Edc2p both increase the
affinity of the decapping complex for RNA and the rate of catalysis [62, 81]. Further analysis
by Schwartz et al. [89] showed that Edc1p and Edc2p are indeed RNA-binding proteins.
Although the RNA binding activity of Edc proteins is independent of the cap, they are able
to overcome the eIF4Ep-mediated inhibition of decapping.
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Both Edc1p and Edc2p are basic proteins. This property, although it does not explain the
specificity for RNA, might be responsible for Edc1p’s RNA binding ability. This is suggested to
be the case as RNA binding could not be attributed to any part of the protein [89]. Schwartz
et al. [89] showed that Edc1p, but not Edc2p, is important for regulation of gene expression
when yeast is switched from fermentative to aerobic respiration. RNA binding properties
of Edc1p do not explain why only Edc1p is involved in this regulation. However, RNA
binding together with decapping complex association, may enhance the substrate binding by
Dcp1p/Dcp2p and/or catalytic activity.
Edc3 Edc3p, also termed Lsm16, was identified as a protein having yeast two hybrid (Y2H)
interactions with the decapping complex and decapping enhancers. Like EDC1 and EDC2,
deletion of EDC3 does not affect either the growth of yeast or degradation of reporter mRNAs.
The function of Edc3p becomes apparent when its deletion is combined with temperature
sensitive yeast mutants in both 5’ to 3’ and 3’ to 5’ decay. In this strain background, the
turnover rate of MFA2 mRNA is slowed down without a change in the deadenylation rate.
Thus, Edc3p is an enhancer of decapping that likely stimulates the Dcp1p/Dcp2p decapping
complex [64].
The human homolog of Edc3p was identified by Fenger-Grøn et al. [13] as an interaction
partner of human Dcp1a and Dcp1b. For the interaction of ectopically expressed human Dcp2
with Edc3, co-expression of Dcp1a and Hedls are required, while the Rck-Edc3 interaction
does not depend on co-expression of any other factor. In addition, association between Edc3
and TTP was also observed, indicating its involvement in ARE-mediated mRNA decay [13].
In the yeast Edc3 protein three domains have been identified: (1) a divergent Sm Like (Lsm)
domain at the N-terminus, (2) a FDF domain in the middle, and (3) a Yjef-N domain at
the C-terminus. The Lsm and FDF domains mediate the interaction with Dcp2p N-terminus
[90, 91, 92]. The FDF domain also associates with C-terminal domain of Dhh1p (S. cerevisiae
homolog of Rck). Surprisingly, the YjeF-N domain interacts with itself, thereby mediating
Edc3p self-interaction [90]. Like Dcp2 and the other enhancer proteins, Edc3 localizes to
P-bodies [64, 13]. Different from the other decapping enhancers, an active role for Edc3p in
P-body assembly has been proposed. Although Edc3p is not required for P-body formation.
Decker et al. [90] suggested that Edc3p acts as a scaffolding protein that supports the formation
of microscopically visible P-bodies via its interaction with other proteins and self-interaction.
Hence, a possible explanation for the decapping enhancement seen by Edc3p is the ability of
the protein to form P-bodies, thus increasing the local concentration of mRNA substrates and
decapping factors. On the other hand, an Edc3p mutant protein lacking the YjeF-N domain
could still rescue the growth and mRNA degradation defects resulting form EDC3 deletion
in cells defective in both 5’ to 3’ and 3’ to 5’ decay pathways [90]. Along the same lines,
deletion of residues in Dcp2p that are required for Edc3p interaction reduces Dcp2p activity
[91]. Furthermore, Nissan et al. [92] showed that recombinant Edc3p stimulates Dcp2p in
the absence of Dcp1p, and the Edc3-Lsm domain is sufficient for this. Together, these data
indicate that Edc3p enhances decapping both by stimulating P-body formation and directly
affecting the activity of Dcp1p/Dcp2p. Genetic interactions between EDC3 and SCD6 point
towards the possibility of redundancy between the two proteins, which might explain the
subtle effect seen in the edc3∆ strain [93].
In an attempt to find mRNAs that are differentially regulated by Edc3p, only one single
mRNA coding for yeast ribosomal protein RPS28B was identified. Rps28p autoregulates its
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own mRNA via binding to a conserved hairpin structure in the 3’ UTR. Edc3p appears to
be important for destabilization of this mRNA together with Rps28p itself [94]. In addition,
Edc3p is also implicated in the cytosolic decay of YRA1 pre-mRNA that escapes to the
cytoplasm without being spliced [95]. Edc3p recognizes and binds to an element in the 5’ half
of the YRA1 intron. Since abolishing the interaction of Edc3p with the decapping complex
does not affect Edc3p-mediated YRA1 pre-mRNA degradation, it is not yet clear how Edc3p
induces mRNA decay [96, 91].
Hedls Hedls (human enhancer of decapping large subunit), also termed Edc4 or Ge-1, was
identified by Fenger-Grøn et al. [13] as another protein interacting with Dcp1a. Unlike
other decapping enhancers, Hedls does not have a yeast homolog. Requirement for Hedls in
decapping emerges from the fact that human Dcp1 and Dcp2 do not interact directly with
each other. All three proteins are needed to form the trimeric complex as neither Dcp2 nor
Hedls interact with Dcp1a alone [13, 97].
In addition to stimulating decapping via complex formation, Hedls also enhances the
catalytic activity of Dcp2. An ARE-containing reporter mRNA that was found to associate
with Hedls was preferentially deadenylated [13]. Hedls localizes to P-bodies. In Drosophila,
the conserved C-terminal part of the protein is necessary and sufficient for P-body localization
[97]. Hedls is an essential P-body protein, and both the number and size of the P-bodies
increases when Hedls is overexpressed [13]. Structural analysis of the C-terminal conserved
domain of the Drosophila protein indicated that in the context of the full length protein, it
can lead to oligomerization [97]. Hedls-mediated oligomerization may then support P-body
formation.
p54/Rck p54/Rck belongs to the family of DEAD-box RNA helicases, which posses RNA-
dependent ATPase activity. In Xenopus and Drosophila early oogenesis, the Rck homologs,
Xp54 and Me31B respectively, were implicated in translational suppression [98, 99, 100]. In
Xenopus oocytes, Xp54 was shown to be part of cytoplasmic, translationally silenced mRNPs
that contain polyA tails [98]. The data on the effect of Xp54 on translation are rather
confusing. Xp54 was shown to suppress the translation of a tethered, in vitro transcribed
and capped mRNA. The efficiency of translational suppression by Xp54 is reduced when the
reporter mRNA has a polyA tail [99]. Confusing the situation even further, mutating residues
that disturb the Xp54 helicase activity (either inhibiting the ATPase or the RNA binding
activities) enhanced translation of the non-adenylated reporter. The mutant proteins did
not affect on translation of the adenylated reporter mRNA. It is possible that Rck-mediated
translational suppression is regulated in vivo by the polyA tail length [99]. Likewise, the
Drosophila homolog, Me31B, was also shown to be required for translational inhibition of
maternal mRNAs while they are transported from nurse cells to the oocyte [100]. The yeast
protein, Dhh1p, is also indicated as a general suppressor of translation under stress conditions
[101]. Overexpression of Dhh1p is sufficient to disassemble polysomes. On the other hand,
single deletion of DHH1 does not lead to detectable changes in translation. When combined
with a pat1∆ strain, DHH1 deletion fails to block translation upon glucose starvation. This
points towards redundant roles of Dhh1p and Pat1p in regulation of translation under stress.
Moreover, the mechanism of suppression does not depend on the cap structure, as suppression
was also observed on reporter mRNAs containing internal ribosome entry sites (IRESs) from
several viruses [101].
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Fischer and Weis [102] provided evidence that the yeast protein, Dhh1p, has a role in mRNA
decapping. Deletion of DHH1 alone leads to stabilization of several mRNAs although their
deadenylation takes place normally. These stabilized mRNAs are still capped. In addition,
Dhh1p interacts with Dcp2p, Xrn1p and Pat1p, supporting its role in 5’ to 3’ mRNA decay
[102, 90]. Strikingly, Dcp1p purified from a dhh1∆ strain was less able to enhance decapping
[102]. Direct interaction of Dhh1p with Dcp2p, through the N-terminus of Dcp2p, was reported
by Nissan et al. [92]. Nevertheless, the authors failed to detect a stimulation of the decapping
complex by recombinant Dhh1p in vitro. The human homolog, Rck or DDX6, was also found
to interact with human Dcp2, Dcp1a and Edc3 [13].
Given the above data, Dhh1p more likely acts on mRNA degradation as a suppressor of
translation rather than directly affecting the catalytic activity of decapping. In turn, Dhh1p
might positively stimulate decapping by increasing the fraction of non-translating mRNPs,
making them substrates for decapping.
DEAD-box RNA helicases contain a core of two RecA-like domains flanked by N- and
C-terminal extensions. Cheng et al. [103] solved the crystal structure of the helicase core of
the yeast Dhh1p protein. The structure confirmed the presence of two RecA-like domains
in Dhh1p although the domain arrangement is unique to Dhh1p, with several inhibitory
interactions between the two domains. The N-terminal RecA-like domain is implicated in
ATP binding and hydrolysis. RNA binding requires residues from both N- and C-terminal
domains. This implies that the RNA binding surface can be rearranged according to the
orientations of the two domains. A cycle of conformational changes has been proposed for
Dhh1p function. ATP binding and hydrolysis would induce conformational changes that could
alter RNA binding, ATP hydrolysis leading to the release of RNA [103, 104]. The structure
of the C-terminal RecA-like domain of human Rck, bound to the FDF peptide of Edc3, was
solved by Tritschler et al. [105]. Mutational analysis of the Drosophila protein showed that
Edc3 interaction is important both for translational suppression and P-body localization
of Me31B. The C-terminal RecA-like domain of Xp54 was also shown to be sufficient for
inhibition of translation of tethered mRNAs. The same domain mediates P-body localization
of the human protein, but conserved residues essential for the proposed helicase activity are
also required [106].
Biochemical characterization of Dhh1p revealed low ATPase activity and no detectable
dsRNA unwinding activity [104]. Although low, the ATPase activity is important for in vivo
mRNA destabilization by Dhh1p. One possible function of Dhh1p might be the transport
of bound mRNAs into P-bodies for translational suppression and decay. Stimulation of the
ATPase activity by P-body proteins would then cause the release of mRNA in P-bodies and
recycling of Dhh1p from P-bodies [104]. Therefore, it has been suggested that the C-terminal
RecA-like domain of Rck mediates the interactions of the protein and that the ATPase (and
the potential helicase) activity mediates RNP remodeling [106]. Supporting this idea, the
C-terminal part, including the RecA-like domain, of Drosophila Me31B was shown to interact
with Lsm1, Edc3 and HPat (Pat1p Drosophila homolog) [107].
Chu and Rana [108] showed that human Rck forms a complex with Ago2, an important
component of RNAi-mediated gene silencing. The Ago2-Rck interaction does not depend on
RNA, and Rck mediates the localization of Ago2 to P-bodies. In addition, Rck was needed
to suppress both general and miRNA-mediated translation. Nevertheless, knockdown of Rck
did not affect siRNA-mediated gene silencing. Thus, the authors suggested that miRNAs use
the general translation suppression property of Rck and recruit the protein to target mRNAs
[108].
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The Lsm1-7 complex Lsm1p was identified by Boeck et al. [109] as a protein, which when
mutated caused accumulation of capped but deadenylated mRNAs. The first hints that the
Lsm proteins form heptameric complex(es) came from interaction analysis using Lsm proteins
as baits. Fromont-Racine et al. [110] detected several interactions among the Lsm proteins
in Y2H screens. In addition, association of Lsm1p with Lsm proteins 2p to 7p were seen by
co-immunoprecipitation assays [111, 112]. Importantly, the yeast Lsm proteins 1p to 7p form
a complex that is functionally distinct from Lsm2p-8p, which associates with and stabilizes
U6 small nuclear RNA (snRNA). Mutations in the yeast Lsm proteins 1p, 2p, 5p, 6p and 7p
lead to slower decay rates of reporter mRNAs, with increased levels of full length mRNAs
and decreased levels of decay intermediates [109, 111, 112, 113]. In contrast, mutations in
Lsm8p did not affect the decay rates of the same reporter mRNAs. In fact, Lsm1p and Lsm8p
seem to compete with each other for complex formation with the Lsm 2p-7p proteins [114].
The defect in mRNA decay in Lsm mutants is less pronounced than that in dcp1∆ or dcp2∆
strains, as is the case for many decapping enhancer proteins [112]. Moreover, Lsm proteins
1p-7p, but not Lsm8p, interact with Dcp1p/Dcp2p and Xrn1p in Y2Hs and in pull-down
assays [109, 112, 110, 111]. Therefore, the Lsm1p-7p complex represents yet another decapping
enhancer.
The Lsm1p-7p complex associates with mRNAs that are targeted for degradation. Several
lines of evidence support this idea. First, the Lsm1p-7p associated mRNAs are deadenylated
but still capped [109, 112, 63]. Second, 5’ to 3’ degradation products are enriched in Lsm1p
pull-downs, also indicating that the Lsm1p-7p complex remains on the 3’ UTR of the RNA
during degradation. Third, interaction of Lsm1p with Dcp2p depends on RNA. While Lsm1p-
7p binding to RNA does not require either the decapping complex or Pat1p, the Lsm1p-7p
complex does increase the affinity of the decapping complex for mRNA substrates [112, 63].
Still, Lsm1p-7p and Pat1p are likely to work together in mRNA degradation as the double
deletion of both genes gives a similar results to the single deletion strains, with respect to
mRNA degradation [101].
The Lsm1p-7p complex-Pat1p interaction was reported several times by Y2H, by in vivo
and by in vitro co-immunoprecipitation assays [109, 115, 112, 110, 111]. Therefore it has been
suggested that Lsm1p-7p proteins form a tight complex with Pat1p, and exert their effect(s)
on mRNA degradation as a complex. The Lsm1p-7p/Pat1p complex was suggested to bind
the 3’ end of mRNAs with short polyA tails and protect the mRNA from further trimming
[109, 116]. Heptameric rings formed by Sm or Lsm proteins are known to bind RNA 3’ ends,
with preference for oligoA or oligoU stretches. Reporter mRNAs that are shorter than the
fully deadenylated species were observed in an lsm1∆ strain [109]. Further analysis showed
that the same mRNA species accumulate also in a pat1∆ strain [116]. Interestingly, trimming
of mRNA 3’ ends was not detected in strains with DCP1 deletion. This implies that trimming
is not a cause of defective decapping, which is also observed in lsm1∆ or pat1∆ strains [116].
In addition, the Lsm1-7 complex was found to bind the unusual 5’ polyA sequence in poxvirus
mRNA, which is capped and polyadenylated, and to stabilize the mRNA [117]. Thus, it is
tempting to speculate that the Lsm1-7/Pat1 complex binds to the remaining 3’ oligoA tail
after deadenylation and prevents its degradation from the 3’ end while stimulating decapping
and 5’ to 3’ decay.
Formation of a mammalian complex similar to yeast Lsm1p-7p was confirmed by Ingelfinger
et al. [118]. Interestingly, Lsm1-7 proteins were found to co-localize with the decapping
proteins Dcp1/Dcp2 in P-bodies in the cytoplasm. The yeast Lsm1p-7p complex also localizes
to cytoplasmic P-bodies, unlike the Lsm2p-8p complex which localizes to the nucleus [114].
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As an exception among the Lsm proteins, Lsm4p contains an additional glutamine/asparagine
(Q/N)-rich prion like domain. This aggregation-prone domain was suggested to participate
actively in P-body formation, especially in the absence of Edc3p [90].
Scd6 Genetic interaction between SCD6 (also termed Lsm14, Rap55, TraI, or CAR-1) and
EDC3 indicated a role for Scd6p in mRNA degradation. In agreement with this, Scd6p was
found to interact with Edc3p, Dcp1p, Dcp2p and Dhh1p in Y2H screens. Although single
deletion of SCD6 does not affect mRNA decay, double deletion of SCD6 and EDC3 blocked
5’ to 3’ degradation of deadenylated mRNAs [93]. These results suggest redundancy between
Scd6p and Edc3p. Recombinant Scd6p was also shown to interact with Dcp2p but not with
Dcp1p [92]. However, recombinant Scd6p failed to stimulate Dcp1p/Dcp2p activity in vitro.
Nissan et al. [92] showed that Scd6p represses translation initiation by interfering with 48S
translation initiation complex formation, regardless of the cap structure on the mRNA. Thus,
Scd6p is likely to enhance decapping activity by increasing the availability of substrate mRNAs
for the decapping enzyme, similar to the activity of Dhh1p.
1.3.3 Nudt16, an Alternative to Mammalian Dcp2?
It came as a surprise that Dcp2 is not uniformly expressed, even being absent in some mouse
tissues, when Jiao et al. [119] analyzed the distribution of Dcp2. This was true both for
protein and mRNA levels. In addition, only modest effects were seen on mRNA half lives
upon disruption of Dcp2 gene expression in mouse embryonic fibroblasts. These data strongly
imply the presence of a second cytoplasmic decapping enzyme. Nudt16 was known to decap
the U8 small nucleolar RNA (snoRNA) in Xenopus. Although this protein is nucleolar in
Xenopus, it represents a potential candidate. Indeed, Jiao et al. [119] showed that Nudt16 is
a cytoplasmic protein, with small amounts detectable in the nuclear fraction of mammalian
cells. Moreover, Nudt16 is expressed in all mouse tissues tested. Recombinant Nudt16 possess
in vitro decapping activity, and its knockdown stabilized some of the tested mRNAs [119].
The existence of two cytoplasmic decapping proteins raises the question which one is more
important in mRNA decay. A recent analysis by Li et al. [120] using single or double knockdown
of Dcp2 and Nudt16 shed light on this question. Dcp2 appears to be the enzyme utilized in
NMD as its absence stabilizes reporter mRNAs containing premature termination codon (PTC),
while there is no effect of Nudt16 knockdown. miRNA-mediated gene silencing uses both
enzymes, making them redundant for this decay pathway. Utilization of the decapping enzymes
in ARE-mediated mRNA decay is transcript-specific. Some mRNAs containing AREs are
effected by the loss of Dcp2, others by the loss of Nudt16, while for some Dcp2 and Nudt16
appear to be redundant [120].
1.4 Processing Bodies
P-bodies are cytoplasmic foci where proteins involved in deadenylation and 5’ to 3’ mRNA
degradation are enriched. They are small, spherical structures, 100-300 nm in diameter in
mammalian cells [121]. Although mammalian cells possess only few P-bodies per cell at
resting state, their number and size increase under stress conditions. P-bodies in S. cerevisiae
are hardly visible unless the cells are stressed, or expression of certain P-body components
is modified. P-bodies do not contain ribosomal proteins or translation factors, with the
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exception of eIF4E, indicating the presence of non-translating mRNPs only. Translationally
suppressed mRNAs can also return from P-bodies to polysomes when translation is activated
[122]. Nevertheless, there are several lines of evidence suggesting that P-bodies have an active
role in mRNA degradation rather than being solely storage sites for translationally silenced
mRNPs. First, all proteins that function in 5’ to 3’ decay co-localize to P-bodies, including
the deadenylase Ccr4-NOT complex, the decapping complex Dcp1/Dcp2, the exonuclease
Xrn1, and the decapping enhancers Lsm1-7, Rck, Edc3, Pat1 and Hedls [118, 13, 123, 124, 27]
(refer to Kulkarni et al. [125] for a broader list of proteins localized to P-bodies). Second,
Sheth and Parker [126] were able to demonstrate the presence of 5’ to 3’ decay intermediates
in yeast P-bodies. Moreover, depletion of Dcp2 or Xrn1 causes the accumulation of mRNAs
in P-bodies, while Dcp2 overexpression leads to their loss. It was also shown that trapping
mRNAs in polysomes, which inhibits mRNA decay, abolishes P-bodies.
In addition, components of several cytoplasmic pathways that repress gene expression,
either via translational inhibition or mRNA degradation, are present in P-bodies. Initial
recognition of the substrate mRNAs is thought to occur diffusely in the cytoplasm. At later
steps of regulation, the mRNA substrates and the associated regulatory proteins of NMD,
RNAi-mediated gene silencing, and AMD are recruited to P-bodies [20, 123]. For example,
the P-body protein GW182 is required for miRNA-mediated mRNA degradation and helps
to recruit Ago proteins and the mRNA targets to P-bodies [20]. Nonetheless, inhibition of
visible P-body assembly by depleting Lsm1 or Rck leads to a diffuse localization of Ago2 in
the cytoplasm, but does not abolish RNAi-mediated gene silencing [108]. This observation
points to the possibility that P-bodies are a consequence rather than a cause of the RNAi
mechanism [108, 127]. P-bodies also accommodate both protein factors and mRNA targets of
AMD [13, 128]. As in the case of RNAi-mediated mRNA degradation, visible P-bodies are
not required for AMD to take place, indicating that the 5’ to 3’ degradation machinery is
also active outside the P-bodies. In fact, Franks and Lykke-Andersen [128] demonstrated that
TTP and BRF1 can nucleate P-bodies in HeLa cells when the decay machinery is limiting.
In this case, P-bodies seem to accumulate the translationally arrested mRNPs. This result
further supports the idea that P-bodies become visible when large amounts of mRNA are
translationally stalled or targeted for decay, as is the case in dcp1∆ or xrn1∆ strains [90].
Even if visible P-bodies are not essential, they may still provide an optimal environment for
regulation to take place [90].
P-bodies are dynamic structures that continuously exchange their protein and mRNA
components with the cytoplasm [129]. Moreover, P-bodies are found to be very motile
structures by real-time fluorescence imaging [129, 130]. Kedersha et al. [129] showed that the
motile P-bodies frequently touch stress granules (SG), suggesting that there is an exchange
of factors between two structures. This observation further supports the hypothesis that
SG are sites of mRNA triage from where mRNAs can be routed to P-bodies for degradation
[59, 90, 121, 131, 58].
A step-wise model for P-body assembly has been suggested based on interaction data and
the careful observation of P-body assembly in S. cerevisiae. According to this model, the first
step is the formation of a repressed mRNP by the recruitment of the Dcp1p, Dcp2p, Edc3p
and Dhh1p decapping complex on the target mRNA after deadenylation. In the next step, the
decapping coactivators Pat1p and Lsm1p-7p, possibly together with Xrn1p, are supposed to
join the mRNP. Lastly, microscopically visible P-bodies form when many mRNP complexes
aggregate via the self-interacting YjeF-N domain of Edc3p and/or the prion-like C-terminal
domain of Lsm4p [124, 90, 91]. In fact, most of the P-body proteins contain aggregation-prone
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regions, suggesting that self- or co-aggregation is a general mechanism driving P-body assembly
[125].
1.5 Pat1
Pat1 was first identified in Xenopus oocytes [132], where the regulation of stage-dependent
protein expression is mainly post-transcriptional. This makes Pat1 (named as P100 in the
original paper) a good candidate for such a regulatory protein in the cell. In a genetic screen
in S. cerevisiae, two genes named MRT1 and MRT3 (mRNA turnover (MRT)) were found
to have a role in the turnover of unstable mRNAs and to be required for efficient decapping
[133, 134]. Mutations in these genes suppress the lethality of PABP deletion by slowing down
the rate of deadenylation-dependent decapping in this strain [133]. Further analysis in S.
cerevisiae by Tharun et al. [112] revealed that MRT1 and PAT1 are the same gene, and that
it interacts with Lsm1p-7p. Pat1p was initially identified as a topoisomerase II interacting
protein, and its deletion was found to slow the growth rate of yeast [135]. Finding that
the Lsm1p-7p complex also interacts with Dcp1p, Dcp2p and Xrn1p in addition to Pat1p
strengthened the idea that Pat1p plays a role in mRNA turnover [112]. Bonnerot et al. [115]
found that the Pat1p-Lsm1p interaction is RNA-independent, and observed the association of
both proteins with free mRNPs, monosomes and polysomes in polysome profiles. Interestingly,
the interaction of Lsm1p with polysomes was dependent on Pat1p. In addition, the authors
also detected that the short lived MFA2 transcript is stabilized in a pat1∆ strain. The
stabilized MFA2 mRNA accumulated as full length mRNA without any decay intermediates
visible [115]. Moreover, mRNAs trimmed at the 3’ end were detected in both pat1∆ and
lsm1∆ strains [109, 116]. This suggests that Lsm1p-7p and Pat1p, likely as a complex, protect
the 3’ end of deadenylated mRNAs from endo- or exoribonucleases. These studies indicated
that yeast Pat1p is an enhancer of decapping and acts after deadenylation [115].
In yeast, the translation initiation factors eIF4Ep, eIF4Gp, and PABPp bind Pat1p in
an RNA-dependent manner. It is interesting that Lsm1p, as a marker of the Lsm1p-7p
complex, does not co-immunoprecipitate with these proteins, and appears to interact only
with deadenylated mRNAs. In contrast, Pat1p was found to bind to polyA+ mRNAs, which
places Pat1p before Lsm1p in the sequence of mRNP rearrangements that lead to mRNA
degradation. Nevertheless, the Lsm1p-7p complex does not require Pat1p for its recruitment
to mRNA since its interaction with mRNA still occurs in a pat1∆ strain. On the other hand,
the efficiency of Lsm1p-Dcp2p co-immunoprecipitation was significantly reduced in pat1∆
cells. Moreover, the interaction of Dcp2p with mRNA was decreased several fold in pat1∆
and lsm1∆ strains, supporting the idea that the Lsm1p-7p/Pat1p complex is an enhancer
of decapping [63]. In line with this idea, stabilization of the full length reporter mRNA was
observed both in pat1∆ and lsm1∆ strains. Sheth and Parker [126] reported that Pat1p
localizes in P-bodies, and that P-bodies are smaller in a pat1∆ strain [112]. In contrast, the
number of P-bodies was increased in an lsm1∆ strain. This observation is consistent with the
differential association of Pat1p and Lsm1p with translation initiation factors, and strengthens
the argument that Pat1p and Lsm1p-7p activate decapping via different mechanisms [126].
Inhibition of translation is another function that is attributed to Pat1. Although recent
data provides solid evidence that Pat1p suppresses translational, earlier studies claimed that
Pat1p enhances translation. Wyers et al. [136] suggested that Pat1p enhances translation
initiation, before or during the recruitment of the 43S pre-initiation complex. A study by
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Noueiry et al. [137] supports this hypothesis by showing that translation of the brome mosaic
virus genomic RNA requires the Lsm1p-7p/Pat1p complex in yeast. Surprisingly, Noueiry
et al. [137] failed to see an effect of PAT1 deletion on polysome profiles, while there was a
clear change in the data from Wyers et al. [136]. So far, these reports have not been confirmed
by other studies. In a later study, Coller and Parker [101] demonstrated that Pat1p and the
helicase Dhh1p function actively as a general repressors of translation. They also show that
Pat1p and Dhh1p act independently of the cap structure and, probably, independently of
each other. As a result of this repressive mechanism, mRNPs are sorted into P-bodies and are
eventually decapped. It was also suggested that Pat1p/Dhh1p compete with the translation
apparatus under normal conditions, and the equilibrium may be shifted towards suppression
of translation under certain conditions like glucose deprivation or amino acid starvation. In
support of Pat1p being a translational repressor, its overexpression was observed to inhibit
growth, decrease polysomes, and cause an accumulation of P-bodies [101].
Teixeira and Parker [124] provided important clues as to the functions of several proteins in
P-body assembly in S. cerevisiae. They reported that the recruitment of Dcp1p and Lsm1p
to P-bodies is dependent on Dcp2p and Pat1p, respectively. Interestingly, a pat1∆ strain
showed reduced numbers of P-bodies, even during glucose deprivation, although repression of
translation was not diminished. This observation suggests that Pat1p plays a role in the early
steps of P-body assembly. Furthermore, the authors proposed that the previously observed
decapping enhancer effect of Pat1p can be explained by the fact that the Lsm1p-7p complex
depends on Pat1p in order to be recruited to P-bodies. Pat1p was claimed to have a scaffolding
role which allows Xrn1p to interact with the Lsm1-7p complex. The Lsm1-7p complex may
function later in P-body assembly, since deletion of its subunits results in accumulation of
mRNPs in larger P-bodies. Another interesting observation was that Pat1p shuttles between
the nucleus and the cytoplasm, and that Lsm1p may regulate nuclear-cytoplasmic localization
of Pat1p [124].
Deletion studies suggested that yeast Pat1p has two distinct domains with separate roles.
The C-terminal half of the protein was shown to mediate repression of translation and
localization of Pat1p in P-bodies. This domain was also required for recruiting Lsm1p and
Dcp2p to P-bodies. This finding is not easy to explain since it is not the C-terminal domain
(aa 422 to 763), but a central domain (aa 254 to 422), that interacts with Lsm1p in a Y2H
assay. Deletion of the central domain causes a defect in mRNA decapping as strong as deletion
of the entire coding region of Pat1p. Pat1 is thought to promote decapping by rearrangement
of mRNPs in P-bodies, generating mRNPs that are more susceptible to decapping. Although
Pat1p does not have any recognizable RNA-binding domains, the authors clearly show that
recombinant Pat1p binds RNA in vitro, with a preference for polyU [88].
For a long time it was thought that there is no homolog of yeast Pat1 in mammals since
database searches did not reveal any sequences with significant homology. Through more
careful analysis, however, we were able to identify two human complementary DNAs (cDNAs)
with a limited homology to yeast Pat1p [138]. In parallel, Scheller et al. [139] identified the
same proteins as human homologs of Pat1p. They showed that one of the Pat1p homologs,
which they name PatL1, co-localize with Lsm1, Rck and Dcp1 in P-bodies. They further
reported that P-body numbers decrease when HeLa cells were treated with an siRNA against
PatL1 [139].
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1.6 Aim of the Study
The goal of my PhD project was to characterize the newly identified human homologs of the
yeast protein Pat1p, Pat1a and Pat1b, with respect to their localization, interactions and
functions in cytoplasmic mRNA decay. During my Master’s studies, I showed that Pat1b
localizes to P-bodies and interacts with several P-body proteins. In my PhD thesis, I wanted
to include the second human homolog, Pat1a, in the analysis, and compare it to Pat1b. Since
no domains have yet been attributed to Pat1b, I focused on describing the role of individual
domains in determining the localization, interactions and functions of Pat1b.
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2.1 Previous Work on Pat1b
During my Master’s studies, I started working on the characterization of human homolog of
yeast Pat1p, Pat1b. According to careful basic local alignment search tool (BLAST) searches
made by Georg Stoecklin, there are two homologs of Pat1 in mammals, named Pat1a and
Pat1b. We were kindly provided with the cDNA clone (accession number: DKFZp451I053) by
Stefan Wiemann, DKFZ Heidelberg . By that time there was no cDNA available for Pat1a,
and cloning proved difficult. Consequently, I began working on Pat1b.
In summary, during my Master’s thesis I was able to achieve the following results:
(1) I cloned the Pat1b cDNA from the original pdEYFP-N1gen vector into pcDNA3-HA and
pcDNA3-YFP vectors (N-terminal Hemagglutinin (HA) or yellow fluorescent protein (YFP)
tags, respectively). In addition, 6 deletion constructs of Pat1b were also cloned in the
pcDNA3-HA vector. The deletion constructs include the N-terminal part of Pat1p until
the homology region (AN, aa 1-388), the centrally located homology region (H, aa 389-348),
the C-terminal part of Pat1b (C, aa 449-770) and combinations of these (see Figure 2.1 for
schematic representation of Pat1b domains).
(2) I showed that HA-Pat1b localizes to P-bodies in several mammalian cell lines. To mark
P-bodies, I did immunofluorescence (IF) staining against several proteins that are known to be
present in P-bodies. Pat1b showed co-localization with endogenous Hedls, Xrn1, Rck, Lsm1,
Upf1, and exogenously expressed RFP-Dcp1a.
(3) Localization studies of Pat1b fragments gave three main results. The HA-tagged full
length protein and Pat1b-dH (homology domain deletion) localized to P-bodies and increased
the number of P-bodies per cell. This implies, first, that although it is highly conserved, the
homology domain is not required for P-body localization, and second, that Pat1b is able to
stimulate P-body formation. Individual domains of Pat1b did not show P-body localization,
suggesting N- and C-terminal parts of the protein are needed for P-body localization of Pat1b.
(4) Interaction studies with overexpressed HA-Pat1b demonstrated that Pat1b interacts with
endogenous Xrn1, Hedls, Rck and Lsm1, but not with eIF3 or eIF4G. Having a C-terminal
YFP tag did not did not change these results. In addition, I was able to confirm these
interactions by pulling on the interacting partner, i.e. immunoprecipitation of endogenous
Xrn1, Hedls, and Rck also brought down HA-Pat1b. Moreover, Pat1b-AN was necessary and
sufficient for the Rck interaction, while the C-terminus mediated the interactions with the
other proteins. I tested the RNA dependency of these interactions and showed that they are
all resistant to RNAse A treatment.
In conclusion, the data of my Master’s thesis confirmed that Pat1b is the human homolog of
yeast Pat1p, and suggested that it may behave as a scaffolding protein that assembles P-body
proteins, and hence, helps in the formation of P-bodies [138].
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2.2 Pat1b, but not Pat1a, Is a P-body Protein
As mentioned above, there appear to be two homologs of yeast Pat1p in mammals. We
termed the human proteins Pat1a and Pat1b, PatL2 and PatL1 according to the nomenclature
suggested by Scheller et al. [139]. The sequence that we identified as Pat1a differs from PatL2
at the N-terminus, Pat1a having an extension compared to PatL2. Pat1a and Pat1b share
25.2% identity and 37.9% similarity in the amino acid level. In addition, Pat1a and Pat1b
share high homology in the homology domain (H, 56.2% identity and 67.2% similarity) and in
the C-terminal domain (C, 32.8% identity and 54.0% similarity) (Figure 2.1). Scheller et al.
[139] failed to detect the PatL2 mRNA on northern blots and concluded that the protein may
have a tissue- or development-specific expression pattern. Consequently, they excluded PatL2
from their analysis. I started my analysis by comparing the localization and interactions of
Pat1a and Pat1b.
Figure 2.1. Schematic representation of Pat1b domains, and amino acid sequence conservation
between Pat1b and Pat1a. A, acidic domain; N, N-terminal aggregation-prone domain; H, homology
domain; C, C-terminal domain. Identity and similarity scores between the full length Pat1a and Pat1b,
as well as between the corresponding domains are indicated (calculated with the Ebi, EMBOSS Needle
pairwise alignment tool). Note that the region of Pat1a corresponding to Pat1b-N is not enriched in
aggregation-prone residues, therefore it is depicted as (N).
2.2.1 Cloning of Pat1a
Oksana Seibert and Jochen Kreth in Georg Stoecklin’s lab cloned the coding region of human
Pat1a using cDNA from HeLa cells. The coding region was subdivided into three parts
for polymerase chain reaction (PCR) amplification. After PCR, the fragments were ligated
together and cloned into pEYFP and pcDNA3-HA vectors, keeping the tags N-terminal. Please
refer to Section 4.2.1 for further details of cloning. It is worth noting that we failed to get PCR
products using cDNA generated from several cell lines. This may be due to low expression
level of Pat1a in these cells lines.
2.2.2 Comparison of Pat1a and Pat1b Localization
Since Pat1a was identified as a homolog of yeast Pat1p, which localizes to P-bodies, and Pat1b
is also known as a P-body protein, I wanted to check the localization of human Pat1a in
mammalian cells. For this purpose, I transfected COS7, HeLa or U2OS cells (see Section 4.2.2
for definitions of cell lines) with YFP-Pat1a. I fixed the cells 24 hrs after transfection,
immunostained P-bodies with an antibody against Hedls, and analyzed the localization of
YFP-Pat1a with regard to Hedls. As can be seen in Figure 2.2, in contrast to the punctate
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localization of YFP-Pat1b in P-bodies, YFP-Pat1a has a diffuse cytoplasmic localization.
Figure 2.2 depicts the localization of YFP-tagged proteins in COS7 cells, as an example.
Quantification of P-bodies per cell in transfected cells is given in Figure 2.2-D. Overexpression
of the YFP tag alone does not influence the number of P-bodies per cell. A slight decrease
in P-body numbers is observed in YFP-Pat1a transfected cells. In contrast, YFP-Pat1b
overexpression strongly increases the number of P-bodies per cell.
Figure 2.2. Localization of (A) YFP, (B) YFP-Pat1a and (C) YFP-Pat1b in COS7 cells. Cells
were transfected with plasmids coding for the indicated YFP-tagged proteins, and fixed 24 hrs post-
transfection. Endogenous Hedls was co-stained to mark P-bodies. (D) Number of P-bodies in transfected
cells was counted, and the average distribution is presented in the graph. Error bars show standard
deviations (SD) based on three independent experiments. Quantification of P-bodies in untransfected
cells is shown as a control. Green: YFP-tagged proteins, Red: Hedls, Blue: Hoechst 33342.
2.2.3 Comparison of Pat1a and Pat1b Interactions
Next, I wanted to compare the interactions of Pata to that of Pat1b, and check whether
Pat1a also interacts with proteins known to localize to P-bodies. To this end, I transfected
HEK293 cells with pcDNA3-HA-Pat1a and collected the cells 24 hrs after transfection. An
antibody against the HA tag was used for immunoprecipitation (IP) of the interacting protein
complexes. After resolving the input and IP samples by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE), western blot (WB) analysis was used to detect the HA-tagged
proteins and potential endogenous interaction partners. The HA tag alone was used as a
negative control. Figure 2.3 represents such an analysis and shows that HA-Pat1a interacts
with Lsm1, and very weakly with Lsm4 and Xrn1. Therefore, Pat1a is likely to bind to “free”
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Lsm1 that is not associated with the other Lsm proteins or Xrn1. Sequestration of Lsm1 from
the Lsm1-7 complex by the overexpressed Pat1a may be the reason for the small decrease
in P-body numbers observed in YFP-Pat1a transfected cells. In comparison to HA-Pat1a,
HA-Pat1b interacts with Rck, Hedls, Xrn1, Lsm1 and Lsm4. WB shows that eIF3B does not
interact with either Pat1a or Pat1b. Thus, the interactions observed are specific. As a result
of the localization and interaction studies, I concluded that Pat1a is not a P-body protein.
Figure 2.3. Interactions of
Pat1a. HEK293 cells transiently
transfected with HA, HA-Pat1b
or HA-Pat1a were lysed 24 hrs
after transfection and used for
IP with anti-HA antibody. WBs
against HA, Rck, Hedls, Xrn1,
Lsm1, Lsm4 and eIF3B are de-
picted.
2.3 Role of Pat1b in P-body Assembly
Pat1b is a P-body protein. Its deletion in yeast S. cerevisiae leads to smaller P-bodies in
glucose deprivation [124], implying the requirement of Pat1 for proper P-body assembly. In
mammalian cell culture, overexpression of Pat1b leads to an increased number of P-bodies per
cell (see Figure 2.2-D for quantification). These findings suggest an active role for Pat1b in
P-body formation. Therefore, I conducted experiments to test this hypothesis.
2.3.1 Pat1b Is Essential for P-body Formation
First, I wanted to test if Pat1b is required for P-body assembly. To answer this question, I
employed a knockdown strategy. If Pat1b is required for P-body formation, its knockdown
should negatively affect P-body formation. Since my aim was to characterize the human
protein, I switched to human osteosarcoma (U2OS) cells in this experiment.
To knockdown Pat1b, I used two siRNAs directed against the coding region, siRNAs T2 and
T3. As controls, I transfected H2O or the unspecific siRNA D0. U2OS cells were transfected
twice with 100 nM final concentration of siRNAs over 5 days. RNA was isolated from the
transfected cells to check the knockdown efficiency. Pat1b mRNA levels were analyzed by
quantitative real time PCR (qPCR), and were found to be reduced to 5% and 6% in T2
and T3 transfected cells, respectively, compared to the mRNA levels in D0 transfected cells
(Figure 2.4-A). After confirming the knockdown levels, I repeated the transfection and prepared
the cells for IF. Cells were stained with an anti-Hedls antibody to detect endogenous Hedls as
a marker of P-bodies. Figure 2.4-B depicts examples of cells after H2O or siRNA transfection,
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Figure 2.4. Pat1b is an essential P-body protein. U2OS cells were transfected with H2O, control
siRNA (D0) or with two different siRNAs against Pat1b (T2 and T3). (A) Endogenous Pat1b mRNA
levels were quantified by qPCR and normalized to nucleolin (Ncl) mRNA levels. Value in D0 transfected
cells was taken as 100%. (B) IF staining of U2OS cells after transfection with indicated siRNAs.
P-bodies are visualized as bright foci in the cytoplasm after immunostaining against endogenous Hedls.
Yellow arrows point towards individual P-bodies. (C) Quantification of P-bodies per cell. Error bars
show standard deviations (SD) based on three independent experiments.
showing that the number of cells with P-bodies dropped considerably in cells transfected with
siRNAs targeting Pat1b. I also quantified this effect by counting the P-body numbers per
cell in control or si-Pat1b transfected cells. Quantification shows that the percentage of cells
lacking P-bodies increased from ∼55% in water or control siRNA transfected cells to ∼90% in
si-Pat1b transfected cells (Figure 2.4-C). Hence, I concluded that Pat1b is essential for P-body
formation.
2.3.2 Localization of Pat1b Deletion Constructs
Knowing that Pat1b overexpression increases P-body numbers, and that endogenous Pat1b is
required for P-body formation, the next question was whether these functions can be attributed
to any domain(s) of Pat1b. During my Master’s studies, I had examined the localization of
deletion constructs of HA-tagged Pat1b. Those data suggested that the entire protein, except
for the homology domain, is needed for proper P-body localization. Since detection of the HA
tag depends on immunostaining, the signal quality was not always very good. Therefore, I
wanted to readdress this question with YFP-tagged deletion constructs. I subdivided Pat1b
into four domains: (1) A, the acidic domain enriched in acidic residues, aa 1-84; (2) N, the
aggregation-prone domain enriched in glutamine, asparagine and proline residues, aa 85-388,
(3) H, the homology domain, aa 389-448, (4) and C, the C-terminal part, aa 449-770. Figure 2.5
shows a scheme of the Pat1b domains and localization of selected deletion constructs. In
addition to single domains, I also analyzed combinations of these domains.
Once again, I used endogenous Hedls as a P-body marker. Deletion of the homology domain
(Pat1b-dH) does not have an effect on P-body localization of YFP-Pat1b, or its ability to
32
2.3 Role of Pat1b in P-body Assembly
Figure 2.5. Lo-
calization of Pat1b
deletion constructs.
(A) Schematic
representation of
Pat1b domains.
A, acidic domain;
N, amino-terminal
aggregation-prone
domain; H, homology
domain; C, carboxy-
terminal region.
COS7 cells were tran-
siently transfected
with (B) YFP-Pat1b,
(C) YFP-Pat1b-dH,
(D) YFP-Pat1b-dA,
(E) YFP-Pat1b-AN,
(F) YFP-Pat1b-N, or
(G) YFP-Pat1b-HC,
and processed for
immunofluorescence
microscopy. P-bodies
in the cytoplasm were
counterstained in red
using an antibody
against Hedls. Images
were acquired by
spinning-disc confocal
microscopy; maxi-
mum projections of
z-stacks are depicted.
Merged images are
shown on the right;
arrowheads point
toward P-bodies. Size
bar, 10 µm.
33
2 Results
induce P-body numbers per cell. Surprisingly, deletion of the acidic domain (Pat1b-dA) leads
to formation of numerous, yet smaller foci. These YFP-Pat1b-dA induced foci correspond to
proper P-bodies since Hedls and Rck (data not shown) co-localize in these foci. YFP-Pat1b-AN
mostly had cytoplasmic diffuse localization, sometimes with irregular patches in the cytoplasm
(data not shown). Interestingly, YFP-Pat1b-AN formed large, bright and round foci in some of
the transfected cells, as shown in Figure 2.5-E. These foci are probably protein aggregates that
do not correspond to P-bodies since there is no Hedls or Rck (data not shown) detected in most
of them. These foci may be explained by the self-aggregation of the Pat1b-N domain, which
is enriched in aggregation-prone residues (also see paragraph Pat1b interacts with itself). In
line with the suggested self-aggregation ability of the Pat1b-N domain, its overexpression also
leads to formation of aggregates. YFP-Pat1b-N aggregates are smaller than the ones formed
by YFP-Pat1b-AN construct. This observation, together with smaller P-bodies observed
in YFP-Pat1b-dA overexpressing cells, implies that Pat1b-A is important for P-body size.
Nonetheless, YFP-Pat1b-A alone has a diffuse localization with a stronger nuclear signal,
similar to the localization of the YFP tag alone. Lastly, YFP-Pat1b-HC diffusely localizes
both to the cytoplasm and the nucleus, and in some cells it was observed weakly in P-bodies.
As a conclusion of the localization data, I suggest that in the context of full length protein,
Pat1b-N can nucleate P-body formation and Pat1b-A can control the size of P-bodies.
2.3.3 Pat1b Induced P-bodies Are Resistant to Cycloheximide
Next, I wanted to check whether Pat1b induced P-bodies would disappear after cycloheximide
(CHX) treatment. CHX blocks translation elongation and traps mRNAs in polysomes. CHX
treatment was also shown to rapidly inhibit P-body assembly [140], presumably by hindering
P-body compatible mRNP formation. If Pat1b overexpression nucleates P-bodies via its
aggregation capacity, these P-bodies should resist CHX treatment. To test this hypothesis, I
treated the YFP-Pat1b or YFP-Pat1b-AN overexpressing cells with 5 µg/ml CHX for 2 hrs
before fixation. I immunostained the samples with antibodies against the P-body proteins
Hedls, Rck, Xrn1 and Lsm4. Microscopic analyses of the cells treated with CHX showed
clearly that there were almost no P-bodies in untransfected cells, while in transfected cells,
YFP-Pat1b or YFP-Pat1b-AN bodies were not affected. In fact, YFP-Pat1b bodies still
co-localized with Hedls and Rck (also with Xrn1 and Lsm4, data not shown), indicating that
these foci correspond to P-bodies. In YFP-Pat1b-AN bodies, which did not co-localize with
other P-body proteins most of the time anyway, there was no detectable Hedls. Nevertheless,
there was low Rck signal detectable in some YFP-Pat1b-AN bodies. This finding is in line
with the data showing that the A domain of Pat1b interacts with Rck.
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Figure 2.6. Localization of Pat1b in presence of cycloheximide (CHX). COS7 cells were transiently
transfected with (A) YFP-Pat1b or (B) YFP-Pat1b-AN, and treated with 5 µg/ml CHX for 2 hours
prior to fixation. By immunofluorescence microscopy, P-bodies in the cytoplasm were counterstained
using antibodies against Hedls and Rck. Images were acquired by spinning-disc confocal microscopy;
maximum projections of z-stacks are depicted. Merged images are shown on the right; arrowheads
point toward P-bodies. Size bar, 10 µm.
2.4 Interactions of Pat1b
Pat1b is an essential P-body protein (Section 2.3.1) and interacts with the decapping enhancers
Rck, Hedls, Lsm1 and Lsm4, and with the exoribonuclease Xrn1 (see Section 2.2). These
data suggest that Pat1 is involved in the 5’ to 3’ mRNA decay pathway. Therefore, I aimed
to determine potential interactions of Pat1b with the Ccr4-NOT deadenylation and the
Dcp1/Dcp2 decapping complexes. In order to characterize Pat1b further, I also included the
domains of Pat1b in the interaction analyses.
2.4.1 Interactions of Pat1b with Decapping Enhancers
Strength of Pat1b interactions with decapping enhancers and Xrn1 Before analyzing
potential interactions of Pat1b with other P-body proteins, I wanted to gain some information
about the stability of the interactions with the decapping enhancers and Xrn1. Ideally, one
would purify recombinant proteins from bacteria and look for direct associations. Taking the
high number of interaction partners of Pat1b and the problems that occurred during bacterial
expression and purification of Pat1b into consideration, I had to look for an alternative strategy.
Increasing the salt concentrations in the washes of the IP protocol will challenge electrostatic
interactions between the proteins and provide an idea about the strength of the interactions.
Therefore, I repeated the anti-HA IP using HA-Pat1b transfected cells, divided the IP into 4
samples before washing, and used different sodium chloride (NaCl) concentrations in the wash
buffer. Afterwards, I followed the regular protocol for elution with Laemmli buffer, SDS-PAGE
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and WB analysis. Figure 2.7 shows the results of such an IP.
Increasing the salt concentration to 500 mM NaCl did not interfere with the amount of the
HA-Pat1b that is pulled down. Lsm1 appears to be the strongest interactor of Pat1b as the
amount of protein co-purifying with HA-Pat1b was not affected by the high salt concentration.
Interestingly, although assumed to represent the same complex, Lsm1-7, the Lsm4 interaction
is weakened already at 300 mM NaCl. This finding suggests that Lsm1 is likely to be the
direct interacting partner of Pat1b, that links the Lsm1-7 complex to Pat1b. There is also a
significant amount of Rck co-precipitating with Pat1b at 500 mM NaCl, indicating a tight
interaction between Rck and Pat1b. However, it is also possible that Lsm1 and Rck interact
with Pat1b via hydrophobic surfaces that would not be affected by high salt concentrations.
On the other hand, the Pat1b interactions with Hedls, Edc3 and Xrn1 were already lost at
300 mM NaCl. These proteins are possibly interacting with Pat1b through other proteins
making it easier to challenge their association with Pat1b.
Figure 2.7. Salt resistance of
Pat1b interactions. HEK293 cells
were transiently transfected with
HA-Pat1b. After 1 day, cytoplas-
mic lysate (input) was prepared for
IP with anti-HA antibody. Before
washes, the IP samples were divided
equally into 4, and each aliquot was
subjected to washes with indicated
NaCl concentrations. HA-Pat1b, en-
dogenous Rck, Hedls, Edc3, Xrn1,
Lsm1 and Lsm4 were detected by
western blotting. ?, immunoglobu-
lin heavy chain.
Domain analysis of Pat1b interactions with decapping enhancers Next, I wondered if it is
possible to attribute these interactions to Pat1b domains. During my Master’s studies, I had
subdivided the protein into N- and C-terminal parts, taking the N-terminus of the homology
domain (H) as the border (these results are shown in Figure 2.8-B). To complete this analysis,
I repeated the anti-HA IPs including all domains of Pat1b, in HEK293 cells. For the washes, I
used 150 mM NaCl unless otherwise stated.
Figure 2.8-B shows that the interactions of Rck and Lsm1 with Pat1b do not depend on
RNA, as incubation with RNase A did not abolish the interactions. Although in WB shown
in Figure 2.8-B RNase A treatment seems to enhance the interactions of Rck and Lsm1
with Pat1b, this observation was not reproducible. The Hedls and Edc3 interactions may
be strengthened by RNase A treatment, implying the presence of RNA interferes with the
Hedls and Edc3 interactions of Pat1b. On the other hand, the Xrn1 interaction seems to be
negatively affected by RNase A treatment, suggesting that this interaction is supported by
RNA (see Figure S7 in Ozgur et al. [141]). Figure 2.8-B also shows that the Rck interaction is
36
2.4 Interactions of Pat1b
mediated by the AN fragment of Pat1b, while the other decapping enhancers, here exemplified
by Lsm1, associate with the HC fragment. To determine if the A or N domain of Pat1b
is necessary for the Rck interaction, I did the IP with HA-dA, HA-AN, HA-N, and HA-A.
Although HA-A is not detectable on the WB due to its small size, it is necessary and sufficient
to interact with Rck (Figure 2.8-C). In order to find out which domain, H or C, is required for
the Pat1b C-terminal interactions, I repeated a similar IP with HA-dH, HA-HC, HA-C, and
HA-ANH. Because HA-H is not detected on WB due to its small size, I employed HA-ANH
as a control to check if H is sufficient for the Lsm1 interaction. This analysis indicates that
neither H nor C alone is sufficient for the Lsm1 interaction, but both are needed. Unlike Lsm1,
Hedls and Lsm4 interact with Pat1b-C, but these interactions are stronger with Pat1b-HC,
implying that Pat1b-H has a positive effect on the Pat1b-C interactions.
Figure 2.8. Separate interaction domains within Pat1b. (A) Schematic representation of Pat1b
fragments. A, acidic domain; N, amino-terminal region; H, homology domain; C, carboxy-terminal
region. (B-D) HEK293 cells were transiently transfected with vector alone, full-length HA-Pat1b, or
the Pat1b deletion constructs indicated on top of the WB images. After 1 day, cytoplasmic lysates
(input) were prepared for IP with anti-HA antibody. The HA-tagged proteins as well as endogenous
Rck, Lsm1, and eIF3B were detected by western blotting. Where indicated, RNase A (0.1 mg/ml) was
added during IP. ?, immunoglobulin heavy chain. The sizes of the molecular weight markers (in kDa)
are indicated on the right.
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2.4.2 Pat1b Interacts with the Decapping Complex
The above analysis shows that different domains of Pat1b mediate interactions with different
proteins. This implies that Pat1b might work as a scaffolding protein which might connect
decapping enhancers to the decapping complex. Subsequently, I tested the association of
Pat1b with the Dcp1/Dcp2 decapping complex.
At this point I switched to GFP-binder as means of immunoprecipitation since it has been
shown as a powerful tool to pull down GFP- or YFP-tagged proteins [142]. We were kindly
provided with the plasmid encoding 6xHis-GFP-binder protein by Elmar Schibel (ZMBH,
University of Heidelberg). I purified the recombinant protein from E. coli BL21-DE3 Codon
plus cells, and coupled it to the NHS-activated sepharose beads (GE Healthcare).
To determine the interaction of Pat1b with the decapping complex, I overexpressed YFP-
Pat1b together with Flag-Dcp1a or Flag-Dcp2 in HEK293 cells. 24 hrs after transfection
I collected the cells and proceeded with IP protocol for GFP-binder. As can be seen in
Figure 2.9, Pat1b interacts with both Flag-Dcp1a and Flag-Dcp2. These interactions are
resistant to RNase A treatment and 1 M NaCl (Figure 2.9-B). Supporting the suggested
scaffolding function of Pat1b, Flag-Dcp2 (Figure 2.9-C) and Flag-Dcp1a (data not shown)
Figure 2.9. Pat1b interacts with Dcp2 and Dcp1a. (A-B) HEK293 cells were transiently transfected
with YFP, YFP-Pat1b Flag-Dcp2 or Flag-Dcp1a. GFP-binder was used for IP, and western blot
analysis was carried out with anti-GFP and anti-Flag antibodies. The sizes of the molecular weight
markers (in kDa) are indicated on the right. Where indicated, RNase A was added during IP. (B) IPs
were carried out with GFP-binder and subjected to increasing NaCl concentrations prior to elution.
(C) HEK293 cells were transiently transfected with YFP, YFP-Pat1b, YFP-A, YFP-N, YFP-AN, or
YFP-HC together with Flag-Dcp2. IP and WB detection was done as described for (A) and (B).
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come down with both Pat1b-N and HC domains. As observed with the deadenylation complex,
Pat1b-AN interacts with the decapping complex more strongly than Pat1b-N alone, even
though Pat1b-A alone does not show detectable interactions.
2.4.3 Pat1b Interacts with the Ccr4-NOT Deadenylation Complex
The data from yeast Pat1p suggest that Pat1p acts at an early step in mRNA degradation.
Although the yeast data do not indicate a role for Pat1p in mRNA deadenylation, I wanted to
test if Pat1b also interacts with the Ccr4-NOT deadenylation complex, and possibly bridges it
to the decapping proteins.
Since the Ccr4-NOT complex is a multi-subunit complex and not many antibodies against its
components are available, I chose tagged CNOT1, Caf1a, Caf1b and Ccr4 (data not shown) as
Figure 2.10. Pat1b interacts with the Ccr4-NOT complex. (A-C) HEK293 cells were transiently
transfected with YFP or YFP-Pat1b together with the proteins indicated on top of the WB images.
GFP-binder was used for IP, and western blot analysis was carried out with anti-GFP, anti-Flag and
anti-HA antibodies. The sizes of the molecular weight markers (in kDa) are indicated on the right.
Where indicated, RNase A was added during IP. On the right side of panel (B) RNA extracted from
unbound fractions and stained with ethidium bromide is shown. (C) After binding to GFP-binder
samples were divided into 4 equal aliquots and subjected to increasing NaCl concentrations prior
to elution. (D) HEK293 cells were transiently transfected with YFP, YFP-Pat1b, YFP-A, YFP-N,
YFP-AN, or YFP-HC and processed for IP with GFP-binder. The YFP-tagged proteins and endogenous
Caf1a were detected by WB.
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markers of the deadenylation complex. I transiently transfected HEK293 cells with YFP-Pat1b
(or its fragments) together with Flag-CNOT1 or HA-Caf1a or HA-Caf1b and pulled down the
YFP tag using GFP-binder. In order to test the RNA dependency of the interactions, I also
added RNase A during the IP where indicated. Figure 2.10 shows that YFP-Pat1b interacts
with an RNA-independent manner with Flag-NOT1, HA-Caf1a and HA-Caf1b (Figure 2.10-A
and B) and myc-Ccr4 (data not shown). Surprisingly, these interactions (Figure 2.10-C) were
resistant to 1 M NaCl. At this salt concentration Rck falls off Pat1b, and the Lsm1 interaction
is also significantly weakened. Next, I conducted IPs with the Pat1b domains to determine
which domain of Pat1b mediates the interaction of Pat1b with the deadenylation complex
(Figure 2.10-D). The aggregation-prone N domain of Pat1b is sufficient for the interaction
with endogenous Caf1a, yet the acidic domain, A, appears to enhance the interaction. There
is no interaction between endogenous Caf1a and Pat1b-HC. On the other hand, Flag-NOT1
and myc-Ccr4 interact with Pat1b-AN. I did also observe a weak interaction of Pat1b-HC
with Flag-NOT1 and myc-Ccr4 (Figure S9 in Ozgur et al. [141]).
2.4.4 Pat1b Enhances the Interaction between Dcp2 and Caf1a
Since Pat1b interacts both with the deadenylation and the decapping complexes, it is appealing
to speculate that Pat1b can connect these two important steps of mRNA degradation. To
confirm this idea, I examined if Pat1b has an effect on the interaction between the deadenylation
and the decapping complexes. For this purpose, I transfected HEK293 cells with GFP-Caf1
together with Flag-Dcp2. In one of the samples I also included HA-Pat1b in the transfection.
After 24 hrs, I collected the cells and continued with IP using GFP-binder. In the absence
of additional Pat1b overexpression, a faint Flag-Dcp2 band is visible after pull down on
GFP-Caf1a. Interestingly, the Flag-Dcp2 band became much stronger when HA-Pat1b was
also overexpressed in the cells. In conclusion, this experiment indicates that Pat1b binds to
the deadenylation and decapping complexes simultaneously, and may thereby connect the two
complexes (Figure 2.11).
Figure 2.11. Pat1b enhances the interaction
between Dcp2 and Caf1a. HEK293 cells were
transiently transfected with Flag-Dcp2 together
with either GFP alone, GFP-Caf1a alone, or
GFP-Caf1a together with HA-Pat1b. Cytoplas-
mic lysates were processed for IP with GFP-
binder and then subjected to WB analysis. In
the IP samples, the Flag antibody cross-reacted
with GFP-Caf1a.
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2.4.5 Other Interactions of Pat1b
During my PhD studies I have also observed several other interactions of Pat1b. While I
was trying to understand the role of Pat1b in mRNA degradation, I have also considered the
option that Pat1b is involved in mRNA-specific decay pathways like ARE-mediated decay or
RNAi. As a quick way to gain information that would support or disprove this possibility,
I tested whether Pat1b interacts with proteins known to have roles in these mRNA decay
pathways.
Pat1b interacts with proteins involved in ARE-mediated mRNA decay TTP is a well
known RNA-binding protein that mediates fast decay of its target mRNAs containing AREs.
BRF1 belongs to the same family as TTP. Therefore, I chose these two proteins as representers
of protein involved in AMD. Overexpression of YFP-Pat1b and HA-TTP or HA-BRF1,
followed by GFP-binder pull down, revealed an RNA-independent interaction of Pat1b with
TTP and BRF1. Both of the proteins interacted with the aggregation-prone N domain of
Pat1b (Figure 2.12).
Figure 2.12. Pat1b interacts with TTP and
BRF1. HEK293 cells were transiently trans-
fected with YFP or YFP-Pat1b together with
(A) HA-TTP or (B) HA-BRF1. After 24 hrs of
expression, cytoplasmic lysates were processed
for IP with GFP-binder and then subjected
to WB analysis with GFP and HA antibodies.
Where indicated, RNase A was added to the
samples during IP. (C) Schematic summary of
the Pat1b domains that mediate the interactions
with the proteins indicated on the left.
Pat1b interacts with proteins of RNAi pathway RNAi targets mRNAs for translational
suppression or for degradation via RISC, which includes Ago proteins and GW182. In
humans there are three homologs of the Drosophila GW182 protein, and these proteins are
termed TNRC6A, TNRC6B and TNRC6C. Recently, PABP was also indicated in si/miRNA-
mediated gene silencing [143]. Hence, I examined if Pat1b would interact with Ago2, Ago4
(data not shown), TNRC6B, TNRC6C or PABP. To this end, I again employed transient
transfection of HEK293 cells with YFP-Pat1b together with the Flag-tagged versions of the
proteins mentioned. Immunoprecipitation with GFP-binder showed that Pat1b, interacts
with Flag-Ago2, Flag-Ago4, Flag-PABP, and Flag-TNRC6B, independently of RNA, and with
Flag-TNRC6C via RNA. Nevertheless, these IPs were done only once in the presence of RNase
A, and need to be repeated to confirm the RNA dependency of the TNRC6C interaction.
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Domain analysis of these interactions revealed that both Pat1b-N and Pat1b-HC domains
interact with Ago2 and Ago4, while TNRC6 proteins require Pat1b-AN for Pat1b interaction.
PABP can associate with Pat1b via Pat1b-N domain alone (see Figure 2.13).
Figure 2.13. Pat1b interacts with effector proteins of RNAi. (A-C) HEK293 cells were transiently
transfected with YFP or YFP-Pat1b together with the Flag-tagged proteins indicated on the WB
images. Cytoplasmic lysates were processed for IP with GFP-binder and then subjected to WB analysis
with GFP and Flag antibodies. Where indicated RNase A was added to the sampled during IP. (D)
Schematic summary of the Pat1b domains that mediate the interactions with the proteins indicated on
left.
Pat1b interacts with itself Localization data indicates that Pat1b can nucleate P-body
assembly. One possible mechanism for Pat1b to induce P-body formation is self-interaction. I
showed already that Pat1b interacts with many proteins which have roles in different aspects
of mRNA degradation. Hence, Pat1b may act as a scaffolding protein in P-body formation
by interacting with other P-body proteins and putting them closer to each other via self-
interaction. To test this hypothesis, I co-expressed HA-Pat1b together with YFP-Pat1b, and
after pulling down the YFP tag, I looked for HA-Pat1b. Figure 2.14 shows that YFP-Pat1b
brought down HA-Pat1b. Except for YFP-Pat1b-A, all other fragments of YFP-Pat1b were
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able to interact with HA-Pat1b. The strongest interaction was observed between HA-Pat1b
and all YFP-tagged fragments of Pat1b that contain the Pat1b-N domain (data not shown).
Figure 2.14. Pat1b interacts with
itself. HEK293 cells were transiently
transfected with YFP or YFP-Pat1b
together with HA-Pat1b. 24 hrs after
transfection, cytoplasmic lysates were
processed for IP with GFP-binder
and then subjected to WB analysis
with GFP and HA antibodies.
Mass Spectrometry analysis of the Pat1b interactome In order to obtain a more complete
picture of Pat1b interacting proteins, I decided to carry out a mass spectrometry (MS) analysis
of proteins that co-purify with Pat1b. Since the efficiency of GFP-binder pull-down is very
high, I chose to use YFP-Pat1b as bait. I also included YFP-Pat1b-A in the analysis, hoping
to find proteins other than Rck that interact with the acidic domain. I transfected HEK293
cells either with YFP, YFP-Pat1b or YFP-Pat1b-A, using two 15 cm dishes per transfection.
After 24 hrs, I collected the cells and performed the IP with GFP-binder. In order to increase
the specificity of the interacting proteins I washed the beads with 300 mM NaCl prior to
elution. Samples were run into SDS-polyacrylamide gel for only 1-2 cm. The gel was stained
with colloidal coomassie and given to the ZMBH Core Facility for Mass Spectrometry and
Proteomics for analysis. Each sample lane was cut into four pieces, and proteins were identified
by HPLC-MS/MS.
Several proteins were found to be enriched in YFP-Pat1b and/or YFP-Pat1b-A compared
to YFP alone (see Table 5.1 for the complete list of enriched proteins). Many proteins that I
previously found to associate with Pat1b are also included in the list (depicted in italic on
Table 5.1), supporting that the proteins identified by MS are valid. Specifically, I found both
Dcp1a and Dcp2, as well as the decapping enhancers Hedls, Rck, Edc3, and all components of
the Lsm1-7 complex except for Lsm5 in the MS data. In addition, PABP1 and Xrn1 were
also included in the list. Although the Pat1b interactions with the decapping complex and
the decapping enhancers are well represented, only CNOT1 among the Ccr4-NOT complex
components was detected by MS. Other proteins that I could show to interact with Pat1b
when expressed exogenously, like the Argonaute proteins or TTP, were not identified by the
MS analysis either. It is possible that these interactions are enhanced when the proteins are
expressed exogenously in high amounts. On the other hand, the MS data is unlikely to cover
all the interacting partners of Pat1b.
There are a large number of ribosomal proteins (72 including mitochondrial ribosomal
proteins) among the proteins identified to interact with Pat1b. It would be important to
confirm these interactions since ribosomal proteins are known as common contaminants in
MS analysis. Also, it would be important to determine if the ribosomal proteins interact
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Pat1b via mRNA (or RNA in general). There are also several RNA-binding proteins in the
list, including RNA helicases and heterogeneous nuclear ribonucleoproteins (HNRPs). I chose
a few candidates from the list of Pat1b interacting proteins for confirmation via western
blot analysis. Figure 2.15 shows that G3BP1, IMP1 and IMP2 do interact with YFP-Pat1b.
G3BP1 and IMP1 appear to associate with Pat1b via RNA, while the IMP2 interaction is
resistant to RNAse A treatment.
Figure 2.15. Confirmation of novel
Pat1b interacting proteins. HEK293
cells were transiently transfected with
YFP or YFP-Pat1b. 24 hrs after
transfection, cytoplasmic lysates were
processed for IP with GFP-binder.
WB analysis against YFP, endoge-
nous G3BP1, IMP1 and IMP2 was
done with specific antibodies. Where
indicated, RNase A was added to the
samples during IP.
Rck is represented with the highest number of unique peptides in the list of proteins that were
identified to interact with Pat1b-A. There are several HNRPs among the Pat1b-A interacting
proteins. A few examples with high numbers of unique peptides among the Pat1b-A interacting
proteins are RACK1, which localizes to stress granules, Peflin, which is a Ca2+-binding protein,
and CDK2, a Ser/Thr protein kinase required for G1/S transition. It will be important to
validate these interactions before drawing any conclusions.
2.4.6 Summary of Pat1b Interactions
My co-IP analyses showed that Pat1b interacts with the Ccr4-NOT deadenylation complex, the
Dcp1/Dcp2 decapping complex, the decapping enhancers Rck, Hedls, Edc3, Lsm1-7, and the
exoribonuclease Xrn1. In addition, Pat1b interacts with TTP and BRF1, which are involved
in ARE-mediated mRNA decay, and Argonaute and TNRC6 proteins, which are involved in
miRNA-mediated mRNA decay. These interactions are mediated via different domains of
Pat1b. The acidic domain, Pat1b-A, mediates the interaction with Rck, and contributes to
the interaction of Pat1b-N with the deadenylation and decapping complexes. Interestingly, the
decapping and the deadenylation complexes, as well as the Argonuate proteins, interact with
both the N and C domains. Moreover, Pat1b-N mediates the interactions with TTP, BRF1
and PABP, while the AN domain is required for the interaction with TNRC6 proteins. The
C-terminal domain of Pat1b connects Pat1b to the decapping enhancers and Xrn1. Although
no interactions have been attributed to the homology domain, it strengthens the Pat1b-C
interactions. A schematic summary of the Pat1b interactions identified to this point is depicted
in Figure 2.16.
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Figure 2.16. Summary of Pat1b in-
teractions. Grey bars represent the
domains of Pat1b that mediate inter-
actions with the proteins indicated on
the left.
2.5 Function of Pat1b
Localization and interaction data strongly suggest that Pat1b is involved in mRNA turnover.
In addition, yeast Pat1p was found to be a translational suppressor (see Section 1.5). To
address the function of human Pat1b, I first tested if knockdown of the human protein would
have an effect on translational control or mRNA half lives. Moreover, I probed the function of
Pat1b using the tethering assays. The results of these functional assays are summarized below.
2.5.1 Pat1b as a Suppressor of Translation?
I used radioactive labeling to determine the effect of Pat1b knockdown on global translation.
35S (radioactive sulfur isotope) labeled methionine and cysteine added to the growth medium
are utilized by the cells for protein synthesis. Therefore, 35S labeling enables the quantification
of the newly synthesized proteins in the cell. To determine if Pat1b is required for translational
control, I employed 35S labeling after siRNA-directed knockdown of Pat1b, in comparison with
cells transfected with control siRNAs. In yeast, Pat1p and Dhh1p have redundant functions in
suppressing translation under conditions of glucose deprivation. Thus, I also included double
knockdown of Rck together with Pat1b. To achieve the knockdown, cells were transfected
twice with siRNAs over 5 days. On the fifth day, cells were labeled with 35S-Met/Cys for 30
min after they had been starved of methionine and cysteine for 2 hrs in depletion medium.
After lysis, radioactivity incorporated into precipitable proteins was measured by scintillation
counting, and normalized to total protein measured by Bradford assay.
Figure 2.17 shows the knockdown efficiency by qPCR (A) and WB (B), and the results of the
35S labeling after Pat1b and/or Rck knockdown. If Pat1b was a suppressor of translation, one
would expect to see an increase in 35S-Met/Cys incorporation after its knockdown. Although
the knockdown both for Pat1b and Rck worked fairly well, there is no effect on global
translation. I was also not able to detect consistent differences in translation upon Pat1b
and/or Rck knockdown after exposing cells to different stress conditions like glucose deprivation
(data not shown). From these experiments I concluded that Pat1b does not have an effect on
general translation.
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Figure 2.17. Pat1b does not affect general translation. U2OS cells were transfected with control
siRNAs (D0, C2, and U0), or with siRNAs against Pat1b (T2, T3), or with siRNAs against Pat1b (T3)
and Rck (R1) at 50 nM final concentration. (A) Endogenous Pat1b mRNA levels were quantified by
qPCR and normalized to nucleolin (Ncl) mRNA levels. The value in D0 transfected cells was taken
as 100%. (B) Western blot analysis shows the Rck protein levels after siRNA transfection. WBs
against Hedls, Lsm1 and Xrn1 are also shown. WB against 14-3-3 serves as loading control. (C) siRNA
transfected cells were labeled with 35S-Met/Cys for 30 min. Scintillation counts of precipitated total
protein were normalized to total protein levels, shown are arbitrary units.
2.5.2 Pat1b as an Essential Protein in mRNA Degradation?
In order to determine whether Pat1b is required for mRNA degradation, I again used siRNA-
directed Pat1b knockdown. Since there are no known targets of Pat1, I tested reporter mRNAs
with short half lives. These reporters contain either 2 target sites for the miRNA let-7A
(7B-lin41), or the TNFα-ARE sequence (7B-ARE) in the 3’ UTR of a rabbit β-globin minigene.
The reporters were stably transfected in HeLa-Tet-On cells, and their expression can be
induced by addition of Doxycycline (Dox) to the cell culture medium. Cells were transfected
twice either with water, control siRNA (D0) or one of the 4 siRNAs against Pat1b, at 50 nM
final concentration over 5 days. Transcription of the reporters was induced for 16 hrs before
sample collection. Transcription was inhibited by addition of actinomycin D (ActD), and total
RNA was isolated at 0, 1, 2 and 3 hrs after inhibition. Such an ActD chase experiment enables
the estimation of mRNA half lives since, after transcriptional blockage, only the decay rates
determine changes in mRNA levels.
As can be seen in Figure 2.18-A, the 7B-ARE reporter mRNA is stabilized upon knock down
of Pat1b with siRNAs T3 and s37, but not with T2 and s38. With all siRNAs against Pat1b,
endogenous Pat1b mRNA levels were reduced down to approximately 20% (as measured by
qPCR) compared to the levels in D0 transfected cells (data not shown). If the stabilization of
the 7B-ARE reporter mRNA was a result of reduced Pat1b protein levels, it should have been
seen with all 4 siRNAs against Pat1b. Consequently, the stabilization seen with T3 and s37
siRNAs is likely to be due to off-target effects of these siRNAs. No significant change in the
decay of the miRNA target, 7B-lin41 mRNA, was observed upon Pat1b knockdown regardless
of the siRNA used. In conclusion, Pat1b does not seem to be essential for the decay of either
the ARE or the miRNA reporter mRNAs.
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Figure 2.18. Pat1b knockdown does not affect degradation of reporter mRNAs. HeLa-Tet-On cells
were transfected either with water, control siRNA (D0), or with siRNAs against Pat1b (T2, T3, s37,
s38) at 50 nM final concentration. Transcription of miRNA (7B-lin41) and ARE (7B-ARE) reporter
mRNAs was induced by 5 µg/ml doxycycline for 16 hrs before sample collection. Transcription was
blocked by addition of actinomycin D (ActD), and total RNA was isolated at indicated time points.
RNA samples were run in 1.6% agarose gel and northern blotting was done to detect the reporter
mRNAs in addition to the endogenous nucleolin mRNA, which serves as loading control. Where labeled
with "dT", the polyA tail of the reporter mRNAs were digested by RNase H treatment after being
incubated with oligo(dT). (A) miRNA reporter 7B-lin41, (B) ARE reporter 7B-ARE.
2.5.3 Pat1b Tethering Assay
Since no substantial differences were detectable in general translation and selected reporter
mRNA half lives upon knockdown of Pat1b, I decided to change the experimental approach. I
used a tethering assay, whereby bringing Pat1b in close proximity of the reporter mRNA. The
tethering strategy that I used is based on an RNA-protein interaction of the Pseudomonas
aeruginosa bacteriophage PP7 [144]. The PP7 coat protein (cp) binds as a dimer with high
affinity to a stem loop in the bacteriophage RNA, the PP7 binding site (bs). To be able to
measure both protein and mRNA levels of the reporter gene, I cloned firefly luciferase (FL) at
the 5’ end of the rabbit β-globin minigene. In the 3’ UTR of this reporter gene (termed FLB),
I cloned six copies of the PP7bs (FLB-PP7bs). In addition, I introduced the PP7cp between
the HA tag and Pat1b. When the two plasmids are co-expressed in cells, Pat1b will be in
close proximity of the reporter mRNA using this strategy (Figure 2.19-A).
Pat1b tethering suppresses mRNA expression levels First, I wanted to make sure that the
tethering system is working. As the binding of PP7cp to PP7bs is of high affinity, it should be
possible to detect the RNA-protein interaction after IP with antibody against the HA tag
on the HA-PP7cp-Pat1b fusion protein. I transfected HeLa cells with plasmids encoding for
FLB or FLB-PP7 together with HA-PP7cp, HA-PP7cp-Pat1b or HA-Pat1b. 24 hrs after
transfection, I collected the cells and conducted the anti-HA IP. Before elution, I split the
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Figure 2.19. Pat1b tethering reduces mRNA levels. (A) Schematic representation of the FLB-PP7bs
reporter containing firefly luciferase fused to rabbit β-globin mRNA. 6 copies of the PP7 binding
sites (PP7bs) were cloned in the 3’ UTR of the FLB reporter. The PP7 coat protein was fused to
Pat1b C-terminal to the HA tag (HA-PP7cp-Pat1b). (B) HeLa cells were transfected with FLB or
FLB-PP7bs reporter together with either HA-PP7cp, HA-PP7cp-Pat1b, or HA-Pat1b. HA-tagged
proteins were immunoprecipitated with anti-HA antibody. RNA and protein were extracted from
both the input and IP samples, and analyzed by northern (top two panels) and western (bottom)
blotting. A longer exposure of the northern blot against the FLB mRNA is also shown. The sizes
of the molecular weight markers (in kDa) are indicated on the right. ?, immunoglobulin heavy and
light chains. Ribosomal protein S7 (RPS7) mRNA serves as RNA loading control. (C) HeLa cells
were transiently transfected with FLB or FLB-PP7bs reporter together with a Renilla luciferase (RL)
reporter and either HA-PP7cp, HA-PP7cp-Pat1a, HA-PP7cp-Pat1b, or HA-PP7cp fused to fragments
of Pat1b. Cells were collected 24 hrs after transfection. One third of the cells were used for luciferase
assay, and total RNA was isolated from two thirds. FLB mRNA levels were determined by northern
blot analysis, normalized to RPS7 mRNA, and quantified. Average values together with error bars
showing SD from three repeat experiments were plotted in the graph.
beads into 2 samples, and isolated both RNA and protein. Figure 2.19-B shows the results of
such an anti-HA IP. As expected, the reporter mRNA lacking the PP7bs did not co-IP with any
of the proteins. Interestingly, overexpression of HA-PP7cp-Pat1b strongly reduced the mRNA
levels of FLB-PP7bs (lane 5), but not of the FLB (lane 2). As can be seen in Figure 2.19-B
lane 7, HA-PP7cp did in fact bring down FLB-PP7bs mRNA. Although this mRNA should
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also bind HA-PP7cp-Pat1b, there is no FLB-PP7bs mRNA detectable in HA-PP7cp-Pat1b
pull down. This is probably due to the low mRNA levels. HA-Pat1b alone without the PP7cp
did not pull down any FLB-PP7bs mRNA although the protein itself was immunoprecipitated
as efficiently as HA-PP7cp.
Figure 2.19-C represents the normalized protein and mRNA levels after tethering of the
constructs (all HA-tagged) indicated at the bottom of the panel. In this experiment, I also
included Pat1a. Tethering of HA-PP7cp-Pat1a leads to a slight increase in FLB-PP7bs mRNA
levels, although a large error bar makes the significance of this results questionable. On the
other hand, tethering of HA-PP7cp-Pat1b results in a clear suppression of mRNA and protein
levels derived from the FLB-PP7bs reporter. Since the low mRNA levels correlated well with
the low protein levels, I concluded that the primary effect of Pat1b tethering is on mRNA levels.
Tethering of the Pat1b fragments AN, HC, dH and dA indicates that Pat1b-AN is responsible
for the observed mRNA suppression. Pat1b-AN probably exerts its effect independently of the
acidic domain, since its deletion (Pat1b-dA) did not abrogate the ability of Pat1b to suppress
mRNA and protein levels.
Pat1b tethering causes mRNA degradation The observed decrease in mRNA levels upon
tethering of Pat1b can be explained either by an increased mRNA turnover rate or by an
indirect effect on transcription. In order to make sure that the effect of Pat1b tethering is
posttranscriptional, transcriptional pulse-chase experiments were conducted by Jochen Kreth.
In these experiments, a reporter mRNA without the firefly luciferase (7B-PP7bs) was used.
HeLa cells were transfected with 7B-PP7bs together with HA, HA-PP7cp, HA-PP7cp-Pat1b
or HA-Pat1b. 24 hrs after transfection, transcription was inhibited by ActD and RNA was
isolated 0, 1, 2, and 3 hrs following ActD addition. Northern blot analysis of the 7B-PP7bs
mRNA together with that of endogenous nucleolin mRNA, which serves as loading control, is
depicted in Figure 2.20-A. This experiment clearly shows that the low reporter mRNA levels
seen after Pat1b tethering are due to an increased mRNA decay rate. Co-expression of HA,
HA-PP7cp or HA-Pat1b did not affect the stability of the reporter mRNA. Quantification
of mRNA half lives is given in Figure 2.20-C. Careful analysis of the northern blot after
HA-PP7cp-Pat1b tethering enables detection of two bands corresponding to adenylated and
deadenylated mRNA. The adenylated species disappear as early as 1 h after transcriptional
inhibition. To determine the change in polyA tail length more clearly, I quantified the northern
blot signal along the vertical axis for all time points (Figure 2.20-B). This quantification
indicates that Pat1b tethering first induces mRNA deadenylation followed by the decay of
the mRNA body. This finding is in line with the interaction of Pat1b with the Ccr4-NOT
deadenylation complex shown in Section 2.4.3.
2.5.4 Pat1b-Mediated mRNA Decay Utilizes Dcp2 and Caf1a
The finding that Pat1b tethering induces mRNA deadenylation suggests that the interaction
of Pat1b with the Ccr4-NOT deadenylation complex is functionally significant. Keeping in
mind that Pat1b also interacts with the Dcp1/Dcp2 decapping complex, I wanted to analyze
the importance of both these interactions for Pat1b-mediated mRNA decay. For this purpose,
I utilized previously published dominant negative mutants of Caf1a (similar to the mutant
described by Zheng et al. [27]) and Dcp2 [70, 68]. These mutations, Caf1a D40A/E42A
(Caf1a-AA) and Dcp2 E147A/E148A (Dcp2-AA) disturb the metal ion binding of Caf1a
and Dcp2, and, hence, abolish the deadenylation and decapping activities. I repeated the
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Figure 2.20. Pat1b tethering induces mRNA decay. HeLa cells were transiently transfected with a
T7-tagged β-globin reporter containing 6 copies of PP7bs (7B-PP7bs) together with either the HA
tag alone, HA-PP7cp, HA-PP7cp-Pat1b, or HA-Pat1b. Total RNA was extracted at 1 h intervals
after blocking transcription with actinomycin D (5 µg/ml). (A) The reporter mRNA was detected by
northern blot analysis; nucleolin mRNA serves as loading control. (B) Deadenylation was visualized by
quantifying the signal intensity (in arbitrary units, A.U.) of 7B-PP7bs mRNA along the length of the
signal and plotting it as a function of mRNA size. (C) The overall signal intensity of 7B-PP7bs mRNA
was quantified and normalized to that of nucleolin mRNA. Average values were plotted as a percentage
of the initial time point. Error bars indicate standard errors (SE). Experiment repeat numbers used for
quantification are shown in each panel.
tethering assays including overexpression of Caf1a-AA and/or Dcp2-AA, and ran the RNA
samples in high percentage agarose gels to better visualize the polyA tail length (Figure 2.21).
Overexpression of Caf1a-wt slightly enhances the degradation of Pat1b tethered reporter
mRNA (7B-PP7bs). The Caf1a-AA dominant negative mutant inhibits deadenylation (note
the size of the reporter mRNA in Figure 2.21-C), but does not significantly stabilize the
mRNA. This indicates that Pat1b is capable of triggering mRNA decay in the absence of
deadenylation activity, even though it clearly triggers Caf1a-mediated deadenylation. I did not
observe a significant change in the reporter mRNA half life after overexpression of Dcp2-wt.
Dcp2-AA, on the other hand, leads to accumulation of deadenylated mRNA (Figure 2.21-E).
The deadenylated reporter mRNA accumulated even more when Caf1a-wt and Dcp2-AA
were overexpressed at the same time. Thus, Pat1b also utilizes Dcp2-mediated decapping
to trigger the degradation of tethered mRNA. Similar to overexpression of Caf1a-AA alone,
mRNA persists in its adenylated form when Dcp2-wt is co-expressed together with Caf1a-AA.
The Pat1b tethered reporter mRNA was completely stabilized when both deadenylation and
decapping was blocked by overexpression of both Caf1a and Dcp2 dominant negative mutants
(Figure 2.21-H). From these results, I concluded that Pat1b triggers both Caf1a-mediated
deadenylation and Dcp2-mediated decapping of the tethered mRNA, thereby increasing the
degradation rate.
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Figure 2.21. mRNA decay induced by Pat1b tethering utilizes Caf1a and Dcp2. HeLa cells were
transiently transfected with a T7-tagged β-globin reporter containing 6 copies of PP7bs (7B-PP7bs)
together with (A) HA-PP7cp-Pat1b and vector alone, (B) Caf1a-wt, (C) dominant negative Caf1a-AA
(D40A/E42A), (D) Dcp2-wt, (E) dominant negative Dcp2-AA (E147A/E148A), (F) Caf1a-wt plus
Dcp2-AA, (G) Caf1a-AA plus Dcp2-wt, and (H) Caf1a-AA plus Dcp2-AA. Total RNA was extracted
at 1 h intervals after blocking transcription with actinomycin D (5 µg/ml). The reporter mRNA
was detected by northern blot analysis; nucleolin mRNA served as a loading control. RNA samples
marked dT were treated with oligo(dT) and RNase H, and serve as a size marker for deadenylated
(A−) reporter mRNA. In the middle panels, deadenylation was visualized by quantifying the signal
intensity of 7B-PP7bs mRNA along the length of the signal and plotting it as a function of mRNA size.
In the bottom panels, the overall signal intensity of 7B-PP7bs mRNA was quantified and normalized
to nucleolin mRNA. Average values were plotted as a percentage of the initial time point. Error bars
indicate standard errors (SE). An asterisk indicates a significant difference in the mRNA half-life
(t1/2) (P < 0.05 by two-tailed Student’s t test) as compared to the vector control depicted in panel A.
Experiment repeat numbers used for quantification are shown in each panel.
2.5.5 Pat1-N Is Necessary and Sufficient for Pat1b Function
In order to determine which domain(s) of Pat1b is required for triggering degradation of
tethered mRNA, I cloned PP7cp into HA-Pat1b deletion constructs, and repeated the tethering
assay. As can be seen in Figure 2.21, the aggregation-prone Pat1b-N domain is sufficient to
induce mRNA decay by tethering. Having the acidic domain together with the N domain
appears to increase the mRNA degradation rate. On the other hand, the acidic domain on
its own lacks the ability to trigger mRNA decay. Tethering the HC domain does not induce
mRNA decay either. Interestingly, C-terminal domain of Pat1b appears to have an inhibitory
role in Pat1b activity. Although Pat1b-N alone is sufficient to induce mRNA decay in the
tethering assay, it is not fully active in the context of HA-PP7cp-dH or HA-PP7cp-dA. It is
possible that the A and H domains of Pat1b act as inducers of Pat1b-N, and their deletion
impairs the Pat1b activity. Because Pat1b-N is active on its own, such stimulatory effect(s)
does not explain the low activity of HA-PP7cp-dH or HA-PP7cp-dA in the tethering assays,
unless the activity of Pat1b-N is inhibited by the Pat1b-C domain. It is likely that the negative
effect of Pat1b-C is regulated by the Pat1b-A and/or Pat1b-H domains since the inhibitory
51
2 Results
effect of Pat1b-C is not detectable in the full length protein.
Figure 2.22. Tethering of Pat1b fragments. HeLa cells were transiently transfected with the 7B-
PP7bs reporter and (A) HA-tagged PP7cp, (B) PP7cp-Pat1b, (C) PP7cp-AN, (D) PP7cp-HC, (E)
PP7cp-A, (F) PP7cp-N, (G) PP7cp-dH, or (H) PP7cp-dA. Degradation of the reporter mRNA was
analyzed and quantified as described in the legend to Figure 2.21. Average values ± SE were plotted as
a percentage of the initial time point. An asterisk indicates a significant difference in the mRNA t1/2
(P < 0.05 by two-tailed Student’s t test) compared to tethering of PP7cp-Pat1b depicted in panel B.
2.5.6 Is Pat1b Required for Caf1a Activity or Coupling of Deadenylation and
Decapping?
Pat1b tethering indicates that Pat1b can recruit Caf1a to the tethered mRNA to mediate
deadenylation. However, this assay does not tell us whether Pat1b is required for Caf1a
activity. Nor does it provide an idea if Pat1b is needed for coupling of the deadenylation
step with decapping in mRNA degradation. In order to test these possibilities, I tethered
Caf1a on the mRNA under normal and Pat1b knockdown conditions, and looked for a change
in mRNA deadenylation and degradation rates. I also included the knockdown of Rrp40,
an exosome core component, to block 3’ to 5’ decay [145]. This would make mRNA decay
entirely dependent on the 5’ to 3’ pathway, thereby making the potential effect of Pat1b
on Caf1a activity and/or decapping more visible. If Pat1b is required for Caf1a activity,
adenylated mRNA species should accumulate after Pat1b knockdown. On the other hand, if
Pat1b is required for coupling deadenylation to decapping, then deadenylated mRNA should
accumulate after Pat1b knockdown. Tethering of Caf1a after control siRNAs transfection
led to rapid mRNA degradation (Figure 2.23). Knockdown of Pat1b or Rrp40 alone did not
change the mRNA half life or the polyA tail length. Double knockdown of Pat1b together with
Rrp40 stabilized Caf1a tethered mRNA slightly, but this effect was statistically not significant
(tested by the Student’s t-test). The distribution of polyA tail length was not changed by
double knockdown of Pat1b and Rrp40. In conclusion, according to this experiment, Pat1b
does not seem to be needed for Caf1a activity or the coupling of deadenylation and decapping.
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Figure 2.23. Effect of Pat1b knockdown on Caf1a activity. HeLa cells were transfected with control
siRNAs (D0 and C2), siRNAs against Pat1b (T3 and s37) and control siRNAs, si-Rrp40 and control
siRNAs, or si-Pat1b (T3 and s37) and si-Rrp40 (all at 50 + 50 nM), twice over a period of 4 days.
In the second siRNA transfection, plasmids encoding for the 7B-PP7bs reporter and HA-PP7cp or
PP7cp-Caf1a were also included in the transfection mix. (A) Western blots against Pat1b, Rrp40, HA
tag and eIF3B (as loading control) are shown. (B) After transcriptional block with actinomycin D (5
µg/ml), total RNA was isolated at 30 min intervals. The reporter mRNA was detected by northern
blot analysis; nucleolin mRNA served as a loading control. (C) Quantification of the total signal,
normalized to nucleolin mRNA. Average values ± SD were plotted as a percentage of the initial time
point. Average mRNA half lives, together with ± SD, as indicated in each graph (n=3).
2.6 Endogenous mRNA Targets of Pat1b
The data that I have shown so far indicate that Pat1b is involved in 5’ to 3’ mRNA decay.
Firstly, Pat1b localizes to and is required for formation of P-bodies, where other proteins
involved in deadenylation and 5’ to 3’ decay are concentrated. Secondly, Pat1b interacts with
the Ccr4-NOT deadenylation complex, several decapping enhancers, the decapping complex
and the 5’ to 3’ exoribonuclease Xrn1. And lastly, tethering of Pat1b to a reporter mRNA
leads to rapid mRNA degradation. Despite these strong data, knockdown of Pat1b by four
different siRNAs did not lead to a significant change in the decay of ARE and miRNA reporter
mRNAs. It is possible that Pat1b acts on some target mRNAs that do not fit to same criteria
as the reporters that I used so far. In order to determine such potential targets and learn
more about the physiological function of Pat1b in the cell, I decided to analyze genome wide
mRNA expression levels after knockdown of Pat1b by microarray analysis.
2.6.1 Strategy and Quality Control of Samples
With all 4 siRNAs I tested, the Pat1b knockdown was very efficient. Therefore, I hypothesized
that any potential target of Pat1b should be up-regulated after a 5 day long siRNA treatment.
In order to avoid off-target effects of individual siRNAs, I combined all four siRNAs against
Pat1b in equal ratios for transfection. Likewise, I also made a pool of three control siRNAs. As
Pat1b and Rck are close interaction partners and were proposed to share roles in translational
suppression, I also included Rck knockdown in the experiment. Overall, I had four knockdown
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Figure 2.24. Quality control
of Rck and Pat1b knockdown lev-
els and integrity of RNA samples
for microarray analysis. U2OS-
TREX cells were transfected
with control siRNAs (1:1:1 mix-
ture of D0, C2 and U0, at 100
nM combined), a pool of siRNAs
against Pat1b (1:1:1:1 mixture
of T2, T3, s37 and s38, at 80
nM combined, together with 20
nM of si-Control mix), a pool of
si-Rck (1:1 mixture of R1 and
s28, at 20 nM combined plus
80 nM of si-Control mix) and
the si-Pat1b pool together with
the si-Rck pool (80 nM plus 20
nM, respectively). siRNA trans-
fection was done twice over five
days. One fifth of the cells (har-
vested from 10 cm dish) were
lysed in Laemmli buffer for pro-
tein analysis, and total RNA
was isolated from the rest of
the cells. RNA samples were
treated with DNase RQ1 before
any further analysis. In total,
three repeat experiments were
done (SO100321, SO100324 and
SO100327). (A) Western blot
analysis with anti-Rck and anti-
14-3-3 antibodies. (B) qPCR
analysis of endogenous Pat1b
mRNA levels, normalized to nu-
cleolin mRNA. (C) Ethidium
bromide staining of 1 µg to-
tal RNA resolved by denatur-
ing agarose gel. (D) Ethidium
bromide staining of PCR ampli-
fied (oligos G1862 and G1863)
GAPDH cDNA. DNA size of the
major marker bands is indicated
on the right, in bp.
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conditions: (1) si-Control, pool of D0, C2 and U0 siRNAs, mixed equally, at 100 nM final
concentration; (2) si-Pat1b, pool of T2, T3, s37 and s38, mixed equally, at 80 nM final
concentration, plus 20 nM si-Control pool to have 100 nM final siRNA concentration; (3)
si-Rck, pool of R1 and s28 siRNAs against Rck, mixed equally, at 20 nM final concentration
combined with 80 nM final concentration of si-Control; (4) mixture of si-Pat1b pool, at 80
nM final concentration, and si-Rck pool, at 20 nM final concentration. I chose to use the
U2OS-TREX cell line in the microarray experiment, for several reasons: (1) it is a human cell
line; (2) it has a large cytoplasm, hence it is convenient for microscopy; (3) U2OS-TREX cells
stably expressing GS-Pat1b were already present.
I transfected the U2OS-TREX cells with siRNAs twice over 5 days, made total lysates
from one fifth of the cells (from 10 cm dish) to check protein levels, and isolated total RNA
from the rest. I then treated the RNA samples with DNase RQ1 to remove potential DNA
contamination. I repeated the experiment three times so that there will be biological repeats
included. Rck knockdown was confirmed by western blot analysis (Figure 2.24-A). In order to
determine Pat1b knockdown efficiency, I measured the endogenous Pat1b mRNA levels via
qPCR (Figure 2.24-B). Both Rck and Pat1b were efficiently suppressed. Before proceeding
with microarray analysis, I tested the quality of the RNA. First, I ran 1 µg total RNA in a
denaturing agarose gel to detect possible degradation of the RNA samples. Figure 2.24-C shows
that there is no significant degradation. Secondly, I tested the integrity of RNA samples via
PCR amplifying cDNAs longer than 1 kb. After reverse transcription with oligo(dT) primer,
PCR was done to amplify cDNAs of GAPDH (oligos G1862 and G1863) and nucleolin (oligos
G1864 and G1865) mRNAs. Figure 2.24-D shows that the GAPDH cDNA was successfully
amplified by PCR at the expected size (PCR for nucleolin mRNA is not shown).
2.6.2 Data Analysis
Total RNA samples from three repeat experiments were given to the EMBL Genomics Core
Facility for microarray analysis. cDNA was prepared with random hexamers, and GeneChip
Human Gene 1.0 ST Arrays from Affymetrix were used. The GeneChip Human Gene 1.0 ST
Array employs 25-mer probes against sense strand. The array offers whole-transcript coverage,
with each of the 28,869 genes being represented on the array by approximately 26 probes
spread across the full length of the transcript. I analyzed the expression data provided by
the EMBL Genomics Core Facility using Chipster software. The data was normalized using
RMA algorithm. The data was filtered by 1 SD eliminating the genes that have smallest
standard deviations. The rationale is that the genes with lowest standard deviations (standard
deviation is calculated for every gene, from all samples, without taking the biological grouping
into account) are the ones that do not show differences in expression levels. Filtering by 1 SD
removes 67% of the genes. Student’s t-test, with Benjamini-Hochberg correction on P-values,
was employed to test the statistical significance of the differences in expression levels compared
to the si-Control transfected cells.
Table 5.2 shows the genes which were up- or down-regulated at least 2-fold in si-Pat1b,
si-Rck and si-Pat1b plus si-Rck transfected cells compared to the si-Control. Despite the
strong effect of Pat1b on tethered mRNAs, there are only 59 mRNAs whose expression levels
change more than 2-fold upon Pat1b knockdown.
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2.6.3 Data Verification
In order to verify the microarray data, I picked 8 up-regulated and 9 down-regulated transcripts
from si-Pat1b list, and 6 up-regulated and 5 down-regulated transcripts from si-Rck list (among
these selected targets, those with fold changes above 2 are depicted in italics in Table 5.2).
I designed qPCR primers for the selected target mRNAs to test if the microarray can be
confirmed by qPCR (see Table 4.1 for qPCR primers). Using the same RNA samples that
were also used for microarray analysis, I was able to confirm the microarray data. However,
when I repeated the siRNA transfections with a new batch of cells, using siRNAs individually
instead of in mixtures, I had strong fluctuations in the data. In the end, it appeared that
the effects observed by microarray were, due to single siRNAs. Even though comparable
knockdown levels of Pat1b and Rck were achieved by individual siRNAs and by the siRNA
pools, the targets tested did not respond similarly to individual siRNAs. Two examples
are represented in Figure 2.25. SLITRK6 mRNA is up-regulated 2.5-fold according to the
microarray data. This effect can be reproduced by using the RNA samples from experiments
100321, 100324 and 100327 (which were used for the microarrays) but not with RNA samples
isolated from later experiments. T2 can be the siRNA responsible for the fold change detected
for SLITRK6 mRNA by microarray analysis. Likewise, down-regulation of PXDN mRNA can
be confirmed with RNA samples used for microarray, but not with RNA isolated from further
repeat experiments. siRNA s37 seems to be a major reason for the observed effect. The same
problem holds true also for the Rck targets. In summary, the fold changes determined by
microarray analysis appear to be due to off-target effects of individual siRNAs.
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Figure 2.25. qPCR analysis of two putative Pat1b targets identified by microarray. RNA samples
were prepared as described in the legend of Figure 2.24. RNA samples from experiments 100321,
100324 and 100327 are the same as the samples used for microarray analysis. Experiments 100722,
100811 and 100824 represent further repeats with siRNA transfections as indicated on the X-axis.
Individual siRNAs against Pat1b were transfected at 80 nM final concentration. Contr, pool of control
siRNAs D0, C2 and U0, at 80 nM combined; all, pool of si-Pat1b (T2, T3, s37 and s38) at 80 nM
combined; all+Contr, si-Pat1b mixture (80 nM) plus si-Control mixture (20 nM); dT, cDNA prepared
with oligo(dT) primer; r6mers, cDNA prepared with random hexamers. mRNA levels were normalized
to GAPDH mRNA levels.
2.7 A Closer Look at the Pat1b-Rck Interaction
In yeast, Pat1p and Dhh1p were shown to suppress translation under stress conditions, their
action being redundant (see Section 1.5). My data also showed that Pat1b and Rck interact
tightly in human cells. Therefore, I wanted to analyze the importance of this interaction for
Pat1b localization and function in more detail.
57
2 Results
2.7.1 Pat1b and Rck Interaction Mutants
I aimed at identifying mutations that would abrogate the interaction between Pat1b and
Rck. On the Pat1b side, I showed that the acidic domain is required for Rck interaction
(Figure 2.8-C). Alignment of the N-terminal acidic domains of Pat1b from different species
points to a conserved DDTF motif (see Figure 2.26-A) [107]. I mutated these amino acids to
alanines, and termed the mutant protein Pat1b-4A. The Pat1b-4A mutant does not interact
with Rck (Figure 2.26-C).
Figure 2.26. Pat1b and Rck interaction mutants. (A) Alignment of Pat1b N-terminal domains
from D. melanogaster, Dm; Homo sapiens, Hs; Danio rerio, Dr. Caenorhabditis elegans, Ce; and S.
cerevisiae, Sc. (B) C-terminal RecA-like domain of human Rck together with FDF peptide of Edc3
(blue) [83]. Positively (yellow) and negatively (cyan) charged surface residues are indicated. Residues
that were mutated to alanines are pointed in color. The same color was used for marking residues
mutated as a group. (C) HEK293 cells were transiently transfected with YFP, YFP-tagged Pat1b or
Pat1b-4A together with HA-tagged Rck. (D) HEK293 cells were transiently transfected with YFP or
YFP-Pat1b together with HA-tagged Rck wild type or mutants. 24 hrs after transfection, cell lysates
were prepared for IP of the YFP tag with GFP-binder. Western blot analyses with antibodies against
YFP and HA tags are shown.
On the Rck side, it is the C-terminal RecA-like domain that interacts with Pat1b (data not
shown). Since Rck interacts with the negatively charged acidic domain of Pat1b, I reasoned
that the positively charged residues on the surface of Rck could mediate Pat1b interaction.
The structure of the Rck C-terminal RecA-like domain was published by Tritschler et al.
[83]. After visualizing the positively charged residues on the Rck surface (Figure 2.26-B) I
mutated them in groups to alanines (residues mutated together are depicted in the same color).
Mutation of residues R346, K352 and K353 to alanines in Rck, termed Rck-m4, abolished the
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interaction of Rck with Pat1b (Figure 2.26-C).
2.7.2 Rck Binding Is not Required for Pat1b-Mediated mRNA Degradation
Lastly, I wanted to test whether the Rck interaction is important for Pat1b function in the
tethering assay. I cloned HA-PP7cp-Pat1b-4A and repeated the tethering assay as described
above (subsection 2.5.3). I utilized the FLB reporter, with or without the PP7bs, to measure
the protein and mRNA levels. Figure 2.27-A shows FL activity, while panel B shows the
mRNA levels. As expected, the FLB reporter without the PP7 binding sites did not show a
significant change, neither in protein nor in mRNA levels, upon co-expression of HA-PP7cp-
Pat1b or HA-PP7cp-Pat1b-4A. FLB-PP7bs, on the other hand, was equally suppressed by
HA-PP7cp-Pat1b and HA-PP7cp-Pat1b-4A tethering. Protein levels were reduced to 30%
compared to HA-PP7cp tethered reporter, and the mRNA levels were reduced to ∼40%. In
conclusion, the Rck interaction is not required for Pat1b function in the tethering assay.
Figure 2.27. Rck is dispensable for
the activity of Pat1b in a tethering
assay. HeLa cells were transfected
with FLB or FLB-PP7bs reporters to-
gether with a Renilla luciferase (RL)
reporter and either HA-PP7cp, HA-
PP7cp-Pat1b or HA-PP7cp-Pat1b-
4A. Cells were collected 24 hrs after
transfection. One third of the cells
were used for luciferase activity mea-
surement, and total RNA was isolated
from two thirds. FLB mRNA lev-
els were determined by northern blot
analysis, normalized to RPS7 mRNA,
and quantified. Average values ±SD
were plotted in the graph. (A) Pro-
tein levels, n=3. (B) mRNA levels,
n=3 for FLB reporter and n=2 for
FLB-PP7bs reporter.
2.7.3 Rck Requires Pat1b Binding for P-body Localization and Formation
Deletion of the Pat1b acidic domain leads to formation of small but numerous P-bodies.
Among the many interaction partners of Pat1b, only Rck interacts with Pat1b-A. Hence, I
hypothesized that the Rck-Pat1b interaction may be important for controlling P-body size.
If this hypothesis holds true, overexpression of the YFP-Pat1b-4A mutant, which does not
interact with Rck, should lead to formation of small P-bodies as seen in YFP-Pat1b-dA
overexpression. To test this hypothesis, I transfected HeLa cells with YFP-Pat1b-4A and
analyzed P-body size and numbers. As can be seen in Figure 2.28-A, P-bodies formed
in YFP-Pat1b-4A expressing cells look more like the P-bodies formed in wild type YFP-
Pat1b expressing cells. Thus, loss of Rck interaction in Pat1b-dA is not enough to explain
the formation of small P-bodies in YFP-Pat1b-dA expressing cells. I have also tested the
requirement of Rck binding for Pat1b-mediated P-body formation. Under normal conditions,
transfected YFP-Pat1b-4A can interact with endogenous Pat1b and thereby be recruited
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to P-bodies passively. siRNA-mediated knockdown of Pat1b inhibits P-body formation as
shown in Section 2.3. If the Pat1b-4A mutant depends on endogenous Pat1b for P-body
formation, it should not be able to form P-bodies in si-Pat1b transfected cells. To be able to
do this experiment, I introduced silent mutations in YFP-Pat1b and YFP-Pat1b-4A, termed
YFP-Pat1b-T3r and YFP-Pat1b-4A-T3r, that would make the Pat1b mRNA resistant to
cleavage by siRNA T3. Figure 2.28-C shows that, like YFP-Pat1b, YFP-Pat1b-4A can still
lead to Pat1b formation, as determined by Hedls localization, after Pat1b knockdown. These
results indicate that Pat1b does not depend on Rck for P-body formation.
Next, I tested if Rck needs Pat1b for P-body localization. Overexpression of YFP-Rck in
HeLa cells shows accumulation of Rck in P-bodies with some diffuse staining in the cytoplasm.
On the other hand, YFP-Rck-m4 has a more diffuse localization in the cytoplasm with only
one third of the cells showing YFP-Rck-m4 in P-bodies. I also checked the ability of Rck
and Rck-m4 to rescue P-body assembly in cells transfected with si-Rck. Like Pat1b, Rck
is an essential P-body protein, whose knockdown results in inhibition of P-body formation.
I introduced silent mutations into YFP-Rck and YFP-Rck-m4, termed YFP-Rck-R1r and
YFP-Rck-m4-R1r, that render the Rck mRNA resistant to si-Rck R1. Overexpression of
YFP-Rck in si-Rck transfected cells leads to P-body formation as judged by Hedls localization.
In contrast, YFP-Rck-m4 failed to rescue P-body assembly after Rck knockdown (Figure 2.28-
H), with only 8% of the YFP-Rck-m4 transfected cells showing few P-bodies. These results
indicate that Rck needs to bind to Pat1b in order to localize in P-bodies and to promote
P-body formation.
Figure 2.28. (Next page) Localization of YFP-Pat1b-4A and YFP-Rck-m4. HeLa cells were
transfected with (A) control siRNA (D0) and YFP-Pat1b-4A, (B) si-Pat1b (T3) and YFP-Pat1b,
which is resistant to siRNA T3, (C) si-Pat1b (T3) and T3 resistant YFP-Pat1b-4A-T3r, (D) YFP-Rck,
(E) YFP-Rck-m4, (F) siRNA against Rck (R1), (G) R1 siRNA and YFP-Rck-R1r resistant to R1,
and (H) R1 siRNA and R1 resistant YFP-Rck-m4-R1r. siRNAs were transfected twice, at 50 nM
final concentration, over 5 days. Plasmids were included in the second siRNA transfection. After 4%
formaldehyde fixation, cells were stained with an antibody against endogenous Hedls to mark P-bodies.
Images were acquired by spinning-disc confocal microscopy with 60x objective; maximum projections
of z-stacks are depicted. Merged images are shown on the right; size bar, 10 µm. (I) Quantification of
number of cells with P-bodies in YFP-Rck or YFP-Rck-m4 transfected cells under control conditions
or after si-Rck transfection. n=1.
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3 Discussion
During my PhD studies, I explored the human homolog of the yeast decapping enhancer
Pat1p. In the yeast and Drosophila genomes, only one homolog of Pat1 has been identified
[112, 107]. In contrast, two homologs of Pat1 were found in Xenopus and mammalian genomes
[146, 139, 141, 147]. The fungal and metazoan proteins share sequence conservation in the
N-terminal 50-70 aa long acidic stretch and in the homology domain located in the middle of
the proteins. The human proteins Pat1a and Pat1b share high homology throughout their
protein sequence. The major difference between Pat1a and Pat1b is the lack of a ∼150 aa long
portion following the acidic region in the Pat1a protein sequence. This N-terminal portion of
Pat1b is enriched in aspartate, glutamine and proline residues.
I started my analysis by investigating whether both of the mammalian Pat1 proteins,
Pat1a (PatL2) and Pat1b (PatL1), represent the functional homologs of the yeast protein
in human somatic cells. Pat1b localizes to P-bodies and interacts with P-body proteins.
In contrast, Pat1a localizes diffusely in the cytoplasm of transfected cells, and no apparent
co-localization with P-body markers was observed (Figure 2.2). In order to determine if Pat1a
interacts with P-body proteins, I overexpressed Pat1a in human HEK293 cells and carried out
immunoprecipitation experiments. Unlike Pat1b, which co-IPs with endogenous Rck, Hedls,
Xrn1, Lsm1 and Lsm4, HA-Pat1a interacts only with Lsm1 and very weakly with Lsm4 and
Xrn1 (Figure 2.3). Taken together, these data imply that Pat1a is not a P-body protein in
the mammalian somatic cell lines tested (COS7, HeLa, U2OS, HEK293).
In fact, the available data suggest that Pat1a is expressed at very low levels in somatic
cells. First, it was difficult to amplify the Pat1a cDNA by PCR from several human somatic
cell lines. Second, Scheller et al. [139] failed to detect PatL2 mRNA in somatic tissues via
northern blot analysis. Third, Marnef et al. [146] and Nakamura et al. [148] showed that
xPat1a is expressed in Xenopus oocytes, degraded during meiotic maturation, and no longer
detected in somatic tissues. Fourth, global microarray expression data shows that Pat1a is
expressed at levels close to background in most human and mouse somatic tissues, with modest
expression levels in mouse placenta, mast cells and the embryonic stem cell lines V26-2-p16
and Bruce4-p13 [149]. xPat1b, on the other hand, starts to be expressed at low levels towards
the end of oogenesis, and remains to be expressed throughout Xenopus embryogenesis in
somatic tissues. In mammals, global microarray expression data shows that Pat1b is expressed
in most mouse somatic tissues with highest expression levels in lymphocytes and macrophages
[149]. In conclusion, Pat1a homologs appear to be expressed only during oogenesis, and are
not associated with somatic P-bodies.
3.1 Role of Pat1b in P-body Formation
Pat1b is clearly a P-body protein. During my Master’s studies, I showed that Pat1b forms
several bright cytoplasmic foci, and that Pat1b co-localizes with endogenous Hedls, Xrn1, Rck,
Lsm1, Upf1 and overexpressed RFP-Dcp1a in these foci. The localization data mark Pat1b
foci as P-bodies. I also examined the localization of endogenous Pat1b with an anti-Pat1b
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antibody, which was kindly provided by Marina Chekulaeva from Witold Filipowicz’s lab, FMI
Basel. The anti-Pat1b antibody, termed Ab387, results in a punctuate staining (see Figure
S4 and Figure 1 in Ozgur et al. [141] for validation of the antibody and for IF with Ab387,
respectively). Among many smaller dots, there are bright and big foci that co-localize with
Hedls and Lsm1 (please refer to Ozgur et al. [141] for IF pictures). P-body localization of
Pat1b in mammalian cell lines was also confirmed by Scheller et al. [139], Braun et al. [147],
and Marnef et al. [146]. Haas et al. [107] showed that HPat, the Drosophila homolog of Pat1,
also localizes to P-bodies in Drosophila S2 cells.
Pat1b is an essential protein for P-body formation. siRNA-mediated knockdown of Pat1b
leads to loss of P-bodies in mammalian cell lines (Figure 2.4) [139, 146]. In S. cerevisiae,
PAT1 deletion does not abolish P-body formation completely, but P-bodies formed in this
strain are smaller and their numbers are reduced, even under stress conditions [126, 124].
These observations indicate that Pat1b is not a passive resident in P-bodies, but plays a
critical role in P-body assembly. In fact, overexpression of HA- or YFP-tagged Pat1b increases
both the numbers and the size of P-bodies. Quantification of P-bodies formed in YFP-Pat1b
transfected cells (Figure 2.2-D) shows that the number of P-bodies per cell increases above 20
in 90% of the transfected cells, while YFP transfected cells have 9 P-bodies per cell on average.
Indeed, many of the HA-Pat1b or YFP-Pat1b transfected cells had 50 or more P-bodies per
cell. The ability to increase P-body numbers so dramatically upon overexpression seems to be
a unique feature of Pat1b, since no other protein has yet been reported to have such an effect.
Interestingly, some of these numerous Pat1b foci, in particular the small ones at the periphery
of the cell, did not co-localize with other P-body proteins. This suggests that Pat1b is able to
aggregate autonomously and nucleate P-body assembly.
Depletion or overexpression of several proteins affect P-body size and numbers. For example,
in S. cerevisiae, deletion of XRN1 or DCP1 leads to dramatic increases in both size and number
of P-bodies [126]. The reason for these observations is suggested to be the accumulation
of mRNA decay intermediates, rather than a direct effect of Xrn1p or Dcp1p on P-body
formation. In this regard, Pat1b is important, since the data suggest an active role for Pat1b in
P-body assembly. Supporting the idea that Pat1b can nucleate P-bodies, Pat1b interacts with
itself (Figure 2.14). In addition, Pat1b interacts with the Ccr4-NOT deadenylation complex,
the decapping complex and several decapping enhancers via its different domains. Therefore,
Pat1b may induce P-body formation by providing an interaction platform for the other P-body
proteins it interacts with. Thereby, Pat1b self-interaction might allow smaller mRNPs to
assemble and form microscopically visible P-bodies. In line with this idea, Pat1b-induced foci
do not disassemble in the presence of CHX. CHX is an inhibitor of the translation elongation
step in protein synthesis. Treatment of cells with CHX was proposed to trap mRNAs in
ribosomes, and thereby inhibit P-body formation [140]. YFP-Pat1b bodies resisted CHX
treatment as long as 6 hrs, while non-transfected cells did not have any P-bodies after 2 hrs
(Figure 2.6). Although I did not check for the presence of mRNA in YFP-Pat1b foci after
CHX treatment, the P-body proteins Hedls, Rck, Xrn1 and Lsm4 were still present in these
foci. This indicates that YFP-Pat1b foci are not solely non-specific aggregates of Pat1b, but
that Pat1b can stabilize protein-protein interactions that lead to proper P-body formation.
Although I could show that Pat1b co-IPs with several proteins in an RNA-independent
manner, it is not known which of these interactions are direct. In yeast, recombinant Pat1p
was shown to interact with the recombinant Dhh1p, Scd6p, Xrn1p, Lsm1p, Dcp1p and Dcp2p.
In addition, the Pat1p-C domain interacts directly with the Pat1p-M and C domains [88]. In
Drosophila, recombinant Edc3-FDF peptide was able to compete with the HPat for Me31B
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interaction. This suggests that HPat probably interacts with Me31B directly. For human
Pat1b, the most likely direct interaction partners are Rck (Figure 2.26), Dcp2, Hedls, and
Lsm1 [147], because the interaction of Pat1b with these proteins was abolished by mutating
Pat1b residues. Although these mutations may abolish other interactions that are needed for
Rck, Dcp2, Hedls and Lsm1 to associate with Pat1b, it is more likely that these interactions
are direct protein-protein interactions. My analysis of the strength of Pat1b interactions
with increasing salt concentrations showed that the association of Hedls, Edc3 and Xrn1
is almost lost at 300 mM NaCl (Figure 2.7). These data indicate that Pat1b forms weak
electrostatic interactions with Hedls, Edc3 and Xrn1, which may still be direct. My analysis
also showed that the Pat1b interaction with Lsm1, the decapping and the deadenylation
complex proteins are resistant to 1 M NaCl. Although such strong associations may be due
to hydrophobic interactions, this observation suggests that these interactions are likely to
be direct. Altogether, these data argue in favor of Pat1b being a scaffolding protein that
probably interacts directly with several P-body proteins. However, the precise architecture of
the Pat1b associated complex will only become clear after analysis of these interactions using
recombinant proteins.
Localization studies of Pat1b deletion constructs resulted in two important findings. First,
in line with the ability of Pat1b to initiate P-body formation, the N and AN domains form
autonomous aggregates, which do not correspond to P-bodies, when overexpressed. The N
domain of Pat1b is enriched in glutamine, asparagine and proline residues, which typically
occur in aggregation-prone proteins. In addition, the N and AN domains show the strongest
self-interaction with Pat1b. Thus, in the full length Pat1b protein, the N domain can mediate
Pat1b self-interaction and lead to P-body formation. Interestingly, aggregation-prone Q/N-
rich domains are found in several P-body proteins [125]. This highlights the importance of
Q/N-rich domains in protein-protein interactions that are needed for P-body assembly. For
example, Decker et al. [90] showed that the Q/N-rich C-terminal domain of Lsm4p provides
an alternative way for P-body assembly when Edc3p is absent. As a proof that it is the
aggregation property of Lsm4 Q/N-rich tail which is important for P-body assembly, the
C-terminus of Lsm4p can be functionally replaced by the prion domain of Rnq1p. P-bodies
formed in cells expressing a Lsm4-Rnq1 fusion protein were bigger and brighter compared to
P-bodies formed by wild-type Lsm4. This observation indicates that the Rnq1 prion domain
interferes with the dynamic properties of P-bodies. The aggregation-prone C-terminal domain
of Lsm4p is not conserved in the human Lsm4 protein. This puts Pat1b in a more critical
position for P-body formation in human cells. It is worth mentioning that overexpression
of the N and AN domains suppress P-body formation in transfected cells (see Table S2 in
Ozgur et al. [141]). It is likely that N and AN domains sequester endogenous Pat1b into their
autonomous aggregates and therefore have a dominant negative effect on P-body assembly.
The second finding is that Pat1b-A controls the size of P-bodies. Deletion of the Pat1b acidic
domain leads to formation of higher number of P-bodies that are smaller in size. Similarly, the
aggregates formed by the N domain are much smaller than those formed by the AN domain
(Figure 2.5). Although Pat1b-A has a diffuse localization when expressed alone, the A domain
contributes to the fusion of smaller mRNPs into larger P-bodies in the context of the full
length Pat1b. The only interaction partner of Pat1b-A identified so far is Rck. Therefore, I
hypothesized that the loss of the Rck interaction in Pat1b-dA might be the reason for the small
P-bodies observed in Pat1b-dA overexpressing cells. I introduced four alanine mutations in
the Pat1b acidic domain (mutant construct named Pat1b-4A) that abolish the Rck interaction.
Overexpression of the YFP-Pat1b-4A mutant led to the formation of P-bodies that resemble
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P-bodies induced by YFP-Pat1b, but not YFP-Pat1b-dA (Figure 2.28). Moreover, YFP-Pat1b-
4A-T3r, just like YFP-Pat1b-T3r, rescued P-body formation when overexpressed in cells that
were transfected with the anti-Pat1b siRNA T3. Furthermore, I observed that YFP-Pat1b
and YFP-Pat1b-4A can induce P-body formation in si-Rck transfected cells (data not shown,
n=1). Altogether, these data indicate that Pat1b can form P-bodies regardless of the Rck
interaction, and that Pat1b-A controls P-body size independently of Rck. There is no other
P-body protein among the proteins identified by mass spectrometry to interact with Pat1b-A.
In the list of Pat1b-A interacting proteins, RACK1 is the only one known to localize to stress
granules [150]. Since P-bodies and stress granules have dynamic contacts [129], RACK1 might
be the factor through which Pat1b-A controls P-body size. An alternative hypothesis is that
Pat1b-A contributes to the size of P-bodies via its negative charge. It is possible that the A
domain interacts with positively charged residues on other P-body proteins, thereby bridging
small mRNPs to P-bodies.
Rck seems to depend on the Pat1b interaction for P-body localization. The Rck-m4 mutant,
which does not interact with Pat1b, mostly localizes diffusely in the cytoplasm, and only one
third of the transfected cells showed YFP-Rck-m4 in P-bodies (Figure 2.28). In contrast, YFP-
Rck localizes to P-bodies in ∼90% of the transfected cells. In addition, unlike YFP-Rck-R1r,
YFP-Rck-m4-R1r could not rescue P-body formation after Rck knockdown. Therefore, despite
the ability of Pat1b to form P-bodies independently of Rck, Rck seems to depend on Pat1b to
localize to P-bodies.
3.2 Role of Pat1b in mRNA Degradation
In yeast, Pat1p was shown to suppress translation upon glucose starvation [101]. Pilkington
and Parker [88] found that the C-terminal domain of Pat1p (aa 422-763) is required for
translational suppression. Interestingly, overexpression of Pat1p is sufficient to suppress
translation by ∼50% under normal conditions. Nissan et al. [92] showed that the recombinant
Pat1p-M+C domain efficiently suppresses translation of luciferase mRNA in an in vitro assay.
(Refer to Figure 3.1 for comparison of Pat1 domains from different species and studies.) The
authors demonstrated that the Pat1p-M+C domain reduces 48S translation initiation complex
formation on MFA2 reporter mRNA, and suggested that Pat1p inhibits the association of
the 43S pre-initiation complex with mRNA. Despite these strong data for yeast Pat1p, I
could not detect a significant effect of Pat1b knockdown on translation in mammalian cells,
neither under control conditions nor upon stress. Since Dhh1p and Pat1p were shown to be
redundant suppressors of translational, I also included a double knockdown of Pat1b and Rck
in my analysis. Nevertheless, I could not record any translational up-regulation in the double
knockdown either. Marnef et al. [146] detected that xPat1b suppresses translation of tethered
luciferase mRNA when injected in Xenopus oocytes. In these experiments, the authors used
capped but non-polyadenylated mRNAs and did not observe a difference in mRNA levels.
The lack of changes in mRNA levels is not surprising given the fact that in oocytes, mRNA
degradation does not take place. Although the data are convincing, the system employed is
somewhat artificial since xPat1b is not expressed in Xenopus oocytes. It is also possible that
in the course of evolution, Pat1b lost its ability to suppress translation.
Pat1b interacts with decapping enhancers, which points towards a role of Pat1b in mRNA
degradation. Tethering Pat1b on the FLB reporter mRNA results in a clear reduction of
mRNA levels, which is also reflected by low reporter protein expression. Actinomycin D chase
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Figure 3.1. Summary of Pat1 interactions and functional domains. Pat1 data from different species
are compared. Boundaries of domains used in different studies are also indicated, not to scale. Figure
was reproduced from Marnef and Standart [151].
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experiments showed that the low levels of Pat1b tethered mRNA are due to an increased
mRNA decay rate. mRNA decay induced by Pat1b tethering is fast. The Pat1b tethered
7B-PP7bs mRNA has a half life of 1.7 h ± 0.27, while the half life of HA-PP7cp tethered
mRNA is more than 6 hrs (Figure 2.20). Since no domain with potential enzymatic activity can
be identified in Pat1b sequence, Pat1b is likely to induce mRNA decay via interacting proteins.
In fact, Pat1b interacts with the Ccr4-NOT deadenylation and the Dcp1/Dcp2 decapping
complexes. Supporting a role of deadenylation in Pat1b tethered mRNA degradation, the
adenylated 7B-PP7bs mRNA disappears faster in transcriptional chase experiments. In order
to test whether Pat1b-mediated mRNA decay depends on deadenylation and/or decapping, I
used dominant negative mutants of the deadenylase Caf1a and the decapping enzyme Dcp2.
Overexpression of the Caf1a-AA dominant negative mutant in Pat1b tethering experiments
inhibits deadenylation. Interestingly, although mRNA deadenylation is blocked, the mRNA
is still degraded with a half life comparable to transfection of vector alone (Figure 2.21).
On the other hand, transfection of the Dcp2-AA dominant negative mutant in the Pat1b
tethering assay, causes accumulation of deadenylated mRNA species, yet again does not inhibit
mRNA decay completely. The Pat1b tethered mRNA is stabilized only in cells overexpressing
both Caf1a-AA and Dcp2-AA. Therefore, Pat1b tethering causes mRNA deadenylation and
decapping independently.
The Pat1b tethered reporter mRNA is stabilized by 2-fold in cells co-expressing Dcp2-AA,
compared to the half life of Pat1b tethered mRNA in cells co-transfected with vector alone.
This finding indicates that decapping is a critical step in Pat1b-mediated mRNA decay. By
comparing the effect of deadenylation inhibition to the effect of decapping inhibition, it appears
that Pat1b-mediated mRNA decay depends on decapping more than deadenylation. Although
Totaro et al. [152] suggested that Pat1b induces deadenylation of c-fos mRNA, the effect
of Pat1b knockdown they observed is rather subtle. I also did not see a significant effect
of Pat1b knockdown on decay of Caf1a tethered mRNA. This observation indicates that
Pat1b is unlikely to stimulate deadenylation by Caf1a (Figure 2.23). My data are in line
with the decapping enhancer activity attributed to yeast Pat1p. In fact, the recombinant
yeast Pat1p N, M and C domains were recently shown to stimulate Dcp1p/Dcp2p in an in
vitro decapping assay [92]. Pat1p-M and Pat1p-C interact with the N-terminal part of Dcp2p,
at aa 100-300 which was used to test this interaction. This implies that the Pat1p-Dcp2p
interaction is necessary for Pat1p to enhance decapping. Nevertheless, Pat1p-M+C, which
does not interact with Dcp2-(aa 100-300), also enhances decapping, although to a lesser
extent than Pat1-C. It is possible that Pat1p-M+C binds to the C-terminal part of Dcp2p,
or to Dcp1, to enhance decapping. Alternatively, it might activate decapping via influencing
substrate availability to the decapping complex. Despite the results from the in vitro assay,
it was shown that Pat1p-M is necessary for in vivo stimulation of decapping in yeast [88].
Haas et al. [107] showed that in Drosophila S2 cells, the HPat Mid and C-terminal domains
are required for in vivo decapping. The authors reached this result indirectly: they used
GW182 tethered mRNA whose degradation is dependent on decapping. They could show that
HPat rescues decay, and therefore decapping, of GW182 tethered mRNA in an HPat/ME31B
double knockdown background. Braun et al. [147] were able to detect decapping activity with
GFP-Pat1b immunoprecipitated from human cells on an in vitro synthesized mRNA. This
activity seems to depend on Dcp2 that is pulled down together with GFP-Pat1b, because
Pat1b mutants and Pat1b N-terminal domains, which do not bind Dcp2, failed to show any
decapping activity. Therefore, although the yeast Pat1p can clearly enhance decapping by
recombinant Dcp1p/Dcp2p, the ability of the Drosophila and human Pat1 proteins to stimulate
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decapping is not clear.
A possible role of Pat1b in mRNA degradation is to connect the two critical steps of mRNA
degradation: deadenylation and decapping. Pat1b is likely to interact with the Ccr4-NOT
and the Dcp1/Dcp2 complexes simultaneously. I conducted experiments to determine whether
there is a competition between the two complexes for Pat1b binding. I tried to compete out
Dcp1 or Dcp2 with overexpression of Ccr4-NOT complex components, but could not observe
any competition between the deadenylation and the decapping complexes (data not shown).
Although it is possible that I did not see any competition because I did not use the direct
interaction partners of Pat1b, these results suggest that both complexes bind Pat1b at the
same time. Moreover, the Pat1b self-interaction provides another way for Pat1b to bring the
deadenylation and the decapping complexes together. My results show that Pat1b interacts
with the Ccr4-NOT and the Dcp1/Dcp2 complexes both through the N and C domains. This
strongly indicates that Pat1b acts as a scaffolding protein. The most convincing evidence
for Pat1b being a physical link between the deadenylation and the decapping complex came
from the following experiment (Figure 2.11). When immunoprecipitated, GFP-Caf1a brings
down very small amounts of co-expressed Flag-Dcp2. When HA-Pat1b is also expressed in the
same cells, the amount of Flag-Dcp2 co-IPed with GFP-Caf1a increases significantly. Hence,
Pat1b increases the association between Caf1a, which served as a marker for the deadenylation
complex, and Dcp2 used as a marker of the decapping complex. If Pat1b has decapping
enhancing activity, it would then further stimulate decapping in addition to complex formation
with the Ccr4-NOT deadenylation complex.
My deletion analysis showed that the aggregation-prone N domain of Pat1b is necessary and
sufficient to induce decay of tethered mRNA. Tethering of AN or N resulted in faster mRNA
decay than tethering of full length Pat1b. The N and AN domains of Pat1b interact with the
deadenylation and the decapping complexes. Thus, Pat1b-N appears to induce degradation of
the tethered mRNA by recruiting the deadenylation and the decapping complexes. Supporting
the role of Pat1b-N in mRNA decay, Haas et al. [107] showed that the P-rich region of
HPat, which corresponds to Pat1b-N, is also sufficient to induce decay of tethered mRNA
in Drosophila S2 cells. Interestingly, although Pat1b-HC also interacts with the Ccr4-NOT
and the Dcp1/Dcp2 complexes, its tethering does not lead to mRNA decay. The association
of Pat1b-HC with the deadenylation and the decapping complexes is weaker than that of
Pat1b-N. Nevertheless, this is not sufficient to explain the difference observed in the tethering
assay. Actually, Pat1b-HC interacts with most of the decapping enhancers and, hence, would
be expected to have higher activity than Pat1b-N or Pat1b-AN. One possible explanation is
that by interacting with the endogenous full length Pat1b, Pat1b-(A)N can induce formation
of a complex with higher activity. On the other hand, Pat1b-C appears to have an inhibitory
role in Pat1b-mediated mRNA decay. Although Pat1b-N alone is active in mRNA degradation,
its activity is repressed in Pat1b-dH and Pat1b-dA mutants, which include the C domain.
Tethering of Pat1b-dH or Pat1b-dA leads to accumulation of deadenylated reporter mRNA
species, implying that the decapping step is inhibited (Figure 2.22). Inhibition of HPat
activity in a tethering assay was also observed after deletion of HPat-N (which corresponds
to Pat1b-A) in Drosophila S2 cells. It is possible that Pat1b-C negatively regulates Pat1b
activity by interfering with the interactions of Pat1b-N. The inhibitory effect of Pat1b-C might
be balanced by Pat1b-A and/or Pat1b-H in full length Pat1b. In fact, the crystal structure of
the Pat1b C-terminal domain (aa 517-767) shows that the surface of this domain is enriched
in positively charged residues [147]. One may speculate that the negatively charged Pat1b-A
domain interacts with the positively charged surface of Pat1b-C and thereby provides a self
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regulatory mechanism for Pat1b activity. The negative effect of Pat1b-C would be antagonized
by its interaction with Pat1b-A. It would be interesting to test the proposed hypothesis by
overexpressing the A domain in the tethering assay together with PP7cp-Pat1b-dA. The
overexpressed A domain should interact with the C domain of Pat1b-dA and relieve the
inhibition on the N domain. Alternatively, if the suggested regulation depends on electrostatic
interactions, replacing the A domain with another negatively charged protein sequence should
not affect Pat1b activity in the tethering assay, while replacing the A domain with a positively
charged protein sequence should reduce Pat1b activity.
Despite its strong effect in tethering assays, the physiological role of Pat1b in mRNA
degradation is not clear. Pat1 binds RNA and this property seems to be evolutionarily
conserved. In yeast, the Pat1p M and C domains are individually able to bind polyU, but not
polyC, RNA [88]. In Drosophila, HPat was shown to pull down reporter mRNA independently
of Lsm1 [107]. Marnef et al. [146] showed that in vitro translated xPat1b as well as human
Pat1b binds to polyU and polyG RNA. Weaker binding to polyA RNA was also detected
with human Pat1b by Marnef et al. [146], while no interaction with polyA and poly(dU) was
observed by Braun et al. [147]. Since AREs are U-rich sequences, it is possible that Pat1b
may have a role in ARE-mediated mRNA decay via binding to AU-rich elements. I tried to
determine whether Pat1b is required for ARE-mediated or miRNA-mediated mRNA decay via
Pat1b knockdown. I used four different siRNAs against Pat1b in these assays and achieved
comparable knockdown levels by the individual siRNAs. It appeared that reporter mRNA
stabilization, which I observed with two different siRNAs, is due to off-target effects of the
two siRNAs. Likewise, I could not reproduce the effect of Pat1b knockdown on potential
Pat1b target mRNAs identified by microarray analysis using individual siRNAs. One possible
reason for the lack of a significant effect of Pat1b knockdown may be the redundancy between
decapping enhancers in mammalian cells. In Drosophila, at least two decapping enhancers
need to be co-depleted to inhibit decapping [107]. Redundancy is also supported indirectly by
the fact that Pat1b interacts with protein components of both the ARE-mediated and the
miRNA-mediated mRNA decay pathways.
3.3 Summary
During my PhD thesis, I showed that human Pat1b is an essential P-body protein that
has an active role in P-body formation. Moreover, Pat1b interacts with the Ccr4-NOT
deadenylation complex, the Dcp1/Dcp2 decapping complex, several decapping enhancers,
the 5’ to 3’ exoribonuclease and many other proteins with roles in mRNA decay. These
interactions have functional implications as Pat1b induces degradation of a reporter mRNA
when tethered. Pat1b-mediated mRNA decay utilizes both Caf1a induced deadenylation
and Dcp2-mediated decapping. In fact, Pat1b increases the association of the deadenylation
complex with the decapping complex. Pat1b interacts with the above mentioned proteins via
its different domains mostly in an RNA-independent manner. Therefore, Pat1b is likely to act
as a scaffolding protein and provide a platform for the formation of degradation compatible
mRNPs. Pat1b may further stimulate mRNA degradation by clustering these mRNPs in
P-bodies by means of Pat1b self-interaction. I suggest that Pat1b is recruited to the mRNA
via its interaction with the Ccr4-NOT deadenylation complex, and that it then bridges the
deadenylation complex with the decapping complex, thereby enhancing mRNA decay. In
addition, Pat1b may also stimulate the decapping step itself. The association of Pat1b with
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proteins involved in ARE- and miRNA-mediated mRNA decay further suggests that Pat1b is
a general factor in 5’ to 3’ mRNA decay. As it was not possible to detect any effect of Pat1b
knockdown on tested reporter mRNAs, Pat1b possibly shares redundant functions with other
decapping enhancers.
3.4 Possible Future Directions
My data suggest that Pat1b is a rather general factor in mRNA decay because there was no
significant effect of Pat1b knockdown on reporter mRNAs, and because the microarray results
could not identify reliable Pat1b target mRNAs. It is still possible that Pat1b is not only
a general factor, but required for the decay of a subset of mRNAs under certain conditions.
As a future experiment, it would be important to have one more attempt to identify Pat1b
targets. Instead of using a knockdown strategy, crosslinking followed by immunoprecipitation
and microarray or RNA-sequencing methodology is more likely to identify mRNAs that
preferentially interact with Pat1b. The suggested experiment can be repeated under several
stress conditions to cover possible conditions under which Pat1b activity might be more
essential.
One possibility is that Pat1b stimulates the activity of Dcp2 directly. The yeast data
clearly shows that Pat1p induces decapping, but there is no data showing direct stimulation of
Dcp2 activity by human Pat1b. An in vitro decapping assay is probably more challenging in
mammalian systems since formation of a decapping complex is known to require at least Hedls.
Lykke-Andersen [61] was able to set up an in vitro decapping assay using proteins purified
from HEK293 cells. Considering the tight interaction of Pat1b with Dcp2, such an assay would
not be conclusive unless the purity of proteins is assured. Moreover, purification of full length
Pat1b from bacteria is not straightforward. For the yeast protein, individual domains of Pat1p
are sufficient for significant increase in decapping activity by recombinant Dcp1p/Dcp2p. It
might be possible to conduct an reliable experiment with recombinant Dcp2 and recombinant
domains of Pat1b. An alternative to the proposed in vitro decapping assay might be to test
the effect of Pat1b knockdown on decapping in vivo. Splinted-ligation RT-PCR assay was
used by Hu et al. [153] to measure the levels of endogenous decapped mRNAs in S. cerevisiae.
This assay depends on the knowledge of the exact transcription start site, and it would be
necessary to determine the 5’ end of the transcript(s) of interest, for example by 5’ RACE.
Considering the redundancy of Pat1b with other decapping enhancers, it would be important
to test double knockdown of Pat1b with other decapping enhancers, and to conduct rescue
assays. The splinted-ligation RT-PCR assay may provide evidence whether Pat1b is required
to stimulate decapping in vivo.
In addition to the interactions that I detected by immunoprecipitation experiments, Pat1b
interacts with many more proteins identified by mass spectrometry. I was able to confirm
that Pat1b interacts with G3BP1, for which only 2 peptides were detected in MS analysis.
Therefore, it is likely that many of the proteins identified by MS indeed associate with Pat1b.
Among these proteins, there are several RNA-binding and ribosomal proteins. One interesting
candidate is Stau1 which is known to bind dsRNA and induce mRNA decay by an unknown
mechanism. Pat1b may be required for Stau1-induced mRNA decay. On the other hand, it is
worth exploring the interaction of Pat1b with ribosomal proteins. If the association can be
confirmed, they may provide a mechanism for Pat1b to be recruited to mRNAs.
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4.1 Materials
Lists of DNA and RNA oligos, antibodies, technical equipment, chemicals and enzymes, and
disposable materials and kits used in this work are given in the following.
4.1.1 DNA and RNA Oligos
Table 4.1. DNA oligos used in this study. DNA oligoes were perchased from Invitrogen or Eurofins
MWG. F, forward primer; R, reverse primer.
Oligo Sequence Description Restriction site
G18 ACATTCGGCCGGGTCGACCACTG β-globin F SalI
G19 AATTGATATCCACCATGGCCAGCATGACCGGCGGC β-globin R EcoRV
CAGCAGATGGGCGTGCATCTGTCCAG
G78 GGTGGTCGGAAAGCTATC NB probe for RPS7 F
G83 TTACAAAGTCACTCAGGATG NB probe for nucleolin F
G85 AGCTTACCACCATGTACCCATACGATGTTCCAGAT HA oligo F
TACGCTGGTACCGGATCCG
G86 AATTCGGATCCGGTACCAGCGTAATCTGGAACATC HA oligo R
GTATGGGTACATGGTGGTA
G243 ATATAAGCTTCCACCATGGTGAG YFP F HindIII
G244 ATATGGTACCCTTGTACAGCTCG YFP R KpnI
G1000 GTGCATCTGTCCAGTG NB probe for β-globin F
G1001 GCCGATTTAGGTGACACTATAGAATACCCTGAAGT NB probe for β-globin R
TCTC
G1008 GCCGATTTAGGTGACACTATAGAATACTATAGACA NB probe for RPS7 R
CCAG
G1009 GCCGATTTAGGTGACACTATAGAATACTTAGCGTC NB probe for nucleolin R
TTCG
G1198 TTAATCTAGATCAGTAAATCCAGGCAAACTCC Pat1a C-term (2nd PCR) R XbaI
G1219 GCCAAGATGAATTGCCTTGAAG Pat1a N-term (1st PCR) F
G1221 ACTGCTTGCAGCTTCTATATCC Pat1a mid R Pat1a D
G1222 GTCTGATGATTCAACTTCC Pat1a C-term (1st PCR) R
G1225 ATATGGTACCATGTTCCGCTACGAG Pat1b-AN F KpnI
G1226 TATACTCGAGTTAGTGACTTCCTCTATCTCC Pat1b-AN R XhoI
G1227 ATATGGTACCCGGAGCAGTCATCAAG Pat1b-H F KpnI
G1228 TATACTCGAGTTATTCTTCAGCAGCTGAC Pat1b-H R XhoI
G1229 ATATGGTACCATACAAGGTGATGGC Pat1b-C F KpnI
G1230 TATACTCGAGTTATCGTATCCCCTGAAC Pat1b-C R XhoI
G1243 TGTTGGTAGTCCACTTGC Pat1b Internal Primer
G1253 ATATCTCGAGTTAACCCTTGTACAGC Pat1b-YFP R XhoI
G1256 ATATAAGCTTCCACCATGGAAGACGCC Fluc F HindIII
G1257 ATATGGTACCCACGGCGATCTTTC Fluc R KpnI
G1268 ATATGGATCCATGTTCCGCTACGAG Pat1b cloning into p2434 F BamHI
G1269 GCCTCAGAACTTCAGATCC Pat1b cloning into p2434 R
G1270 TTGGGGATCCAGCTGTACTT Pat1a qPCR (UPL) F
G1271 CATACCAGGGGCCTTGACT Pat1a qPCR (UPL) R
G1272 CACCAGCACTCTCCAATCCT Pat1b qPCR (UPL) F
G1273 AGCAGTGACAGGCCAAACTT Pat1b qPCR (UPL) R
G1295 CTCCAGTTTTTCAAACTTTCGGAGATG Pat1b homology domain deletion R
Continued on Next Page. . .
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G1296 CATCTCCGAAAGTTTGAAAAACTGGAG Pat1b homology domain deletion F
G1302 ATCACTCGAGTTAAGGTTTCTCATCTTCTAC Rck R aa 483 XhoI
G1315 CTTCTGAGGAGGAGCTGGTGTCTG Pat1a mid F
G1332 CTCGCCGAGCTATTGATGC Pat1a C-term (1st and 2nd PCR) F
G1340 CAAGGAGGCAAGTGACATTC Pat1a N-term (1st and 2nd PCR) R
G1353 ATATGGATCCGAATTCATGAATTGCCTTGAAGGGC Pat1a N-term (2nd PCR) F BamHI, EcoRI
G1377 TAGTGGATCCATGAGCACGGCCAGAACAGAGAACC Rck synthetic primer for aa 1-11 F BamHI
CTGTTATAATGGGTCTGTCCAGTC
G1408 ATATGGTACCAATCTGGCAGAAAGG Pat1b-dA F KpnI
G1425 TATACTCGAGTTACTCCTCATGGTCACC Pat1b acidic domain R XhoI
G1501 ATATGGTACCATGTCCAAAACCATC PP7cp F KpnI
G1502 ATATGGTACCACGGCCCAGCGGCAC PP7cp R KpnI
G1777 ACCCAGAAGACTGTGGATGG GAPDH qPCR F
G1778 CAGTGAGCTTCCCGTTCAG GAPDH qPCR R
G1784 CAGAAGTAATGTTTATGGCAACACGAGAAC Pat1b T3 resistant mutant F
G1785 ATAAACATTACTTCTGTCCACTGATTATTTTG Pat1b T3 resistant mutant R
G1816 GAATATGCTTTGCCTCAGAGGC Pat1b qPCR F
G1817 CGGACACAGAATCTGTTGGGTG Pat1b qPCR R
G1862 CAGCCTCCCGCTTCGCTCTC hGAPDH F
G1863 TGGCAGGGACTCCCCAGCAG hGAPDH R
G1864 CAGCCAAAGCAGTTACCACA hNCL F
G1865 TTCCAAGGAGACCACAGGAC hNCL R
G1883 CAGGGGTACCTAGCAAAATCAGG Dcp2-E147Q,E148Q F KpnI
G1884 CTTTGATATCAAAACCAGTTGCTGCAAAGACCTCTC Dcp2-E147Q,E148Q R EcoRV
G2047 TTGAAGGCAAAGACATGGCAGCAG TAGLN qPCR F
G2048 TCCACGGTAGTGCCCATCATTCTT TAGLN qPCR R
G2049 AACACTTTCCTGCTCCTCTCTGTC ACTA2 qPCR F
G2050 CGAGTCAGAGCTTTGGCTAGGAAT ACTA2 qPCR R
G2077 GCACTGCACAGATGGCTGGTTT Myocardin qPCR F
G2078 TCTGCTGACTCCGGGTCATTTGC Myocardin qPCR R
G2079 TCATGAATTCCCATTTGCAG RCK F EcoRI
G2080 AATTGCTAGCCAAGAAGATTTCTC RCK F NheI
G2081 CTTGGCTAGCAATTCAACTCG RCK R NheI
G2082 CGCCAAAAAGTAGCCTGCCTCAACACACTTTTCTCC RCK-H323A,R331A (m1) F
GCGCTTCAGATA
G2083 TATCTGAAGCGCGGAGAAAAGTGTGTTGAGGCAGGC RCK-H323A,R331A (m1) R
TACTTTTTGGCG
G2084 CATATGATGATGCCTTCAACCTGGCAAGTATTGAGG RCK-R443A,K447A (m2) F
G2085 CCTCAATACTTGCCAGGTTGAAGGCATCATCATATG RCK-R443A,K447A (m2) R
G2086 GATCAATTCAATGCTGCTGCAGCTGGGTCAGGTG Pat1b-4A F
G2087 CACCTGACCCAGCTGCAGCAGCATTGAATTGATC Pat1b-4A R
G2088 CTCCTCTCAGGCAGTTGAATTGCTAGCCGCGGCGAT RCK-R346A,K352A,K353A (m4) F
TTCTCAAC
G2089 GTTGAGAAATCGCCGCGGCTAGCAATTCAACTGCCT RCK-R346A,K352A,K353A (m4) R
GAGAGGAG
G2090 GGAACATCGAAATGCTGTATTTGCTGATTTCGCAAA RCK-R375A,H378A,R381A (m5) F
TGGCTTATGC
G2091 GCATAAGCCATTTGCGAAATCAGCAAATACAGCATT RCK-R375A,H378A,R381A (m5) R
TCGATGTTCC
G2098 CAGCTCACTCAGCCACACACACC ACTG2 qPCR F
G2099 CCACCATCACACCCTGGTGGCGA ACTG2 qPCR R
G2104 TTCGGGTCTCCAGCTCGACCC PXDN qPCR F
G2105 AAAGCCCGCCAGAAGGCGTG PXDN qPCR R
G2106 CCCTATAAACTGAAAAAGGAGAAGGAGCTG PPP2R5D qPCR F
G2107 CGTTGAGTCCTGCCCGCTTCA PPP2R5D qPCR R
G2108 CACAGTCGAGCAGTGCTTTGGTG CYFIP1 qPCR F
G2109 GCCGCTGCTGCCCAAGAAGTA CYFIP1 qPCR R
G2110 CACTACCAGCGGGCGGACTTC FKBP8 qPCR F
G2111 TCCTCCTCGAACGTCATGTCCACTTTGG FKBP8 qPCR R
G2114 GCCGCCGGAGGAACCTTGAT CALM3 qPCR F
G2115 GGAGAAGGCCTCCTTGAACTCTGCA CALM3 qPCR R
G2116 TCGGAGCTACACTTGGCTGTGCT APOBEC3B qPCR F
G2117 GAGGCTTGAAATACACCTGGCCTCG APOBEC3B qPCR R
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G2118 GCGAGTAGAACCGCTGAGGCG PARN qPCR F
G2119 TCACTGATTCCTGAAAACTCCCCATCGA PARN qPCR R
G2120 TGCGGAAGGAGAAATGCACGAG IPO5 qPCR F
G2121 GTCCACAGTCCTCCAGAAGTCTGT IPO5 qPCR R
G2122 TGTGCTGCCGTAGCAAATTGGA NCBP1 qPCR F
G2123 TCACTTCGCCGTTTGTGTTGCCT NCBP1 qPCR R
G2126 ACTCAGAGGAGGCGCCATGTCAGA CDKN1A qPCR F
G2127 AGCCCGCCATTAGCGCATCAC CDKN1A qPCR R
G2128 TCTGCAGCCCGAGCTAGGATAGA RCAN2 qPCR F
G2129 TCTCTGGAGTCTGAACCTGTGCAAA RCAN2 qPCR R
G2130 GCGAGGCAATCGTCCGGTGT G3BP2 qPCR F
G2131 GCTGCACAATGTCAAATGCTAGAGG G3BP2 qPCR R
G2132 ACGAACACCTGTCAGCCCAGTCAA RPS6KB1 qPCR F
G2133 GGTGCCGATGCTTCCCCACTC RPS6KB1 qPCR R
G2134 GGAAGAGTCTCTGCTTTACAGAATCGG SLITRK6 qPCR F
G2135 AGCCTCTGGATGAGAGCACTGGA SLITRK6 qPCR R
G2136 CCTGCCTGGAGAGAGCCAAAGAGT RGS16 qPCR F
G2137 GCTCAGCAGCAGGTCGAACGAC RGS16 qPCR R
G2138 TGCATCGTCCTTTCAAGGTGCCA SLC7A11 qPCR F
G2139 ACGCAGGGACTCCAGTCAGAGT SLC7A11 qPCR R
G2142 GACCCACCCATTGACCCTGGGA AMTN qPCR F
G2143 TAGTGCCCTGGGCTCCAAGTTGT AMTN qPCR R
G2169 TGCACTGCAACCATGAGTGAGAACA IFIT2 qPCR F
G2170 GCCAGTAGGTTGCACATTGTGGC IFIT2 qPCR R
G2171 CCATCCTCTTTGGCGCTGCGT RNPEP qPCR F
G2172 GTCGTCCGGGTCAACGCCTG RNPEP qPCR R
G2173 TCTACAAGCCAAGGGGAAAGCAAG RANBP2 qPCR F
G2174 CGGCTGACTGGGTTCCGACTG RANBP2 qPCR R
G2175 AGTCTGAGCAGTTGGCGCGA ROCK1 qPCR F
G2176 TGCTTCTTCAAGCCGACTAACAGTG ROCK1 qPCR R
G2177 CCGGGACCTTCGCGACACAC BRF1 qPCR F
G2178 TTGTTACCCTTGCATAAAACTTCGCTCA BRF1 qPCR R
G2179 AAACAAGGATCGTCCAGCGATGC UPF3B qPCR2 F
G2180 TGGTGCTGTCATCAGGGGGACA UPF3B qPCR2 R
G2264 TCATGAATTCCCATTTaCAaAAgCCaTAcGAaATT RCK-R1 resistant mutant F EcoRI
AACCTGATGGAGG
Table 4.2. List of siRNAs used in this study. siRNAs were synthesized by Ambion (sense strand),
and purchased from Applied Biosystems or Eurofins MWG.
No Target Acc. # 1st nt in CDS Sequence
D0 (s002) unspec. GCAUUCACUUGGAUAGUAAdTdT
C2 (s014) unspec. GGUCCGGCUCCCCCAAAUGdTdT
U0 (s015) unspec. GAAUGCUCAUGUUGAAUCAdTdT
T1 (s009) hPat1a NM_001145112 955 GAGGAAGGCUGGAAGUAUAdTdT
T2 (s010) hPat1b NM_152716 259 GCAGAAAGGCUCAGUAAGAdTdT
T3 (s011) hPat1b NM_152716 2141 GGACGGAGGUGAUGUUCAUdTdT
s037 hPat1b 3’UTR NM_152716 3738 in mRNA AGGGACAGGUUAUGGUAUUdTdT
s038 hPat1b NM_152716 1167 GAGCAGUCAUCAAGAUCAUdTdT
R1 (s008) hRck NM_004397 876 GCAGAAACCCUAUGAGAUUdTdT
s028 hRCK NM_004397 968 UCUCCAGGCUUCAGAUAAAdTdT
s041 hRRP40 AF281132.1 59 CACGCACAGUACUAGGUCAdTdT
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4.1.2 List of Antibodies
Table 4.3. Antibodies used in this study. IP, immunoprecipitation; WB, western blotting; IF,
immunofluorescence.
Antibody Clonality Species Method Dilution / Source (order nr.)
Amount
14-3-3 polyclonal rabbit IP 1µg Santa Cruz Biotechnology (sc-629)
WB 1:2000
Caf1a monoclonal rabbit WB 1:1000 Ann-Bin Shyu, Uni. of Texas, Houston, TX
eIF3B polyclonal goat IP 1µg Santa Cruz Biotechnology (sc-16377)
WB 1:1000
IF 1:500
eIF4G polyclonal mouse IP 1µg Cell Signaling(NEB) (#2498)
WB 1:500
eIF4E (P-2) monoclonal mouse IP 1µg Santa Cruz Biotechnology (sc-9976)
WB 1:500
FLAG M2 monoclonal mouse WB 1:500 Sigma F 3165
G3BP1(TT-Y) monoclonal mouse Santa Cruz sc-81940
GFP polyclonal rabbit WB 1:10000 Abcam ab290
IMP1 (E-20) polyclonal goat WB 1:500 Santa Cruz Biotechnology (sc-21026)
IMP2 (P-16) polyclonal rabbit WB 1:500 Santa Cruz Biotechnology (sc-99464)
HA.11 monoclonal mouse IP 1µg Covance Innovative Antibodies (MMS-101P)
WB 1:500
HA-Y11 polyclonal rabbit IF 1:500 Santa Cruz Biotechnology (sc805)
Lsm1 polyclonal chicken IP 1µg Genway (15-288-22100F)
WB 1:2000
IF 1:500
Lsm4 polyclonal chicken WB 1:2000 Abcam (19101)
IF 1:500
p-S6K (Hedls) monoclonal mouse IP 1µg Santa Cruz Biotechnology (sc8416)
WB 1:500
IF I:1000
Pat1b (Ab387) monoclonal rabbit IF 1:500 Witek Filipowicz, FMI, Basel, Switzerland
Pat1b monoclonal rabit WB 1:2000 Tillmann Achsel, VWB, Leuven, Belgium
RCK polyclonal rabbit IP 1µg BETHYL (A300-461A)
WB 1:10000
IF 1:1000
Rrp40 rabbit WB 1:2000 Georg Stoecklin
Xrn1 polyclonal rabbit IP 1µg BETHYL (A300-443A-1)
WB 1:500
IF 1:500
mouse-HRP donkey WB 1:10000 Jackson ImmunoResearch (715-035-150)
rabbit-HRP donkey WB 1:10000 Jackson ImmunoResearch (711-035-152)
chicken-HRP donkey WB 1:10000 Jackson ImmunoResearch (703-035-155)
goat-HRP donkey WB 1:10000 Jackson ImmunoResearch (705-035-147)
Cy2-rabbit donkey IF 1:500 Jackson ImmunoResearch (711-225-152)
Cy3-mouse donkey IF 1:500 Jackson ImmunoResearch (715-165-150)
DyLigth 649-rabbit donkey IF 1:500 Jackson ImmunoResearch (711-495-152s)
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4.1.3 Technical Equipment
Table 4.4
Equipment Company
Freezer -20°C Liebherr
Freezer -80°C Liebherr
Fridge 4°C Liebherr
Cell Culture Incubator Binder
Centrifuge (5417R) Eppendorf
Centrifuge (J2-MC, rotor JA-17) Beckman
Centrifuge (Labofuge M) Heraeus Sepatech
Centrifuge (Multifuge 1S) Thermo
Centrifuge (Pico17) Thermo
Film Development Apparatus (HyperProcessor) Amersham
GeneAmp PCR System 9700 Applied Biosystems
Heating Block (neoBlock 1) NeoLab
Intelli-mixer NeoLab
Laminar Flow Cabinet NUAIRE
Magnetic Stirrer (MR3001) NeoLab
Micropipettes Gilson
Microwave Privileg
Mini Protean 3 Cell BIORAD
Mini Trans Blot Cell BIORAD
Nanodrop ND 1000 PeQLab
pH Meter (766 Calimetic) Knick
Poly-Prep column Biorad
Power Supply (powerpack300) Biorad
Scale (440-47N) Kern
Shaker (DOS-20S) NeoLab
Shaker (PMR-30) Grant-bio
Sorvall Discovery 90SE Thermo Scientific
Speedvac Eppendorf Concentrator
TurboBlotter (northern blotting) Whatman
UV Gel Documentation System Raytest IDA
UV Table (TVL-312A) Specktroline
Vortex NeoLab
Waterbath GFL
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4.1.4 Chemicals and Enzymes
Table 4.5
Chemical/Enzyme Company
10x Taq Polymerase Buffer QIAgen
10x NB blocking solution Roche
10x RNaseH Buffer New England Biolabs
2-Mercaptoethanol (2-ME, β-ME) Sigma
5x Transcription Buffer Promega
Acetic Acid Fluka
Actinomycin D AppliChem
Adenosine triphosphate (ATP) Fermentas
Agar Roth
Agarose Biozym Scientific GmbH
Ammonium acetate Fluka
Ammoniumsulfate Roth
Ammoniumpersulfate AppliChem
Ampicillin Applichem
Bradford Sigma-Aldrich
Bromphenol blue Applichem
Bovine Serum Alubmin (BSA) New England Biolabs
Calf Intestine Phosphatase (CIP) New England Biolabs
Chloroform VWR
Complete Protease Inhibitor Cocktail Tablets, EDTA-free Roche
Coomassie Brillant Blue R250 ROTH
Coomassie Brillant Blue R250 AppliChem
Desoxyadenosine triphosphate (dATP) Fermentas
Desoxycytidine triphosphate (dCTP) Fermentas
Desoxyguanosine triphosphate (dGTP) Fermentas
Desoxythymidine triphosphate (dTTP) Fermentas
DH5α competent E. coli cells Invitrogen
DIG easy hyb solution Roche
DIG labelling mix Roche
Dithiothreitol (DTT) Applichem
Dimethylsulfoxid (DMSO) Serva Electrophoresis
Disodiumhydrogenphosphate Roth
Doxycycline AppliChem
Ethanol Riedel-de-Haen
Ethidium bromide (EtBr) Applichem
Ethylenediaminetetraacetic acid (EDTA) Roth
Formaldehyde Merck
Formamide AppliChem
Gene Ruler 1kb Ladder Plus Fermentas
Continued on Next Page. . .
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Glycerol Roth
Glycine Gerbu
Heparin sulfate Sigma
HEPES Roth
IgG sepharose GE Healthcare
Isopropanol Sigma-Aldrich
Kanamycinesulfate Roth
Lipofectamine 2000 Invitrogen
L-glutamine PAN
Magnesium chloride Merck
Maleic acid Fluka
Methanol Fluka
Milk powder Roth
MOPS Roth
NEG-772 EASYTAG express protein labeling mix, 35S-Cys/Met PerkinElmar
Nonidet P-40 (NP-40) US Biological
Ocadaic acid Sigma-Aldrich
O’GeneRuler 100bp Plus DNA Ladder Fermentas
O-phosphoric acid Roth
PageRuler Prestained Protein Ladder Fermentas
Paraformaldehyde AppliChem
Polyethyleneimine (PEI) Polysciences Europe
Penicillin-streptomycin PAN
Ponceau S MD
Potassiumacetate Roth
Potassiumchloride Roth
Potassiumdihydrogenphosphate Roth
Puromycin AppliChem
Protein A/G Ultra Link Resin Thermo Scientific
Random hexamers Fermentas
Restriction Enzymes New England Biolabs
RNase A Genomed
RNase H New England Biolabs
RNase inhibitor RNasin Promega
Rotiphorese Acrylamide Solution Roth
RQ1 DNase Promega
Sodium arsenite Fluka
Sodium azide AppliChem
Sodium chloride Sigma-Aldrich
Sodiumdihydrogenphosphate Riedel de Haen
Sodium dodecyl sulphate (SDS) Gerbu
Sodiumfluoride Sigma-Aldrich
Sodium hydroxide pellets Riedel-de-Haen
Continued on Next Page. . .
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Sodiumvanadate Sigma-Aldrich
SP6 polymerase Fermentas
Streptavidin sepharose GE Healthcare
T4 DNA Ligase Fermentas
T4 DNA Polymerase New England Biolabs
T4 Polynucleotide Kinase Promega
Taq Polymerase QIAgen
TEMED AppliChem
Thermo polymerase buffer New England Biolabs
Transcriptor reverse transcriptase Roche
Transcriptor reverse transcriptase 5x reaction buffer Roche
Trifast PeQLab
Trisodiumcitrate VWR
Triton-X-100 Applichem
Trizma base Sigma-Aldrich
Trypsin/EDTA PAN
Tryptone AppliChem
Tween-20 Sigma-Aldrich
Vent DNA Polymerase New England Biolabs
Xylenecyanol Applichem
Yeast Pyrophosphatase Sigma
Yeast tRNA Ambion
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4.1.5 Disposable Materials and Kits
Table 4.6
Material Company
1.5 ml, 2 ml Reaction Tubes Eppendorf
15 ml, 50 ml Falcon Tubes Falcon, Greiner, Nunc
2 ml Cryotubes Nunc
Filter tips StarLab
Filter paper Whatman 3MM Whatman
Cellscraper CoStar Corning Inc.
CellStar Tissue culture flasks (T75, T25) Greiner Bio-One
CellStar Tissue culture dishes (6, 10, 15cm) Greiner Bio-One
CellStar Cell culture plates (6-well, 12-well, 24-well) Greiner Bio-One
DIG labelling Kit Ambion
Gloves Meditrade
Mini quick spin RNA columns Roche
Pipette tips Steinbrenner, Starlab
PureYield Plasmid Midi Prep System Promega
PureLink HiPure Plasmid Midiprep Kit Invitrogen
PureLink HiPure Plasmid Maxiprep Kit Invitrogen
QIAquick Gel Extraction Kit QIAgen
QIAprep Spin Miniprep Kit QIAgen
QIAquick PCR Purification Kit QIAgen
QIAquick Nucleotide Removal Kit QIAgen
Rapid DNA Ligation Kit Fermentas
RNeasy Plus Mini Kit QIAgen
RNA Isolation Kit EURx, Roboklon
Transcriptor First Strand cDNA Synthesis Kit Roche
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4.2 Methods
All kits and reagents were used according to the manufacturer’s instructions, unless otherwise
stated.
4.2.1 Plasmids and Cloning
The following plasmids have been described previously: pCMV-FLAG-NOT1 [154], pcDNA3-
Myc-Ccr4, pcDNA3-Flag-Dcp1a and pcDNA3-Flag-Dcp2 [9], pCIneo-RL [155]. To generate
pcDNA3-HA (p2003), oligos G85 / G86 were annealed and cloned into the HindIII - EcoRI
sites of pcDNA3 (Invitrogen).
For pcDNA3-YFP (p2168), YFP was amplified with oligos G243 / G244 and then ligated into
the HindIII - KpnI sites of pcDNA3-HA (p2003), thereby replacing the HA tag. For plasmid
pEYFP-Pat1a (p2639), the human Pat1a coding sequence was amplified in three portions
from cDNA of HeLa cells and ligated sequentially into the BglII-XbaI sites of pEYFP-C1
(Clontech / BD Biosciences). The following primer pairs were used: G1332 / G1222 (1st
PCR) and G1332 / G1198 (2nd PCR) for the Pat1a C-terminal portion, ligated as a KpnI -
XbaI fragment; G1315 / G1221 for the middle portion, ligated as a BglII - KpnI fragment;
G1219 / G1340 (1st PCR) and G1353 / G1340 (2nd PCR) for the Pat1a N-terminal portion,
ligated as a BamHI - BglII fragment and thereby introducing an EcoRI site upstream of the
start codon. For pcDNA3-HA-Pat1a (p2638), the human Pat1a coding sequence was excised
from pEYFP-Pat1a (p2639) as an EcoRI - XbaI fragment, and cloned into the same sites of
pcDNA3-HA (p2003).
A human Pat1b cDNA clone (DKFZp451I053) fused at the C-terminus to YFP was kindly
provided by Stefan Wiemann (German Cancer Research Center, Heidelberg). In order to
generate HA-tagged Pat1b constructs, fragments were amplified by PCR from human Pat1b
cDNA and inserted into the KpnI - XhoI sites of pcDNA3-HA (p2003). The following primers
were used: G1225 / G1230 for pcDNA3-HA-Pat1b (p2516), G1225 / G1226 for pcDNA3-HA-
Pat1b-AN (p2511), G1225 / G1228 for pcDNA3-HA-Pat1b-ANH (p2514), G1227 / G1228 for
pcDNA3-HA-Pat1b-H (p2512), G1227 / G1230 for pcDNA3-HA-Pat1b-HC (p2515), G1229 /
G1230 for pcDNA3-HA-Pat1b-C (p2513), G1225 / G1425 for pcDNA3-HA-Pat1b-A (p2591),
G1408 / G1226 for pcDNA3-HA-Pat1b-N (p2592) and G1408 / G1230 for pcDNA3-HA-Pat1b-
dA (p2675). For pcDNA3-HA-Pat1b-dH (p2542), the N- and C-terminal regions of Pat1b
were first amplified as separate fragments with primers G1225 / G1295 and G1296 / G1230,
respectively. The PCR products were then aligned, Pat1b lacking the H domain was amplified
with primers G1225 / G1230, and the PCR product was cloned into the KpnI - XhoI sites of
pcDNA3-HA (p2003).
pcDNA3-YFP-Pat1b full length (p2521), pcDNA3-YFP-Pat1b-A (p2630), pcDNA3-YFP-
Pat1b-AN (p2626), pcDNA3-YFP-Pat1b-N (p2627), pcDNA3-YFP-Pat1b-ANH (p2522),
pcDNA3-YFP-Pat1b-H (p2632), pcDNA3-YFP-Pat1b-C (p2628), pcDNA3-YFP-Pat1b-HC
(p2629), pcDNA3-YFP-Pat1b-dA (p2631) and pcDNA3-YFP-Pat1b-dH (p2633) were generated
by replacing the HA tag in the corresponding HA-tagged Pat1b constructs with YFP excised as
a HindIII - KpnI fragment from pcDNA3-YFP (p2168). For pcDNA3-HA-Pat1b-YFP (p2520),
Pat1b-YFP was amplified by PCR with primers G1225 - G1253 using clone DKFZp451I053 as
template, and inserted into the KpnI - XhoI sites of pcDNA3-HA-Pat1b (p2516).
In order to generate pcDNA3-HA-PP7cp-Pat1b (p2634), pcDNA3-HA-PP7cp-Pat1b-AN
(p2658), pcDNA3-HA-PP7cp-Pat1b-HC (p2659), pcDNA3-HA-PP7cp-Pat1b-dA (p2663),
80
4.2 Methods
pcDNA3-HA-PP7cp-Pat1b-dH (p2660), pcDNA3-HA-PP7cp-Pat1b-A (p2747), pcDNA3-HA-
PP7cp-Pat1b-N (p2748), and pcDNA3-HA-PP7cp-Pat1a (2661), PP7cp [144] was amplified
by PCR using primers G1501 - G1502 and inserted into the KpnI site of corresponding
pcDNA3-HA-Pat1b constructs and pcDNA3-HA-Pat1a (p2638). Orientation of the insert was
verified by sequencing. pcDNA3-HA-PP7cp-Caf1a was cloned by Sahil Sharma (unpublished
work).
For pcDNA3-Bgl (p2001), the BglII site in pcDNA3 (Invitrogen) was removed by digestion
with BglII and blunt-end religation, thereby introducing a novel ClaI site. pcDNA3-7B (p2308)
expressing a T7-tagged rabbit β-globin gene was subsequently generated by amplifying β-globin
by PCR with primers G18 / G19 from plasmid puroMXbglobin [156]. The fragment was
digested with EcoRV and SalI, and ligated into the BamHI/blunt - XhoI sites of pcDNA3-Blg.
For pcDNA3-7B-PP7bs (p2314), six repeats of the PP7 binding site were excised as a BamHI
- BglII fragment from pSP73-6xPP7bs [144] and introduced into the BglII site of pcDNA3-7B
(p2308). For pFLB (p2524), firefly luciferase cDNA was amplified by PCR using primers
G1256 / G1257 from pGL3-Control (Promega) and cloned into the HindIII - KpnI sites of
pcDNA3-7B (p2308). From there, the 6xPP7bs repeats were cloned as an EcoRI - BglII
fragment from pcDNA3-7B-PP7bs (p2314) into the corresponding sites of pFLB (p2524) to
generate pFLB-PP7bs (p2646).
For TOpuro-Caf1a-mycSG (p2485), the human Caf1a cDNA was amplified by RT-PCR
using primers G1122 and G1123 and cloned as into the BamHI - XhoI sites of TOpuro-mycSG
(p2484). For pTOpuro-Caf1a-AA-mycSG (p2737) containing the D40A/E42A mutation, a
fragment amplified by PCR with primers G1730 and G1731 was inserted into the KpnI -
EcoRI sites of TOpuro-Caf1a-mycSG (p2485). For pEGFP-TEV-Caf1a (p2793), Caf1a cDNA
was cloned as a BamHI - XhoI fragment into the BglII - XhoI sites of pEGFP-N1 containing a
TEV cleavage site. To generate pcDNA3-Flag-Dcp2-AA (p2798), the E147A/E148A mutation
was introduced into the KpnI - EcoRV sites of pcDNA3-Flag-Dcp2 [9] using a PCR fragment
amplified with primers G1883 and G1884.
Rck coding sequence was PCR amplified with oligos G1377 / G1302 using cDNA from
HeLa cells as template, and was inserted into BamHI-XhoI sites of pcDNA3-HA (p2003).
Point mutations were introduced into pcDNA3-HA-Rck (p2570) and pcDNA3-YFP-Pat1b-A
(p2630) by PCR. 5’ and 3’ regions flanking the mutation sites (including mutations) were PCR
amplified with oligos G2079 / G2083 (5’) and G2082 / G2081 (3’) for pcDNA3-HA-Rck-m1
(p2839), G2080 / G2085 (5’) and G2084 / G 1302 (3’) for pcDNA3-HA-Rck-m2 (p2840), G2079
/G 2089 (5’) and G2988 / G1302 (3’) for pcDNA3-HA-Rck-m4 (p2842), G2080 / G2091 (5’)
and G2090 / G1302 (3’) for pcDNA3-HA-Rck-m5 (p2843), G1225 / G2087 (5’) and G2086
/ G1425 (3’) for pcDNA3-YFP-Pat1b-A-4A (p2844), and G1225 / G2085 (5’) and G2086 /
G1269 (3’) for pcDNA3-YFP-Pat1b-4A (p2845). The 5’ and 3’ PCR fragments were aligned
and mutant Rck and Pat1b fragments were PCR amplified for second time with oligos G2079
/ G2081 for pcDNA3-HA-Rck-m1 (p2839), G2080 / G1302 for pcDNA3-HA-Rck-m2 (p2840),
G2079 / G1302 for pcDNA3-HA-Rck-m4 (p2842), G2080 / G1302 for pcDNA3-HA-Rck-m5
(p2843), G1225 / G1425 for pcDNA3-YFP-Pat1b-A-4A (p2844), and G1225 / G1269 for
pcDNA3-YFP-Pat1b-4A (p2845). Second PCR product carrying m1 mutation was digested
with NheI - EcoRI, second PCR product carrying m2 mutation with NheI - XhoI, second
PCR product carrying m4 mutation with EcoRI - XhoI and inserted into the same sites of
pcDNA3-HA-Rck (p2570). Second PCR product of oligos G1225 / G1425 carrying 4A mutation
was digested with KpnI and XhoI and inserted at the same sites of pcDNA3-YFP-Pat1b-
A (p2630). For pcDNA3-YFP-Pat1b-4A (p2845), second PCR product was digested with
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KpnI - EcoRI and inserted into the same sites of pcDNA3-YFP-Pat1b (p2521). To generate
pcDNA3-HA-Rck-m3 (p2841), fragment containing m2 mutation was cut out by NheI - XhoI
from pcDNA3-HA-Rck-m2 (p2840), and inserted into the same sites of pcDNA3-HA-Rck-m1
(p2839). In order to generate YFP-tagged Rck wt and mutants, pcDNA3-Flag-YFP-Rck
(p2680), pcDNA3-Flag-YFP-Rck-m1 (p2865), pcDNA3-Flag-YFP-Rck-m2 (p2866), pcDNA3-
Flag-YFP-Rck-m3 (p2867), pcDNA3-Flag-YFP-Rck-m4 (p2868), pcDNA3-Flag-YFP-Rck-m5
(p2869), Rck coding sequences were cut out of the corresponding HA plasmids with BamHI -
XhoI restriction digestion, and ligated into the same sites of pcDNA3-Flag-YFP (p2679) [157].
For pcDNA3-HA-PP7cp-Pat1b-4A (p2909), PP7cp was cut out from pcDNA3-HA-PP7cp-
Pat1b (p2634) by KpnI digestion and ligated at the KpnI site of pcDNA3-HA-Pat1b-4A
(p2846). Orientation of the insert was verified by sequencing.
YFP-Pat1b sequence resistant to T3 siRNA was generated by introducing silent mutations
in two RCR steps into Pat1b coding region. The first 5’ and 3’ regions flanking the mutations
were PCR amplified with oligos G1785 / G1229 (5’) and G1784 / G1230 (3’). PCR products
were aligned and second PCR was done with G1229 / G1230. PCR product was digested
with XcmI - XhoI, and inserted into the same sites of pcDNA3-HA-Pat1b (p2516). After
sequencing, the fragment carrying the mutations was digested with XcmI - XhoI out of
pcDNA3-HA-Pat1b-T3r (p2749) and inserted at the same sites of pcDNA3-YFP-Pat1b (p2521)
to generate pcDNA3-YFP-Pat1b-T3r (p2750), and of pcDNA3-YFP-Pat1b-4A (p2845) to
generate pcDNA3-YFP-Pat1b-4A-T3r (p2950). Rck sequence resistant to siRNA R1 was
generated by introducing silent mutations by PCR with oligos G2264 / G2081. PCR product
was digested with EcoRI - NheI, and inserted into the same sites of pcDNA3-Flag-YFP-Rck
(p2680) to generate pcDNA3-Flag-YFP-Rck-R1r (p2900), and of pcDNA3-Flag-YFP-Rck-m4
(p2868) to generate pcDNA3-Flag-YFP-Rck-m4-R1r (p2908).
Plasmids pCMV-3xFlag-Ago4 (p2098) and pcDNA3-Flag-Ago2 (p2093) was kindly provided
by J. Han. Plasmids pcDNA3-HA-hTTP (p2131), pcDNA3-HA-hBrf1 (p2113) and pcDNA3-
Flag-PABP (p2022) were received from P. Anderson. Plasmids pENTR4-TNRC6B (p2757)
and pENTR4-TNRC6C (p2758) were received from Thomas Tuschl.
Gateway entry clones pENTR4-TNRC6B (p2757) and pENTR4-TNRC6C (p2758) were
kindly provided by Thomas Tuschl. pFLAG-TNRC6-B (p2764) and pFLAG-TNRC6-C
(p2765) were cloned into Gateway destination vector pFLAG-CMV-D11 (p2586) (received
from Bernhard Korn) with LR Clonase (Invitrogen).
TOpuroGS-Pat1b (p2534) was generated in two steps. First 5’ 400 nt of Pat1b coding
region was PCR amplified with oligos G1268 / G1269 and inserted into BamHI - EcoRI sites
of TOPuroGS (p2434) (cloned by Heike Sandler [11]). At the second step Pat1b nt 401-2310
were cut out of pcDNA3-HA-Pat1b (p2516) with EcoRI - XhoI and inserted at the same sites
of TOpuroGS-Pat1b(1-400 nt).
4.2.2 Cell Culture and Transfection
HeLa, U2OS, HEK293 and COS7 cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% fetal bovine serum (Biochrom), 2 mM L-glutamine, 100 U/ml
penicillin and 0.1 mg/ml streptomycin (all PAN Biotech) at 37°C / 5% CO2. HeLa-Tet-On-
7B-TNF-ARE, HeLa-Tet-On-lin41, U2OS-TREX-GS and U2OS-TREX-GS-Pat1b cells were
cultures under the same conditions except with DMEM containing 10% Tetracyclin negative
foetal bovine serum (PAA Laboratories). Expression of 7B-TNF-ARE, 7B-lin41, GS and
GS-Pat1b was induced by addition of 1 µg/ml doxycyline to the medium.
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Plasmids were transfected with Lipofectamine 2000 (Invitrogen) for protein interaction
studies, or with Fugene HD (Roche) for immunofluorescence analysis according to the manufac-
turer’s recommendations. Alternatively, polyethyleneimine (Polysciences Europe, 1 mg/ml, pH
7.0) was also used as transfection reagent for interaction and functional studies. siRNAs were
transfected at a concentration of 100 nM with Lipofectamine 2000 twice over a time period
of 4 or 5 days. Where indicated, cells were treated for 2 hours with 5 µg/ml cycloheximide
(Roth).
Table 4.7. Cell lines used in this study.
Cell Line Comment (ATCC Number)
COS7 African green monkey (Cercopithecus eathiops) kidney
fibroblast-like cell line (CRL-1651)
HEK293 Hypotriploid human embryonic kidney cell line (CRL-1573)
HeLa Human ephitalial cervical adenocancinoma cell line (CCL-2)
HeLa-YFP Stable cell line, mass culture. HeLa cells were transfected
with pcDNA3-YFP (p2168) using PEI, and selection was
done with G418.
HeLa-YFP-Pat1a Stable cell line, mass culture. HeLa cells were transfected
with pEYFP-Pat1a (p2639) using PEI, and selection was
done with G418.
HeLa-YFP-Pat1b Stable cell line, mass culture. HeLa cells were transfected
with pcDNA3-YFP-Pat1b (p2521) using PEI, and selection
was done with G418.
HeLa-Tet-On-7B-TNF-ARE Stable cell line, regulated expression of 7B-TNR-ARE upon
tetracycline or doxycycline addition to cell culture media,
recieved from Jochen Kreth, Georg Stoecklin lab
HeLa-Tet-On-7B-lin41 Stable cell line, regulated expression of 7B-lin41 upon tetra-
cycline or doxycycline addition to cell culture media, recieved
from Jochen Kreth, Georg Stoecklin lab
U2OS Chromosomally highly altered, human osteosarcoma cell line
(HTB-96)
U2OS-TREX U2OS cells which stably expressing Tet repressor, which
enables regulated gene expression upon tetracycline or doxy-
cycline addition to cell culture media.
U2OS-TREX-GS Stable cell line, single colony. U2OS-TREX cells were trans-
fected with TOPuroGS (p2434) using FuGENE, and selection
was done with puromycin.
U2OS-TREX-GS-Pat1b Stable cell line, single colony. U2OS-TREX cells were trans-
fected with TOPuroGS-Pat1b (p2534) using FuGENE, and
selection was done with puromycin.
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4.2.3 Immunofluorescence Microscopy
24 hours after transient transfection, cells grown on glass coverslips were fixed in 4% para-
formaldehyde for 10 minutes at room temperature. Cell membranes were then permeabilized
in -20°C cold methanol for 10 minutes. Phosphate buffered saline (PBS) containing 0.1%
sodium-azide and 5% horse serum was used for blocking and antibody dilution. DNA was
visualized using Heochst dye (#33342, Sigma, 1 µg/ml). After washing in PBS, cells were
mounted onto glass slides using a solution of 14% polyvinol-alcohol (P8136, Sigma) and 30%
glycerol in PBS. P-bodies were counted on an upright epi-fluorescence microscope (BX60,
Olympus). Images were acquired at the Nikon Imaging Center, Heidelberg, either on an
upright epi-fluorescence microscope (90i, Nikon) or by spinning disc confocal microscopy
(Ultraview ERS, Perkin Elmer, on a TE2000 inverted microscope, Nikon) using a EM-CCD
camera (Hamamastu).
4.2.4 Co-IP and Western Blot Analysis
24 hours after transient transfection, HEK293 cells from a confluent 10-cm dish were collected
and lysed in 400 µl ice cold hypotonic lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 10 mM
M EDTA, 0.5% Triton-X100 with freshly added Complete protease inhibitors, Roche). Nuclei
were removed by centrifugation at 500 g for 5 minutes at 4°C. The cytoplasmic lysate was
precleared by the addition of 30 µl protein A/G agarose beads (Pierce or Santa Cruz) for 1
hour at 4°C and incubated with 1 µg of antibody for 2 hours. 30 µl of protein A/G beads
were added for additional 2 hours and washed 6 times in NET2 buffer (50 mM Tris pH 7.5,
150 mM NaCl, 0.5% Triton-X100). Protein complexes were eluted with 25 µl SDS sample
buffer with or without 100 mM DTT. Where indicated, RNase A (Sigma, 0.1 mg/ml) was
added to the lysates after preclearing. Proteins were resolved on 10 or 12% polyaclyamide
gels and transferred onto 0.2 µm pore size nitrocellulose membrane (Peqlab) for Western
blotting. Horseradish peroxidase-coupled secondary antibodies (Jackson Immunoresearch) in
combination with Western Lightning enhanced chemiluminescence substrate (Perkin Elmer)
were used for detection. The GFP-binder was used for IP of YFP-tagged proteins as described
[142].
4.2.5 Northern Blot Analysis
For RNA decay experiments, actinomycin D (Applichem) was added to cell cultures at 5
µg/ml, and total RNA was extracted using the Genematrix Total RNA purification kit (Eurx,
Roboklon). For RNase H digestion, 20 µg RNA samples were first annealed with oligo(dT) (4
µl of 1 nmol/µl oligo(dT), 4 µl of 1 mM EDTA in 35 µl final volume) by incubation at 26°C
for 15 min. After annealing, 4 µl of 10x RNase H reaction buffer and 5 U of RNase H (New
England Biolabd) were added, and the reaction mixture was incubated at 37°C for 15 min.
Phenol/chloroform/isoamylalcohol extraction was done to purify the RNase H digested RNA.
5-20 µg of RNA was resolved by 1.1% agarose / 2% formaldehyde / MOPS gel electrophoresis
and blotted overnight with 8x SSC onto Hybond-N+ Nylon membranes (Amersham, GE).
Membranes were hybridized overnight with digoxigenin-labeled RNA probes at 55°C, washed
twice with 2x SSC / 0.1% SDS for 5 minutes, and twice with 0.5x SSC / 0.1% SDS for
20 minutes at 65°C. Alkaline phosphatase-labeled anti-DIG Fab fragments and CDP-Star
substrate (both Roche) were used for detection according to the manufacturer’s instructions.
The following primers were used to generate templates for Sp6 probes by PCR: G78 / G1001
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for the probe against exon 1 and 2 of rabbit β-globin; G78 / G1008 for the probe against
human RPS7; and G083 / G1009 for the probe against nucleolin.
4.2.6 Quantitative Real Time PCR
Pssible DNA contamination in RNA samples was eliminated with RQ1 DNase (Promega)
according to manufacturer’s protocol (1U enzyme per µg of RNA). RNA was precipitated
with ammonium-acetate and dissolved in RNase free water. cDNA was generated from 1 µg
total RNA by reverse transcription using oligo(dT18) or random hexamers as primer and
transcriptor reverse transcriptase (Roche). The reaction mixture contained the following
components: 1 µg total RNA, 4 µl 5x reverse transcription buffer (Promega), 2 µl 10 mM
dNTPs (dATP, dGTP, dTTP, dCTP), 2.5pmol oligo(dT18) or 0.01 µg random hexamer primer,
0.5 µl RNase inhibitor (Promega), 10 U transcriptor reverse transcriptase (Roche). Reaction
mixture was incubated at 55°C for 30 min for cDNA synthesis and the enzyme was inactivated
at 85°C for 5 min.
cDNA was prepared fresh for each run of SYBR Green 480 (Roche) quantitative real time
PCR (qPCR). The qPCR reaction was performed in a total volume of 10 µl containing 2.5 µl
cDNA (1:5 diluted in PCR grade water), 4 pmol target-specific forward and reverse primers
plus 5 µl SYBR Green Mastermix (2x). Primers G1576 / G1577 against human nucleolin, or
G1777 / G1778 against human GAPDH (for verification of microarray analysis) were used as
control for internal normalization. Quantitiative real time PCR (Light Cycler 480, Roche)
was carried out according to the manufacturer’s instructions with modified PCR program as
presented in table 4.8.
Table 4.8. Light Cycler Program.
Program Target (°C) Aquisition Mode Hold Ramp Rate
Pre-Incubation 95 none 5 min 4.4
Amplification 95 none 10 sec 4.4
55 none 15 sec 2.5
72 single 25 sec 4.8
Melting curve 95 none 5 sec 4.8
60 none 1 min 2.5
97 continuous - 0.11
Cooling 40 none 10 sec 2
4.2.7 35S-Methionine/Cysteine Metabolic Labeling and Autoradiography
U2OS or HeLa cells were seeded in 6-well plates on the second day of siRNA transfection.
When needed, the cells were incubated overnight in glucose-free medium before labeling, for
these cells glucose-free medium was used in the following steps also. 2 hrs before labeling, the
medium was replaced with cysteine/methionine-free DMEM containing 10% dialysed FBS
(dialysed against 1X PBS twice overnight, 4°C, and filter sterilized). Cells were metabolically
labelled with 55 µCi/ml final concentration for 30 min. Cells were trypsinized, and lysed
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in 200 µl lysis buffer (15 mM Tris-HCl pH 7.4, 15 mM MgCl2, 300 mM NaCl, 1% Triton-X
100, protease inhibitors, Roche). Nuclei were pelleted by centrifugation (2000 rpm, 2 min)
and 100 µl of the supernatant was precipitated on ice for at least 30 min after adding 100 µl
20% TCA. The precipitated proteins were then bound to glass microfibre filters in vacuum,
washed 3x with ice cold 20% TCA and then 3x with ice cold acetone. Filters were dried
and 35S incorporation was subsequently measured in 4 ml Econofluor-2 operating a liquid
scintillation counter. Another aliquot of the supernatant was used for determining the total
amount of proteins with Bradford Assay Kit (Sigma-Aldrich) according to the manufacturer’s
instructions.
4.2.8 Luciferase Assay
One third of a 6-cm dish of transiently transfected HeLa cells was lysed in 150 µl of passive
lysis buffer (Dual-Luciferase Reporter Assay System, Promega) and frozen at -20°C. After
thawing, nuclei were removed by centrifugation for 2 minutes at 13,000 rpm at 4°C. 20 µl
of the supernatant was mixed with 50 µl of 1:3 diluted substrates from the Dual-Luciferase
Reporter Assay System. Firefly and Renilla luciferase activities were measured on a Fluostar
Optima (BMG Labtech) plate reader.
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Acronyms
aa amino acid
ActD actinomycin D
Ago Angonaute
AMD ARE-mediated mRNA decay
ARE-BP ARE-binding protein
ARE AU-rich element
BLAST basic local alignment search tool
CBP80 cap-binding protein 80
cDNA complementary DNA
CHX cycloheximide
Dcp mRNA decapping enzyme
Dox Doxycycline
dsRNA double stranded RNA
Edc enhancer of mRNA decapping
eIF4E eukaryotic translation initiation factor 4E
EVH1 Enabled/VASP homology 1
HA Hemagglutinin
Hedls human enhancer of decapping large subunit
HNRP heterogeneous nuclear ribonucleoprotein
IF immunofluorescence
IP immunoprecipitation
IRES internal ribosome entry site
JNK c-Jun N-terminal kinase
LRR leucine-rich repeat
Lsm Sm Like
m7GDP 7-methylated guanosine diphosphate
m7G 7-methylated guanosine cap
Mg2+ magnesium
miRNA microRNA
Mn2+ manganese
mRNA messenger RNA
mRNP messenger ribonucleoprotein
MRT mRNA turnover
NaCl sodium chloride
NMD nonsense-mediated mRNA decay
NMR nuclear magnetic resonance
NTD Residues N-terminal to Dcp2p NudiX domain
nt nucleotide
NudiX Nucleotide diphosphate linked to an X moiety
P-bodies Processing bodies
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PABP polyA-binding protein
PAN polyA nuclease
PARN polyA-specific ribonuclease
PCR polymerase chain reaction
polyA poly adenosine
polyG poly guanosine
PRS proline-rich sequence
PTC premature termination codon
qPCR quantitative real time PCR
RISC RNA-induced silencing complex
RNAi RNA interference
RNase ribonuclease
RRM RNA-recognition motif
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SG stress granules
siRNA small interfering RNA
snoRNA small nucleolar RNA
snRNA small nuclear RNA
ssRNA single stranded RNA
TTP tristetraprolin
U-tract uridine tract
UTR untranslated region
WB western blot
wt wild type
Y2H yeast two hybrid
YFP yellow fluorescent protein
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5 Appendix
5.1 Results of HPLC-MS/MS Analysis
Table 5.1. List of proteins identified to interact with YFP-Pat1b and/or YFP-Pat1b-A by HPCL-
MS/MS. Proteins that were shown to interact with Pat1b are depicted in italic. Proteins with special
interest are depicted in bold. Sorted according to the number of unique peptides identified in YFP-Pat1b
IP.
Num. of Unique Peptides Peptide Ratio
YFP- YFP-
MW YFP- YFP- Pat1b Pat1b-A
Symbol Description (kDa) Pat1b YFP Pat1b-A / YFP / YFP
PATL1 Protein PAT1 homolog 1 87 65 5 4 13.00 0.80
Hedls Enhancer of mRNA-decapping protein 4 152 58 1 0 58.00 0.00
SART3 Squamous cell carcinoma antigen recognized
by T-cells 3
110 45 0 0
Rck Probable ATP-dependent RNA helicase DDX6 54 34 0 43
NUCL Nucleolin 77 27 8 9 3.38 1.13
RS3 40S ribosomal protein S3 27 22 0 6
RS3A 40S ribosomal protein S3a 30 19 0 3
PABP1 Polyadenylate-binding protein 1 71 19 5 5 3.80 1.00
PRP8 Pre-mRNA-processing-splicing factor 8 274 19 3 12 6.33 4.00
DDX21 Nucleolar RNA helicase 2 87 18 9 16 2.00 1.78
RS4X 40S ribosomal protein S4, X isoform 30 17 0 4
RS2 40S ribosomal protein S2 31 15 0 7
IMP1 Insulin-like growth factor 2 mRNA-
binding protein 1 IF2B1
63 15 1 1 15.00 1.00
EDC3 Enhancer of mRNA-decapping protein 3 56 15 0 0
ADT2 ADP/ATP translocase 2 33 14 6 14 2.33 2.33
CBR1 Carbonyl reductase [NADPH] 1 30 14 0 12
RS7 40S ribosomal protein S7 22 14 2 3 7.00 1.50
DCP1A mRNA-decapping enzyme 1A 63 14 0 0
RS6 40S ribosomal protein S6 29 14 0 1
HNRPR Heterogeneous nuclear ribonucleoprotein R 71 13 4 10 3.25 2.50
U520 U5 small nuclear ribonucleoprotein 200 heli-
case
245 13 4 11 3.25 2.75
RACK1 Guanine nucleotide-binding protein sub-
unit beta-2-like 1
35 13 0 9
ILF3 Interleukin enhancer-binding factor 3 95 13 0 4
DHX30 Putative ATP-dependent RNA helicase
DHX30
134 13 0 0
HNRH1 Heterogeneous nuclear ribonucleoprotein H 49 12 4 6 3.00 1.50
PTBP1 Polypyrimidine tract-binding protein 1 57 12 5 9 2.40 1.80
CA069 Putative transferase C1orf69, mitochondrial 38 12 5 12 2.40 2.40
CAPZB F-actin-capping protein subunit beta 31 12 4 9 3.00 2.25
HNRPK Heterogeneous nuclear ribonucleoprotein K 51 12 5 8 2.40 1.60
H2AY Core histone macro-H2A.1 40 12 7 4 1.71 0.57
ISOC1 Isochorismatase domain-containing protein 1 32 12 0 7
CDK2 Cell division protein kinase 2 34 12 0 11
RS18 40S ribosomal protein S18 18 12 1 3 12.00 3.00
RL7A 60S ribosomal protein L7a 30 12 0 1
RS8 40S ribosomal protein S8 24 11 2 0 5.50 0.00
HNRPL Heterogeneous nuclear ribonucleoprotein L 64 11 6 12 1.83 2.00
RL6 60S ribosomal protein L6 33 11 4 1 2.75 0.25
HNRPD Heterogeneous nuclear ribonucleoprotein D0 38 11 6 3 1.83 0.50
RL3 60S ribosomal protein L3 46 11 6 0 1.83 0.00
RL7 60S ribosomal protein L7 29 11 0 2
RS19 40S ribosomal protein S19 16 11 0 1
XRN1 5’-3’ exoribonuclease 1 194 11 0 0
RS9 40S ribosomal protein S9 23 11 2 1 5.50 0.50
MBB1A Myb-binding protein 1A 149 10 3 11 3.33 3.67
MPCP Phosphate carrier protein, mitochondrial 40 10 2 9 5.00 4.50
RS5 40S ribosomal protein S5 23 10 1 1 10.00 1.00
RL4 60S ribosomal protein L4 48 10 1 2 10.00 2.00
RL23A 60S ribosomal protein L23a 18 10 2 5 5.00 2.50
DDX5 Probable ATP-dependent RNA helicase
DDX5
69 10 1 1 10.00 1.00
PEF1 Peflin 30 9 1 8 9.00 8.00
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YFP- YFP-
MW YFP- YFP- Pat1b Pat1b-A
Symbol Description (kDa) Pat1b YFP Pat1b-A / YFP / YFP
LSM4 U6 snRNA-associated Sm-like protein LSm4 15 9 0 0
RS13 40S ribosomal protein S13 17 9 2 6 4.50 3.00
RS10 40S ribosomal protein S10 19 9 1 1 9.00 1.00
FHL1 Four and a half LIM domains protein 1 36 9 1 11 9.00 11.00
RS16 40S ribosomal protein S16 16 9 2 3 4.50 1.50
ROAA Heterogeneous nuclear ribonucleoprotein A/B 36 9 3 1 3.00 0.33
RBM14 RNA-binding protein 14 69 9 0 3
RL17 60S ribosomal protein L17 21 9 0 0
G3BP2 Ras GTPase-activating protein-binding
protein 2
54 9 0 0
RS27A Ubiquitin-40S ribosomal protein S27a 18 8 4 5 2.00 1.25
NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2 29 8 3 7 2.67 2.33
RS15 40S ribosomal protein S15 17 8 0 0
PSME2 Proteasome activator complex subunit 2 27 8 0 7
CATD Cathepsin D 45 8 0 7
MTAP S-methyl-5’-thioadenosine phosphorylase 31 8 0 7
LSM2 U6 snRNA-associated Sm-like protein LSm2 11 8 0 0
GLO2 Hydroxyacylglutathione hydrolase, mitochon-
drial
34 8 0 8
6PGL 6-phosphogluconolactonase 28 8 2 5 4.00 2.50
RL13 60S ribosomal protein L13 24 8 2 3 4.00 1.50
CNOT1 CCR4-NOT transcription complex subunit 1 267 8 5 2 1.60 0.40
RS12 40S ribosomal protein S12 15 8 2 3 4.00 1.50
LSM1 U6 snRNA-associated Sm-like protein LSm1 15 8 0 0
RL8 60S ribosomal protein L8 28 8 0 2
CAPR1 Caprin-1 78 8 0 0
PSME3 Proteasome activator complex subunit 3 30 7 0 9
PROSC Proline synthase co-transcribed bacterial ho-
molog protein
30 7 0 6
NOP56 Nucleolar protein 56 66 7 0 9
YBOX1 Nuclease-sensitive element-binding pro-
tein 1
36 7 0 0
RL5 60S ribosomal protein L5 34 7 1 2 7.00 2.00
ELAV1 ELAV-like protein 1 36 7 0 6
SRSF3 Serine/arginine-rich splicing factor 3 19 7 0 3
RS14 40S ribosomal protein S14 16 7 1 1 7.00 1.00
RS11 40S ribosomal protein S11 18 7 1 3 7.00 3.00
RS17 40S ribosomal protein S17 16 7 1 3 7.00 3.00
SPRE Sepiapterin reductase 28 6 3 3 2.00 1.00
LSM7 U6 snRNA-associated Sm-like protein LSm7 12 6 0 0
HNRPQ Heterogeneous nuclear ribonucleoprotein Q 70 6 1 3 6.00 3.00
RL14 60S ribosomal protein L14 23 6 3 1 2.00 0.33
VIME Vimentin 54 6 0 4
RS15A 40S ribosomal protein S15a 15 6 2 2 3.00 1.00
RL15 60S ribosomal protein L15 24 6 0 1
RS26 40S ribosomal protein S26 13 6 1 1 6.00 1.00
LSM6 U6 snRNA-associated Sm-like protein LSm6 9 6 0 0
RAN GTP-binding nuclear protein Ran 24 6 1 2 6.00 2.00
THOC4 THO complex subunit 4 27 6 0 3
RL10 60S ribosomal protein L10 25 6 1 2 6.00 2.00
RL18A 60S ribosomal protein L18a 21 6 0 1
DNJA3 DnaJ homolog subfamily A member 3, mito-
chondrial
52 6 0 0
SRSF1 Serine/arginine-rich splicing factor 1 28 6 0 2
RL26 60S ribosomal protein L26 17 6 0 1
RL24 60S ribosomal protein L24 18 6 1 0 6.00 0.00
RM12 39S ribosomal protein L12, mitochondrial 21 6 0 0
PRPF3 U4/U6 small nuclear ribonucleoprotein Prp3 78 6 0 0
PRP4 U4/U6 small nuclear ribonucleoprotein Prp4 58 6 0 0
GSH0 Glutamate–cysteine ligase regulatory subunit 31 5 2 5 2.50 2.50
NAA38 N-alpha-acetyltransferase 38, NatC auxiliary
subunit
10 5 0 0
RPIA Ribose-5-phosphate isomerase 33 5 0 8
RL23 60S ribosomal protein L23 15 5 2 3 2.50 1.50
UCK2 Uridine-cytidine kinase 2 29 5 0 4
C1QBP Complement component 1 Q subcomponent-
binding protein, mitochondrial
31 5 1 1 5.00 1.00
BCLF1 Bcl-2-associated transcription factor 1 106 5 1 4 5.00 4.00
DCP2 mRNA-decapping enzyme 2 48 5 0 0
NONO Non-POU domain-containing octamer-
binding protein
54 5 0 4
KCTD6 BTB/POZ domain-containing protein
KCTD6
28 5 0 1
RL31 60S ribosomal protein L31 14 5 1 1 5.00 1.00
CDK5 Cell division protein kinase 5 33 5 0 4
RS25 40S ribosomal protein S25 14 5 1 0 5.00 0.00
RT29 28S ribosomal protein S29, mitochondrial 46 5 0 0
RL11 60S ribosomal protein L11 20 5 1 2 5.00 2.00
RS23 40S ribosomal protein S23 16 5 1 1 5.00 1.00
LC7L2 Putative RNA-binding protein Luc7-like 2 47 5 2 0 2.50 0.00
HNRDL Heterogeneous nuclear ribonucleoprotein D-
like
46 5 0 2
ROA0 Heterogeneous nuclear ribonucleoprotein A0 31 5 1 1 5.00 1.00
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Num. of Unique Peptides Peptide Ratio
YFP- YFP-
MW YFP- YFP- Pat1b Pat1b-A
Symbol Description (kDa) Pat1b YFP Pat1b-A / YFP / YFP
1433T 14-3-3 protein theta 28 5 0 1
RT22 28S ribosomal protein S22, mitochondrial 41 5 0 0
YTDC2 Probable ATP-dependent RNA helicase
YTHDC2
160 5 0 0
UFC1 Ubiquitin-fold modifier-conjugating enzyme 1 19 4 2 5 2.00 2.50
ADT3 ADP/ATP translocase 3 33 4 1 3 4.00 3.00
DDX18 ATP-dependent RNA helicase DDX18 75 4 2 4 2.00 2.00
RL18 60S ribosomal protein L18 22 4 1 2 4.00 2.00
LSM3 U6 snRNA-associated Sm-like protein LSm3 12 4 1 0 4.00 0.00
MSRB2 Methionine-R-sulfoxide reductase B2, mito-
chondrial
20 4 2 4 2.00 2.00
SAFB1 Scaffold attachment factor B1 103 4 1 6 4.00 6.00
MTNB Probable methylthioribulose-1-phosphate de-
hydratase
27 4 0 3
TFAM Transcription factor A, mitochondrial 29 4 0 5
RS27 40S ribosomal protein S27 9 4 2 2 2.00 1.00
WIPI3 WD repeat domain phosphoinositide-
interacting protein 3
38 4 0 3
CHM1A Charged multivesicular body protein 1a 22 4 0 5
DDX3X ATP-dependent RNA helicase DDX3X 73 4 0 1
RALY RNA-binding protein Raly 32 4 2 2 2.00 1.00
NH2L1 NHP2-like protein 1 14 4 1 3 4.00 3.00
RL10A 60S ribosomal protein L10a 25 4 0 1
RUXE Small nuclear ribonucleoprotein E 11 4 1 1 4.00 1.00
RLA2 60S acidic ribosomal protein P2 12 4 0 1
RL9 60S ribosomal protein L9 22 4 0 1
LMNB2 Lamin-B2 68 4 0 1
CPPED Calcineurin-like phosphoesterase domain-
containing protein 1
36 4 0 2
RL35 60S ribosomal protein L35 15 4 0 2
RPF2 Ribosome production factor 2 homolog 36 4 0 1
LARP1 La-related protein 1 124 4 1 0 4.00 0.00
RL19 60S ribosomal protein L19 23 4 0 0
PABP4 Polyadenylate-binding protein 4 71 4 0 0
BAG2 BAG family molecular chaperone regulator 2 24 4 0 0
RT27 28S ribosomal protein S27, mitochondrial 48 4 0 0
RCD1 Cell differentiation protein RCD1 homolog 34 4 0 0
TADBP TAR DNA-binding protein 43 45 4 0 0
RM15 39S ribosomal protein L15, mitochondrial 33 4 0 0
H2AX Histone H2A.x 15 3 1 3 3.00 3.00
SMD1 Small nuclear ribonucleoprotein Sm D1 13 3 1 2 3.00 2.00
U5S1 116 U5 small nuclear ribonucleoprotein com-
ponent
109 3 1 6 3.00 6.00
MCM5 DNA replication licensing factor MCM5 82 3 1 8 3.00 8.00
RS24 40S ribosomal protein S24 15 3 1 2 3.00 2.00
PSME1 Proteasome activator complex subunit 1 29 3 0 4
RL7L 60S ribosomal protein L7-like 1 29 3 1 1 3.00 1.00
RSMB Small nuclear ribonucleoprotein-associated
proteins B and B’
25 3 1 2 3.00 2.00
AIBP Apolipoprotein A-I-binding protein 32 3 0 2
IMA2 Importin subunit alpha-2 58 3 0 1
RS30 40S ribosomal protein S30 7 3 0 1
RCC1 Regulator of chromosome condensation 45 3 0 2
RL30 60S ribosomal protein L30 13 3 0 1
IRS4 Insulin receptor substrate 4 134 3 0 1
RL21 60S ribosomal protein L21 19 3 1 1 3.00 1.00
SRP14 Signal recognition particle 14 protein 15 3 0 1
RL22 60S ribosomal protein L22 15 3 0 1
UPP1 Uridine phosphorylase 1 34 3 0 1
DKC1 H/ACA ribonucleoprotein complex subunit 4 58 3 0 1
ZCCHV Zinc finger CCCH-type antiviral protein 1 101 3 1 0 3.00 0.00
XRCC5 X-ray repair cross-complementing protein 5 83 3 0 1
RL28 60S ribosomal protein L28 16 3 0 1
DDX17 Probable ATP-dependent RNA helicase
DDX17
72 3 0 0
RM38 39S ribosomal protein L38, mitochondrial 45 3 0 0
SRSF5 Serine/arginine-rich splicing factor 5 31 3 0 0
TRA2A Transformer-2 protein homolog alpha 33 3 0 0
ATD3A ATPase family AAA domain-containing pro-
tein 3A
71 3 0 0
CPVL Probable serine carboxypeptidase CPVL 54 3 0 0
H1X Histone H1x 22 3 0 0
RL13A 60S ribosomal protein L13a 24 3 0 0
STPAP Speckle targeted PIP5K1A-regulated poly(A)
polymerase
94 3 0 0
FUS RNA-binding protein FUS 53 3 0 0
TIPRL TIP41-like protein 31 3 0 0
RL35A 60S ribosomal protein L35a 13 3 0 0
COX17 Cytochrome c oxidase copper chaperone 7 2 1 4 2.00 4.00
CYBP Calcyclin-binding protein 26 2 0 6
RL38 60S ribosomal protein L38 8 2 1 3 2.00 3.00
AIMP2 Aminoacyl tRNA synthase complex-
interacting multifunctional protein 2
35 2 1 2 2.00 2.00
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YFP- YFP-
MW YFP- YFP- Pat1b Pat1b-A
Symbol Description (kDa) Pat1b YFP Pat1b-A / YFP / YFP
HMGCL Hydroxymethylglutaryl-CoA lyase, mitochon-
drial
34 2 0 2
DCTP1 dCTP pyrophosphatase 1 19 2 1 3 2.00 3.00
UAP56 Spliceosome RNA helicase BAT1 49 2 1 1 2.00 1.00
H2A2B Histone H2A type 2-B 14 2 0 2
RASL2 Ras GTPase-activating protein 4 90 2 1 1 2.00 1.00
CH082 UPF0598 protein C8orf82 24 2 1 1 2.00 1.00
SRSF9 Serine/arginine-rich splicing factor 9 26 2 0 2
SMRC1 SWI/SNF complex subunit SMARCC1 123 2 0 2
RUXF Small nuclear ribonucleoprotein F 10 2 0 2
RL27 60S ribosomal protein L27 16 2 0 2
MTCH2 Mitochondrial carrier homolog 2 33 2 0 1
RUXG Small nuclear ribonucleoprotein G 8 2 1 1 2.00 1.00
HN1L Hematological and neurological expressed 1-
like protein
20 2 1 1 2.00 1.00
RUVB1 RuvB-like 1 50 2 1 1 2.00 1.00
SFPQ Splicing factor, proline- and glutamine-rich 76 2 0 2
RIPK1 Receptor-interacting serine/threonine-protein
kinase 1
76 2 1 1 2.00 1.00
EBP2 Probable rRNA-processing protein EBP2 35 2 1 0 2.00 0.00
RRP12 RRP12-like protein 144 2 0 1
GGH Gamma-glutamyl hydrolase 36 2 0 1
DHB12 Estradiol 17-beta-dehydrogenase 12 34 2 0 0
DHX36 Probable ATP-dependent RNA helicase
DHX36
115 2 0 0
RM21 39S ribosomal protein L21, mitochondrial 23 2 0 0
NPM3 Nucleoplasmin-3 19 2 1 0
DNJC9 DnaJ homolog subfamily C member 9 30 2 0 1
BYST Bystin 50 2 0 0
DDX1 ATP-dependent RNA helicase DDX1 82 2 0 0
MK67I MKI67 FHA domain-interacting nucleolar
phosphoprotein
34 2 0 0
RM19 39S ribosomal protein L19, mitochondrial 34 2 0 0
SMD2 Small nuclear ribonucleoprotein Sm D2 14 2 0 0
STAU1 Double-stranded RNA-binding protein
Staufen homolog 1
63 2 0 0
TRA2B Transformer-2 protein homolog beta 34 2 0 0
RM28 39S ribosomal protein L28, mitochondrial 30 2 0 0
RM17 39S ribosomal protein L17, mitochondrial 20 2 0 0
MAGD1 Melanoma-associated antigen D1 86 2 0 0
RS29 40S ribosomal protein S29 7 2 0 0
RBM39 RNA-binding protein 39 59 2 0 0
BRX1 Ribosome biogenesis protein BRX1 homolog 41 2 0 0
H2AW Core histone macro-H2A.2 40 2 0 0
RCL1 RNA 3’-terminal phosphate cyclase-like pro-
tein
41 2 0 0
RENT1 Regulator of nonsense transcripts 1 124 2 0 0
SNR40 U5 small nuclear ribonucleoprotein 40 protein 39 2 0 0
PRC2C Protein PRRC2C 317 2 0 0
RM03 39S ribosomal protein L3, mitochondrial 39 2 0 0
KHDR1 KH domain-containing, RNA-binding, signal
transduction-associated protein 1
48 2 0 0
FHL3 Four and a half LIM domains protein 3 31 2 0 0
DHX37 Probable ATP-dependent RNA helicase
DHX37
130 2 0 0
G3BP1 Ras GTPase-activating protein-binding
protein 1
52 2 0 0
SRSF2 Serine/arginine-rich splicing factor 2 25 2 0 0
VAPA Vesicle-associated membrane protein-
associated protein A
28 1 0 14
NU205 Nuclear pore complex protein Nup205 228 1 0 4
UT14A U3 small nucleolar RNA-associated protein 14
homolog A
88 1 0 3
NU160 Nuclear pore complex protein Nup160 162 1 0 2
HMGA1 High mobility group protein HMG-I/HMG-Y 12 1 0 3
NPA1P Nucleolar pre-ribosomal-associated protein 1 254 1 0 3
BAZ1A Bromodomain adjacent to zinc finger domain
protein 1A
179 1 0 2
ACYP2 Acylphosphatase-2 11 1 0 2
RN114 RING finger protein 114 26 1 0 3
UTP20 Small subunit processome component 20 ho-
molog
318 1 0 2
HMGN1 Non-histone chromosomal protein HMG-14 11 1 0 2
MYL6 Myosin light polypeptide 6 17 1 0 2
HMGN2 Non-histone chromosomal protein HMG-17 9 1 0 2
ANX11 Annexin A11 54 1 0 2
NOL11 Nucleolar protein 11 81 1 0 2
TOP1 DNA topoisomerase 1 91 1 0 2
FAKD5 FAST kinase domain-containing protein 5 87 1 0 2
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5.2 Results of Microarray Analysis
Table 5.2. List of mRNAs that are up- or down-regulated more than 2-fold, upon siRNA-mediated
knockdown of Pat1b, Rck and/or Pat1b together with Rck (Pat1b + Rck). Target mRNAs that were
tested with qPCR analysis are depicted in italic. FC, fold change.
FC (Linear Scale)
si-Pat1b
Gene ID Symbol Description si-Pat1b si-Rck + si-Rck
P
at
1b
on
ly
113791 PIK3IP1 phosphoinositide-3-kinase interacting protein 1 3.26
84898 PLXDC2 plexin domain containing 2 2.46
158572 LOC158572 hypothetical LOC158572 2.31
8140 SLC7A5 solute carrier family 7 (cationic amino acid transporter,
y+ system), member 5
2.10
4211 MEIS1 Meis homeobox 1 2.05
5955 RCN2 reticulocalbin 2, EF-hand calcium binding domain 2.03
808 CALM3 calmodulin 3 (phosphorylase kinase, delta) 0.50
54741 LEPROT leptin receptor overlapping transcript 0.49
6385 SDC4 syndecan 4 0.49
80196 RNF34 ring finger protein 34 0.49
338811 FAM19A2 family with sequence similarity 19 (chemokine (C-C
motif)-like), member A2
0.47
9231 DLG5 discs, large homolog 5 (Drosophila) 0.47
1404 HAPLN1 hyaluronan and proteoglycan link protein 1 0.47
5577 PRKAR2B protein kinase, cAMP-dependent, regulatory, type II,
beta
0.46
4674 NAP1L2 nucleosome assembly protein 1-like 2 0.46
8539 API5 apoptosis inhibitor 5 0.44
3936 LCP1 lymphocyte cytosolic protein 1 (L-plastin) 0.41
9813 KIAA0494 KIAA0494 0.40
56938 ARNTL2 aryl hydrocarbon receptor nuclear translocator-like 2 0.39
989 SEPT7 septin 7 0.38
P
at
1b
&
P
at
1b
+
R
ck
401138 AMTN amelotin 4.58 3.60
23657 SLC7A11 solute carrier family 7, (cationic amino acid transporter,
y+ system) member 11
3.13 2.71
6004 RGS16 regulator of G-protein signaling 16 2.87 3.31
84189 SLITRK6 SLIT and NTRK-like family, member 6 2.49 2.45
3887 KRT81 keratin 81 2.42 3.27
10962 MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 11
2.36 2.23
144165 PRICKLE1 prickle homolog 1 (Drosophila) 2.33 2.78
51647 FAM96B family with sequence similarity 96, member B 2.26 3.45
54732 TMED9 transmembrane emp24 protein transport domain con-
taining 9
2.24 2.35
9652 TTC37 tetratricopeptide repeat domain 37 2.16 2.51
6744 SSFA2 sperm specific antigen 2 2.15 2.20
51088 KLHL5 kelch-like 5 (Drosophila) 2.14 3.61
7286 TUFT1 tuftelin 1 2.13 3.10
3516 RBPJ recombination signal binding protein for immunoglobu-
lin kappa J region
2.10 2.36
2632 GBE1 glucan (1,4-alpha-), branching enzyme 1 2.09 2.58
51614 ERGIC3 ERGIC and golgi 3 2.07 2.22
3295 HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 2.01 2.45
4591 TRIM37 tripartite motif-containing 37 0.49 0.43
57687 VAT1L vesicle amine transport protein 1 homolog (T.
californica)-like
0.48 0.45
51280 GOLM1 golgi membrane protein 1 0.48 0.32
79794 C12orf49 chromosome 12 open reading frame 49 0.47 0.48
4893 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 0.46 0.47
10713 USP39 ubiquitin specific peptidase 39 0.44 0.47
3572 IL6ST interleukin 6 signal transducer (gp130, oncostatin M re-
ceptor)
0.44 0.39
3925 STMN1 stathmin 1/oncoprotein 18 0.44 0.46
27248 C2orf30 chromosome 2 open reading frame 30 0.43 0.39
3397 ID1 inhibitor of DNA binding 1, dominant negative helix-
loop-helix protein
0.43 0.40
6386 SDCBP syndecan binding protein (syntenin) 0.42 0.45
3930 LBR lamin B receptor 0.41 0.45
55326 AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5
(lysophosphatidic acid acyltransferase, epsilon)
0.40 0.31
10592 SMC2 structural maintenance of chromosomes 2 0.39 0.40
29940 DSE dermatan sulfate epimerase 0.38 0.23
9768 KIAA0101 KIAA0101 0.38 0.37
7706 TRIM25 tripartite motif-containing 25 0.32 0.36
23770 FKBP8 FK506 binding protein 8, 38kDa 0.28 0.34
23191 CYFIP1 cytoplasmic FMR1 interacting protein 1 0.27 0.38
5528 PPP2R5D protein phosphatase 2, regulatory subunit B, delta isoform 0.16 0.17
7837 PXDN peroxidasin homolog (Drosophila) 0.15 0.17
219988 PATL1 protein associated with topoisomerase II homolog 1
(yeast)
0.09 0.09
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R
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72 ACTG2 actin, gamma 2, smooth muscle, enteric 9.94
59 ACTA2 actin, alpha 2, smooth muscle, aorta 7.14
6876 TAGLN transgelin 3.99
57381 RHOJ ras homolog gene family, member J 2.94
3897 L1CAM L1 cell adhesion molecule 2.33
3690 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen
CD61)
2.27
7414 VCL vinculin 2.13
51704 GPRC5B G protein-coupled receptor, family C, group 5, member
B
2.11
10398 MYL9 myosin, light chain 9, regulatory 2.05
51199 NIN ninein (GSK3B interacting protein) 0.42
6051 RNPEP arginyl aminopeptidase (aminopeptidase B) 0.39
R
ck
&
P
at
1b
+
R
ck 3491 CYR61 cysteine-rich, angiogenic inducer, 61 2.53 2.46
143888 KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 2 0.28 0.23
1656 DDX6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 0.07 0.09
P
at
1b
+
R
ck
55681 SCYL2 SCY1-like 2 (S, cerevisiae) 6.68
1317 SLC31A1 solute carrier family 31 (copper transporters), member
1
5.10
148362 C1orf58 chromosome 1 open reading frame 58 4.17
169200 TMEM64 transmembrane protein 64 3.47
10026 PIGK phosphatidylinositol glycan anchor biosynthesis, class
K
3.39
1136 CHRNA3 cholinergic receptor, nicotinic, alpha 3 3.38
8549 LGR5 leucine-rich repeat-containing G protein-coupled recep-
tor 5
3.10
79719 FLJ11506 alpha- and gamma-adaptin-binding protein p34 2.98
1004 CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 2.96
54838 C10orf26 chromosome 10 open reading frame 26 2.87
284119 PTRF polymerase I and transcript release factor 2.72
3632 INPP5A inositol polyphosphate-5-phosphatase, 40kDa 2.69
8076 MFAP5 microfibrillar associated protein 5 2.63
4238 MFAP3 microfibrillar-associated protein 3 2.63
6502 SKP2 S-phase kinase-associated protein 2 (p45) 2.53
85236 HIST1H2BK histone cluster 1, H2bk 2.47
2690 GHR growth hormone receptor 2.47
127933 UHMK1 U2AF homology motif (UHM) kinase 1 2.44
11022 TDRKH tudor and KH domain containing 2.41
29101 SSU72 SSU72 RNA polymerase II CTD phosphatase homolog
(S, cerevisiae)
2.39
1000 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 2.39
586 BCAT1 branched chain aminotransferase 1, cytosolic 2.37
9802 DAZAP2 DAZ associated protein 2 2.36
22862 FNDC3A fibronectin type III domain containing 3A 2.33
53 ACP2 acid phosphatase 2, lysosomal 2.30
7052 TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase)
2.28
1809 DPYSL3 dihydropyrimidinase-like 3 2.23
55161 TMEM33 transmembrane protein 33 2.22
5437 POLR2H polymerase (RNA) II (DNA directed) polypeptide H 2.19
6302 TSPAN31 tetraspanin 31 2.19
1718 DHCR24 24-dehydrocholesterol reductase 2.19
3685 ITGAV integrin, alpha V (vitronectin receptor, alpha polypep-
tide, antigen CD51)
2.17
89970 RSPRY1 ring finger and SPRY domain containing 1 2.17
79822 ARHGAP28 Rho GTPase activating protein 28 2.16
9213 XPR1 xenotropic and polytropic retrovirus receptor 2.15
9929 JOSD1 Josephin domain containing 1 2.15
3836 KPNA1 karyopherin alpha 1 (importin alpha 5) 2.13
9520 NPEPPS aminopeptidase puromycin sensitive 2.13
10900 RUNDC3A RUN domain containing 3A 2.13
4047 LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cy-
clase)
2.11
80146 UXS1 UDP-glucuronate decarboxylase 1 2.10
10195 ALG3 asparagine-linked glycosylation 3, alpha-1,3- mannosyl-
transferase homolog (S, cerevisiae)
2.09
8992 ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit
e1
2.08
3678 ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypep-
tide)
2.06
9241 NOG noggin 2.06
23196 FAM120A family with sequence similarity 120A 2.06
51474 LIMA1 LIM domain and actin binding 1 2.05
9188 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 2.04
6198 RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 2.03
51706 CYB5R1 cytochrome b5 reductase 1 2.03
Continued on Next Page. . .
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5.2 Results of Microarray Analysis
FC (Linear Scale)
si-Pat1b
Gene ID Symbol Description si-Pat1b si-Rck + si-Rck
523 ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit
A
2.02
8048 CSRP3 cysteine and glycine-rich protein 3 (cardiac LIM pro-
tein)
2.02
93663 ARHGAP18 Rho GTPase activating protein 18 2.02
1024 CDK8 cyclin-dependent kinase 8 2.01
81575 APOLD1 apolipoprotein L domain containing 1 0.50
114908 TMEM123 transmembrane protein 123 0.50
3696 ITGB8 integrin, beta 8 0.50
55536 CDCA7L cell division cycle associated 7-like 0.49
63901 FAM111A family with sequence similarity 111, member A 0.49
3024 HIST1H1A histone cluster 1, H1a 0.49
6241 RRM2 ribonucleotide reductase M2 polypeptide 0.49
25945 PVRL3 poliovirus receptor-related 3 0.49
9582 APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3B
0.48
P
at
1b
+
R
ck
348235 FAM33A family with sequence similarity 33, member A 0.48
8787 RGS9 regulator of G-protein signaling 9 0.48
10457 GPNMB glycoprotein (transmembrane) nmb 0.48
5627 PROS1 protein S (alpha) 0.48
135293 PM20D2 peptidase M20 domain containing 2 0.48
26002 MOXD1 monooxygenase, DBH-like 1 0.48
6364 CCL20 chemokine (C-C motif) ligand 20 0.48
405 ARNT aryl hydrocarbon receptor nuclear translocator 0.47
3920 LAMP2 lysosomal-associated membrane protein 2 0.47
51514 DTL denticleless homolog (Drosophila) 0.47
134829 RLBP1L2 retinaldehyde binding protein 1-like 2 0.47
1812 DRD1 dopamine receptor D1 0.47
79598 CEP97 centrosomal protein 97kDa 0.47
28951 TRIB2 tribbles homolog 2 (Drosophila) 0.47
3672 ITGA1 integrin, alpha 1 0.46
142679 DUSP19 dual specificity phosphatase 19 0.46
90381 C15orf42 chromosome 15 open reading frame 42 0.45
23532 PRAME preferentially expressed antigen in melanoma 0.45
220988 HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 0.45
113146 AHNAK2 AHNAK nucleoprotein 2 0.44
9897 KIAA0196 KIAA0196 0.44
26503 SLC17A5 solute carrier family 17 (anion/sugar transporter), mem-
ber 5
0.42
23306 TMEM194A transmembrane protein 194A 0.42
57088 PLSCR4 phospholipid scramblase 4 0.41
53904 MYO3A myosin IIIA 0.40
51136 RNFT1 ring finger protein, transmembrane 1 0.39
3075 CFH complement factor H 0.38
93649 MYOCD myocardin 0.35
57157 PHTF2 putative homeodomain transcription factor 2 0.35
84767 SPRYD5 SPRY domain containing 5 0.34
79365 BHLHE41 basic helix-loop-helix family, member e41 0.32
59084 ENPP5 ectonucleotide pyrophosphatase/phosphodiesterase 5
(putative function)
0.32
6414 SEPP1 selenoprotein P, plasma, 1 0.32
3037 HAS2 hyaluronan synthase 2 0.17
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In eukaryotic cells, degradation of many mRNAs is initiated by removal of the poly(A) tail followed by
decapping and 5-3 exonucleolytic decay. Although the order of these events is well established, we are still
lacking a mechanistic understanding of how deadenylation and decapping are linked. In this report we identify
human Pat1b as a protein that is tightly associated with the Ccr4-Caf1-Not deadenylation complex as well as
with the Dcp1-Dcp2 decapping complex. In addition, the RNA helicase Rck and Lsm1 proteins interact with
human Pat1b. These interactions are mediated via at least three independent domains within Pat1b, suggesting
that Pat1b serves as a scaffold protein. By tethering Pat1b to a reporter mRNA, we further provide evidence
that Pat1b is also functionally linked to both deadenylation and decapping. Finally, we report that Pat1b
strongly induces the formation of processing (P) bodies, cytoplasmic foci that contain most enzymes of the RNA
decay machinery. An amino-terminal region within Pat1b serves as an aggregation-prone domain that nucle-
ates P bodies, whereas an acidic domain controls the size of P bodies. Taken together, these findings provide
evidence that human Pat1b is a central component of the RNA decay machinery by physically connecting
deadenylation with decapping.
By controlling gene expression at the posttranscriptional
level, cells can rapidly induce, suppress, or fine-tune the pro-
duction of specific proteins. A well-studied example is a class of
mRNAs that contain AU-rich elements (AREs) in their 3
untranslated region (UTR), which causes rapid mRNA decay.
The degradation of ARE mRNAs can be inhibited by extra-
cellular signals, a mechanism that contributes to the efficient
production of cytokines in activated cells of the immune system
(37). Another prominent example are mRNAs targeted by
microRNAs (miRNAs), which generally cause translational
inhibition and/or accelerated mRNA decay (7). The reversible
transit of an actively translating mRNA to a state of transla-
tional silencing and the irreversible step that elicits mRNA
degradation involve crucial rearrangements of the ribonucleo-
protein (RNP) composition. In some cases, the transit of an
mRNA to a repressed state is associated with its recruitment to
processing (P) bodies (3, 14, 35). P bodies are cytoplasmic foci
that contain many enzymes of the general mRNA decay path-
way, such as the Ccr4-Caf1-Not deadenylase complex and the
decapping enzyme Dcp2 together with its activators Dcp1,
Edc3, and Hedls, as well as the 5-3 exoribonuclease Xrn1 that
is tightly associated with the heptameric ring of the Lsm1-7
proteins (2, 10, 13, 21, 24, 35, 41, 43, 47).
For most eukaryotic mRNAs, deadenylation is the first step
in the decay pathway. Once the poly(A) tail is removed, the
mRNA is either degraded in the 3-5 direction by the exosome
or decapped at the 5 end and subsequently degraded in the
5-3 direction by Xrn1 (15). Both ARE-mediated mRNA de-
cay and miRNA-mediated mRNA decay make use of this gen-
eral decay pathway by delivering mRNAs at an accelerated
rate to the decay machinery.
An unsolved question is how deadenylation at the 3 end of
an mRNA is linked to decapping at the 5 end. Since dead-
enylated but capped mRNAs are virtually undetectable in wild-
type (wt) cells, the two events seem to be coupled very tightly.
However, it is not clear which factors physically connect the
deadenylation and decapping complexes.
Studies of Saccharomyces cerevisiae suggest that Pat1 (pro-
tein associated with topoisomerase II, also termed MRT1)
might play a role in coupling deadenylation with decapping.
On the one hand, yeast mutants lacking Pat1 show reduced
rates of mRNA degradation and accumulate deadenylated but
capped mRNA (18). Thus, Pat1 was proposed to enhance
mRNA decay by activating the decapping reaction. On the
other hand, Pat1 was found to interact with the cytoplasmic
Lsm1-7 proteins, which form a heptameric ring structure (5, 6).
The Lsm1-7–Pat1 complex was shown to preferentially bind to
the 3 end of mRNAs that contain short poly(A) tails (8, 42).
Since strains lacking Lsm1 or Pat1 generate transcripts that are
truncated at the 3 end, the Lsm1-7–Pat1 complex also appears
to protect mRNA from further trimming after deadenylation
(19). Thus, the Lsm1-7–Pat1 complex was proposed to serve
as a linker that recognizes oligo- or deadenylated mRNAs at
the 3 end and activates the subsequent step of decapping at
the 5 end.
To further pursue the mechanism by which deadenylation is
coupled to decapping, we sought to study the function of hu-
man Pat1 homologs. For many years, a metazoan counterpart
of yeast Pat1 has not been identified since routine BLAST
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analysis does not reveal homologous proteins. In 2007, Scheller
et al. identified two human homologs which they termed PatL1
and PatL2 (34). This report showed that human PatL1 local-
izes to P bodies and that its depletion by small interfering RNA
(siRNA) causes loss of P bodies. We have independently iden-
tified the same two proteins as possible homologs of yeast Pat1.
In accordance with the two orthologs in Xenopus laevis, we
termed the two proteins Pat1a and Pat1b (Nancy Standard,
personal communication). In the present study we provide
evidence that human Pat1b (PatL1) physically and function-
ally connects the deadenylation and decapping machinery.
Whereas no function could be attributed to Pat1a (PatL2),
we found that Pat1b also controls the assembly of P bodies.
MATERIALS AND METHODS
Plasmids. The following plasmids have been described previously: pCMV-
FLAG-NOT1 (45), pcDNA3-Myc-Ccr4, pcDNA3-Flag-Dcp1a, pcDNA3-Flag-
Dcp2 (25), and pCIneo-RL (31).
To generate pcDNA3-HA (p2003), oligonucleotides G85/G86 (for primer
sequences, see Table S1 in the supplemental material) were annealed and cloned
into the HindIII-EcoRI sites of pcDNA3 (Invitrogen). For pcDNA3-YFP
(p2168), yellow fluorescent protein (YFP) was amplified with oligonucleotides
G243/G244 and then ligated into the HindIII-KpnI sites of pcDNA3-HA
(p2003), thereby replacing the hemagglutinin (HA) tag.
For plasmid pEYFP-Pat1a (p2639), the human Pat1a coding sequence was
amplified in three portions from the cDNA of HeLa cells and ligated sequentially
into the BglII-XbaI sites of pEYFP-C1 (Clontech/BD Biosciences). The follow-
ing primer pairs were used: G1332/G1222 (1st PCR) and G1332/G1198 (2nd
PCR) for the Pat1a C-terminal portion, ligated as a KpnI-XbaI fragment; G1315/
G1221 for the middle portion, ligated as a BglII-KpnI fragment; and G1219/
G1340 (1st PCR) and G1353/G1340 (2nd PCR) for the Pat1a N-terminal por-
tion, ligated as a BamHI-BglII fragment and thereby introducing an EcoRI site
upstream of the start codon. For pcDNA3-HA-Pat1a (p2638), the human Pat1a
coding sequence was excised from pEYFP-Pat1a (p2639) as an EcoRI-XbaI
fragment and cloned into the same sites of pcDNA3-HA (p2003).
A human Pat1b cDNA clone (DKFZp451I053) fused at the C terminus to
YFP was kindly provided by Stefan Wiemann (German Cancer Research Center,
Heidelberg, Germany). In order to generate HA-tagged Pat1b constructs, frag-
ments were amplified by PCR from human Pat1b cDNA and inserted into the
KpnI-XhoI sites of pcDNA3-HA (p2003). The following primers were used:
G1225/G1230 for pcDNA3-HA-Pat1b (p2516), G1225/G1226 for pcDNA3-
HA-AN (p2511), G1225/G1228 for pcDNA3-HA-ANH (p2514), G1227/G1228
for pcDNA3-HA-H (p2512), G1227/G1230 for pcDNA3-HA-HC (p2515),
G1229/G1230 for pcDNA3-HA-C (p2513), G1225/G1425 for pcDNA3-HA-A
(p2591), G1408/G1226 for pcDNA3-HA-N (p2592), and G1408/G1230 for
pcDNA3-HA-dA (p2675). For pcDNA3-HA-dH (p2542), the N- and C-terminal
regions of Pat1b were first amplified as separate fragments with primers G1225/
G1295 and G1296/G1230, respectively. The PCR products were then aligned,
Pat1b lacking the H domain was amplified with primers G1225/G1230, and the
PCR product was cloned into the KpnI-XhoI sites of pcDNA3-HA (p2003).
pcDNA3-YFP-Pat1b full length (p2521), pcDNA3-YFP-A (p2630), pcDNA3-
YFP-AN (p2626), pcDNA3-YFP-N (p2627), pcDNA3-YFP-ANH (p2522),
pcDNA3-YFP-H (p2632), pcDNA3-YFP-C (p2628), pcDNA3-YFP-HC (p2629),
pcDNA3-YFP-dA (p2631), and pcDNA3-YFP-dH (p2633) were generated by
replacing the HA tag in the corresponding HA-tagged Pat1b constructs with YFP
excised as a HindIII-KpnI fragment from pcDNA3-YFP (p2168). For pcDNA3-
HA-Pat1b-YFP (p2520), Pat1b-YFP was amplified by PCR with primers G1225/
G1253, using clone DKFZp451I053 as a template, and inserted into the KpnI-
XhoI sites of pcDNA3-HA-Pat1b (p2516).
In order to generate pcDNA3-HA-PP7cp-Pat1b (p2634), pcDNA3-HA-
PP7cp-AN (p2658), pcDNA3-HA-PP7cp-HC (p2659), pcDNA3-HA-PP7cp-dA
(p2663), pcDNA3-HA-PP7cp-dH (p2660), and pcDNA3-HA-PP7cp-Pat1a
(2661), PP7cp (46) was amplified by PCR using primers G1501/G1502 and
inserted into the KpnI site of corresponding pcDNA3-HA-Pat1b constructs
and pcDNA3-HA-Pat1a (p2638). Orientation of the insert was checked by
sequencing.
For pcDNA3-Bgl (p2001), the BglII site in pcDNA3 (Invitrogen) was removed
by digestion with BglII and blunt-end religation, thereby introducing a novel ClaI
site. pcDNA3-7B (p2308) expressing a T7-tagged rabbit -globin gene was sub-
sequently generated by amplifying -globin by PCR with primers G18/G19 from
plasmid puroMXbglobin (39). The fragment was digested with EcoRV and SalI
and ligated into the BamHI/blunt-XhoI sites of pcDNA3-Blg. For pcDNA3-7B-
PP7bs (p2314), six repeats of the PP7 binding site were excised as a BamHI-BglII
fragment from pSP73-6xPP7bs (46) and introduced into the BglII site of
pcDNA3-7B (p2308). For pFLB (p2524), firefly luciferase (FL) cDNA was am-
plified by PCR using primers G1256/G1257 from pGL3-Control (Promega) and
cloned into the HindIII-KpnI sites of pcDNA3-7B (2308). From there, the 6
PP7bs repeats were cloned as an EcoRI-BglII fragment from pcDNA3-7B-PP7bs
(p2314) into the corresponding sites of pFLB (p2524) to generate pFLB-PP7bs
(p2646).
For TOpuro-Caf1a-mycSG (p2485), the human Caf1a cDNA was amplified by
reverse transcription (RT)-PCR using primers G1122 and G1123 and cloned into
the BamHI-XhoI sites of TOpuro-mycSG (p2484). For pTOpuro-Caf1a-AA-
mycSG (p2737) containing the D40A/E42A mutation, a fragment amplified by
PCR with primers G1730 and G1731 was inserted into the KpnI-EcoRI sites of
TOpuro-Caf1a-mycSG (p2485). For pEGFP-TEV-Caf1a (p2793), Caf1a cDNA
was cloned as a BamHI-XhoI fragment into the BglII-XhoI sites of pEGFP-N1
containing a tobacco etch virus (TEV) cleavage site. To generate pcDNA3-Flag-
Dcp2-AA (p2798), the E147A/E148A mutation was introduced into the KpnI-
EcoRV sites of pcDNA3-Flag-Dcp2 (25) using a PCR fragment amplified with
primers G1883 and G1884.
Cell culture and transfection. HeLa, U2OS, HEK293, and COS7 cells were
cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal
bovine serum (PAA Laboratories), 2 mM L-glutamine, 100 U/ml penicillin, and
0.1 mg/ml streptomycin (all PAN Biotech) at 37°C/5% CO2. Plasmids were
transfected with Lipofectamine 2000 (Invitrogen) for protein interaction studies
or with Fugene HD (Roche) for immunofluorescence analysis according to
the manufacturer’s recommendations. Alternatively, polyethyleneimine (Poly-
sciences Europe; 1 mg/ml, pH 7.0) was also used as a transfection reagent for
interaction and functional studies. siRNAs were transfected at a concentration of
100 nM with Lipofectamine 2000 twice over a time period of 4 days. Where
indicated, cells were treated for 2 h with 5 g/ml cycloheximide (Roth).
siRNAs. siRNAs used in this study were synthesized by Ambion against the
following sequences (sense strand): D0 (control), 5-GCAUUCACUUGGAUA
GUAAdTdT-3; T2 (human Pat1b), 5-GCAGAAAGGCUCAGUAAGAdTdT-
3; and T3 (human Pat1b), 5-GGACGGAGGUGAUGUUCAUdTdT-3.
Immunofluorescence microscopy. Twenty-four hours after transient transfec-
tion, cells grown on glass coverslips were fixed in 4% paraformaldehyde for 10
min at room temperature. Cell membranes were then permeabilized in 20°C
cold methanol for 10 min. Phosphate-buffered saline (PBS) containing 0.1%
sodium azide and 5% horse serum was used for blocking and antibody dilution.
DNA was visualized using Hoechst dye (no. 33342, 1 g/ml; Sigma). After
washing in PBS, cells were mounted onto glass slides using a solution of 14%
polyvinyl alcohol (P8136; Sigma) and 30% glycerol in PBS. P bodies were
counted on an upright epifluorescence microscope (BX60; Olympus). Images
were acquired at the Nikon Imaging Center, Heidelberg, Germany, either on an
upright epifluorescence microscope (90i; Nikon) or by spinning-disc confocal
microscopy (Ultraview ERS [Perkin Elmer] on a TE2000 inverted microscope
[Nikon]) using an electron-multiplying charge-coupled-device (EM-CCD) cam-
era (Hamamastu).
Coimmunoprecipitation (co-IP) and Western blot analysis. Twenty-four hours
after transient transfection, HEK293 cells from a confluent 10-cm dish were
collected and lysed in 400 l ice-cold hypotonic lysis buffer (10 mM Tris [pH 7.5],
10 mM NaCl, 10 mM M EDTA, 0.5% Triton X-100 with freshly added protease
inhibitors [Complete; Roche]). Nuclei were removed by centrifugation at 500 
g for 5 min at 4°C. The cytoplasmic lysate was precleared by the addition of 30
l protein A/G-agarose beads (Pierce or Santa Cruz) for 1 h at 4°C and incu-
bated with 1 g of antibody for 2 h. A total of 30 l of protein A/G beads was
added for an additional 2 h and washed six times in NET2 buffer (50 mM Tris
[pH 7.5], 150 mM NaCl, 0.5% Triton X-100). Protein complexes were eluted with
25 l SDS sample buffer with or without 100 mM dithiothreitol (DTT). Where
indicated, RNase A (Sigma; 0.1 mg/ml) was added to the lysates after preclear-
ing. Proteins were resolved on 10% polyacrylamide gels and transferred onto a
0.2-m-pore-size nitrocellulose membrane (Peqlab) for Western blotting. Horse-
radish peroxidase-coupled secondary antibodies (Jackson Immunoresearch) in
combination with Western Lightning enhanced chemiluminescence substrate
(Perkin Elmer) were used for detection. The green fluorescent protein (GFP)-
binder was used for immunoprecipitation (IP) of YFP-tagged proteins as de-
scribed previously (33).
Antibodies. Polyclonal antibody Ab387 against human Pat1b was produced at
Eurogentec by immunizing rabbits with peptide QGPEDDRDLSERALPR. The
following antibodies were used for IP and Western blotting, and immunofluo-
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rescence analysis: mouse monoclonal antibodies anti-HA (HA.11; Covance) and
anti-Edc3 (Abcam; ab57780-100); a cross-reacting mouse monoclonal phospho-
S6-kinase antibody (sc-8416; Santa Cruz) for detection of Hedls; polyclonal
chicken antibodies against Lsm1 (15-288-22100F; Genway Biotech) and Lsm4
(19101; Abcam); polyclonal rabbit antibodies against Xrn1 (A300-461A; Bethyl
Laboratories), p54/Rck (A300-443A; Bethyl Laboratories), eIF4G (sc-11373;
Santa Cruz), 14-3-3 (sc-629; Santa Cruz), and HA (sc-805; Santa Cruz); and a
polyclonal goat antibody against eIF3B (sc-16377; Santa Cruz). Polyclonal
rabbit anti-Caf1a was kindly provided by Ann-Bin Shyu (University of Texas,
Houston, TX).
Northern blot analysis. For RNA decay experiments, actinomycin D (Appli-
chem) was added to cell cultures at 5 g/ml, and total RNA was extracted using
the Genematrix RNA purification kit (Eurx, Roboklon). A total of 7 to 15 g of
RNA was resolved by 1.1 or 1.6% agarose-2% formaldehyde-MOPS (morpho-
linepropanesulfonic acid) gel electrophoresis and blotted overnight with 8 SSC
(1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) onto Hybond-N Nylon
membranes (Amersham, GE). Membranes were hybridized overnight with
digoxigenin-labeled RNA probes at 55°C and washed twice with 2 SSC-0.1%
SDS for 5 min and twice with 0.5 SSC-0.1% SDS for 20 min at 65°C. Alkaline
phosphatase-labeled anti-DIG Fab fragments and CDP-Star substrate (both
Roche) were used for detection according to the manufacturer’s instructions.
The following primers were used to generate templates for Sp6 probes by PCR:
G1000/G1001 for the probe against exon 1 and 2 of rabbit -globin, G78/G1008
for the probe against human RPS7, and G083/G1009 for the probe against
nucleolin. Primer sequences are listed in Table S1 in the supplemental material.
Luciferase assay. One third of a 6-cm dish of transiently transfected HeLa cells
was lysed in 150 l of passive lysis buffer (dual-luciferase reporter assay system;
Promega) and frozen at 20°C. After thawing, nuclei were removed by centrif-
ugation for 2 min at 13,000 rpm at 4°C. A total of 20 l of the supernatant was
mixed with 50 l of substrates from the dual-luciferase reporter assay system,
diluted 1:3. Firefly and Renilla luciferase activities were measured on a Fluostar
Optima (BMG Labtech) plate reader.
RESULTS
Identification of two human Pat1 homologs. In order to
identify a human homolog of yeast Pat1, we compared Pat1
sequences of different fungi and observed a highly conserved
central region of about 40 amino acids (aa), hereinafter termed
the homology (H) domain. Using this domain, BLAST analysis
was able to identify homologous sequences in various metazoa,
including Caenorhabditis elegans, Drosophila melanogaster,
Danio rerio, and Xenopus laevis (see Fig. S1 in the supplemen-
tal material). Two proteins sharing the H domain were found
in mice and humans, indicative of a gene duplication in mam-
mals. Outside the H domain, the only detectable sequence
conservation between the fungal and metazoan proteins lies in
a highly acidic stretch of 50 to 70 aa at the very amino termi-
nus, hereinafter referred to as the acidic domain (A). We
termed the two human proteins Pat1a and Pat1b. Pat1b is
identical to PatL1 previously identified by Scheller et al. (34).
Pat1a matches the partial sequence that was previously sug-
gested as the human Pat1 ortholog (9) and differs from the
predicted PatL2 sequence at the N terminus (34). An align-
ment between the human Pat1a and Pat1b sequence (see Fig.
S2 in the supplemental material) shows that Pat1a lacks a
region of about 150 aa in the amino-terminal part following the
A domain.
Human Pat1b, but not Pat1a, localizes to P bodies. We first
examined the localization of human Pat1a and Pat1b by ex-
pressing yellow fluorescent protein (YFP)-tagged fusion pro-
teins in COS7 cells. Epifluorescence microscopy showed that
YFP-Pat1a is expressed throughout the cytoplasm, where it has
a reticular distribution, but does not accumulate in P bodies
(Fig. 1B). YFP-Pat1b, however, strongly accumulates in small
cytoplasmic foci (Fig. 1C to E). These foci correspond to P
bodies as determined by colocalization with different markers,
including the enhancer of decapping Hedls (Fig. 1C), the he-
licase Rck (Fig. 1D), and Lsm1 (Fig. 1E). The localization of
Pat1b in P bodies was also observed with a C-terminal fusion of
YFP and with N-terminal HA and Flag tags (data not shown).
We confirmed the localization of Pat1b in P bodies of human
HeLa (data not shown) and U2OS cells (see Fig. S3 in the
supplemental material). Thus, human Pat1b, but not Pat1a,
localizes in P bodies. This is in line with the previously ob-
served localization of Pat1b (PatL1) in HeLa cells (34).
In order to determine whether endogenous Pat1b would also
localize in P bodies, we raised a peptide antibody in rabbit
(Ab387). This antibody was able to detect overexpressed Pat1b
by Western blot analysis (see Fig. S4A in the supplemental
material). By immunofluorescence microscopy, Ab387 gave a
punctate staining in both the nucleus and the cytoplasm of
untransfected COS7 (Fig. 1F and G) and U2OS cells (see Fig.
S3F and G in the supplemental material). The larger foci in the
cytoplasm perfectly overlap with Hedls and Lsm1, indicating
that endogenous Pat1b also localizes to P bodies.
Human Pat1b induces P-body formation. We noticed that
cells transfected with YFP-Pat1b showed strongly increased
numbers of P bodies compared to control cells transfected with
YFP or YFP-Pat1a (compare Hedls staining in Fig. 1A to C).
By counting P bodies using Hedls as a marker, we found that
most COS7 cells overexpressing YFP-Pat1b have20 P bodies
per cell compared to an average of about 9 P bodies per cell in
untransfected or YFP-expressing cells (Fig. 1H). Overexpres-
sion of YFP-Pat1a, however, did not increase the number of P
bodies. The strong increase in P-body numbers by Pat1b over-
expression was confirmed with an HA-tagged version, and the
same was also observed with other cell lines, such as HeLa and
FIG. 1. Intracellular localization of human Pat1a and Pat1b in COS7 cells. COS7 cells were transiently transfected with YFP (A), YFP-Pat1a
(B), or YFP-Pat1b (C to E) and processed for immunofluorescence microscopy. P bodies in the cytoplasm were counterstained in red using an
antibody against Hedls (A to C), Rck (D), or Lsm1 (E). In addition, cells were stained with Hoechst 33342 in blue to visualize nuclei. Images in
panels A to E were acquired by epifluorescence microscopy. Merged images are shown on the right, and the size bar represents 10 m. Arrowheads
point toward P bodies. (F and G) Untransfected COS7 cells were stained in red for endogenous Pat1b with antibody 387 and in green for P bodies
using Hedls (F) or Lsm1 (G) as a marker. Images in panels F and G were acquired by spinning-disc confocal microscopy; maximum projections
of z-stacks are depicted. (H) COS7 cells transiently transfected with either YFP, YFP-Pat1a, or YFP-Pat1b were fixed and stained for P bodies
using an antibody against Hedls. The number of P bodies (PBs) in transfected cells was counted, and the average distribution is represented in the
graph. Error bars show the standard deviations (SD) based on three independent repeats. Untransfected COS7 cells serve as an additional control.
(I) The expression of Pat1b was knocked down in U2OS cells by transfection of two different siRNAs (T2 and T3) at a concentration of 100 nM.
An unspecific siRNA (D0) was transfected as a negative control. The number of PBs per cell was counted after staining for Helds, and the average
distribution is represented in the graph. Error bars show the SD based on three independent repeats.
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U2OS (data not shown). Since Pat1b overexpression causes a
dramatic amplification of P bodies, many of which are very
small, Pat1b may play an active role in nucleating the assembly
of P bodies.
To further address the role of Pat1b in P-body assembly, we
knocked down endogenous Pat1b in U2OS cells. Two different
siRNAs, T2 and T3, reduced Pat1b mRNA levels to 5% and
6%, respectively, compared to the expression level in cells
transfected with control siRNA (see Fig. S5A in the supple-
mental material). Indeed, knockdown of Pat1b led to a nearly
complete loss of P bodies (Fig. 1I; see also micrographs shown
in Fig. S5B in the supplemental material). This result supports
the notion that Pat1b nucleates the assembly of P bodies.
Pat1b domains control P-body assembly. Next, we wanted to
examine the contribution of different Pat1b domains, schemat-
ically depicted in Fig. 2A, to its intracellular localization. Frag-
ments and deletions of Pat1b were expressed as YFP fusion
proteins in COS7 cells and examined by spinning-disc confocal
microscopy. Localization data are summarized in Table S2 in
the supplemental material, and examples are shown in Fig. 2.
As stated above, YFP-Pat1b forms many small- or medium-
size foci, reminiscent of a “salt”-like appearance, and these foci
colocalize with all P-body markers tested, including Hedls,
Rck, Lsm1, and Lsm4 (Fig. 1C to E and 2B; see also Fig. S6E
in the supplemental material). Thus, overexpressed Pat1b lo-
calizes to and strongly amplifies the number of P bodies. De-
letion of the homology domain (YFP-dH) did not change this
localization pattern (Fig. 2C). Deletion of the acidic region
(YFP-dA), however, caused the protein to localize to much
smaller and more numerous foci, reminiscent of a “pepper”-
like appearance. These foci colocalize with Hedls (Fig. 2D)
and with Rck (data not shown). Thus, YFP-dA triggers the
formation of small P bodies, yet deletion of the acidic domain
seems to prevent small aggregates from growing or merging
into larger P bodies.
Localization of the YFP-AN fragment was very heteroge-
neous: in about half of the cells, YFP-AN showed a diffuse
localization in the cytoplasm, and in these cells endogenous P
bodies were strongly suppressed (see Table S2 in the supple-
mental material). In other cells, YFP-AN formed aggregates
apparent as large round foci (Fig. 2E) or irregular patches (not
shown). Many of these round foci and patches did not contain
other P-body markers, suggesting that the AN fragment had
the intrinsic ability to form aggregates. This aggregation-prone
behavior was also observed with the YFP-N fragment lacking
the A region (Fig. 2F). In contrast, the YFP-A fragment had a
diffuse localization indistinguishable from YFP alone (see Ta-
ble S2). The YFP-HC fragment primarily showed a diffuse
localization in the nucleus and the cytoplasm. In some cells,
YFP-HC also accumulated weakly in P bodies (Fig. 2G) yet did
not affect the size or number of P bodies. Taken together, these
results suggested that the HC fragment is passively recruited to
P bodies, whereas the N fragment contains an active aggrega-
tion-prone domain. In the context of full-length Pat1b, the N
region can strongly promote the formation of P bodies. The
idea that Pat1b actively promotes P-body assembly is sup-
ported by our observation that Pat1b interacts with itself in a
coimmunoprecipitation (co-IP) assay (Fig. 2H).
We then tested whether P bodies induced by YFP-Pat1b
would be resistant to treatment with the translation inhibitor
cycloheximide (CHX). CHX was shown to inhibit the forma-
tion of P bodies (10), presumably because mRNAs are trapped
in polysomes by CHX. After 2 h of CHX treatment, P bodies
were nearly absent in untransfected cells, whereas large num-
bers of foci were still present in YFP-Pat1b-expressing cells
(see Fig. S6A, D, and F in the supplemental material). Colo-
calization of Hedls, Rck, Xrn1, and Lsm4 indicated that these
structures had the typical composition of P bodies. Interest-
ingly, Pat1b-induced foci persisted even after 6 h of CHX
treatment (data not shown). Although we cannot tell whether
these P bodies are functional in the presence of CHX, this
results indicates that Pat1b not only nucleates P bodies but also
stabilizes P bodies once assembled. Aggregates induced by the
expression of YFP-AN were also resistant to CHX treatment
(see Fig. S6B in the supplemental material). These aggregates
showed distinct colocalization with Rck but not with Hedls,
suggesting that Rck may interact with the AN fragment.
Tethering of Pat1b accelerates mRNA degradation. Since P
bodies have been implicated in the control of both mRNA
translation and decay, we went on to test if human Pat1b plays
a role in the posttranscriptional control of gene expression. To
this end, we tethered Pat1b to a reporter mRNA using a
heterologous RNA-protein interaction of the Pseudomonas
aeruginosa bacteriophage PP7 (23, 46). The PP7 coat protein
(cp) binds as a dimer with high affinity to a stem loop in the
bacteriophage RNA, the PP7 binding site (bs). We cloned six
copies of the PP7bs into the 3 UTR of a rabbit -globin
reporter gene containing firefly luciferase (FL) (FLB-PP7bs).
A fusion protein containing an HA tag, PP7cp, and Pat1b, as
shown schematically in Fig. 3A, brings Pat1b in close proximity
to the reporter mRNA. When expressed together in HeLa
cells, HA-PP7cp-Pat1b strongly suppressed the expression
level of FLB-PP7bs mRNA compared to HA-PP7cp or HA-
Pat1b alone (Fig. 3B, lanes 4 to 6). In contrast, HA-PP7cp-
Pat1b had only a very weak effect on the FLB mRNA lacking
PP7bs (Fig. 3B, lanes 1 to 3). Similar to HeLa cells used for
Fig. 3, Pat1b was also found to suppress the expression of the
tethered reporter mRNA in U2OS cells (data not shown).
We then compared the effect of tethering Pat1a, Pat1b, and
fragments of Pat1b to the FLB-PP7bs reporter mRNA. We
FIG. 2. Localization of Pat1b subdomains. (A) Schematic representation of Pat1b domains. A, acidic domain; N, amino-terminal region; H,
homology domain; C, carboxy-terminal region. COS7 cells were transiently transfected with YFP-Pat1b (B), YFP-dH (C), YFP-dA (D), YFP-AN
(E), YFP-N (F), or YFP-HC (G) and processed for immunofluorescence microscopy. P bodies in the cytoplasm were counterstained in red using
an antibody against Hedls. Images were acquired by spinning-disc confocal microscopy; maximum projections of z-stacks are depicted. Merged
images are shown on the right; arrowheads point toward P bodies. Size bar, 10 m. Localization of Pat1b subdomains is also summarized in Table
S2 in the supplemental material. (H) HEK293 cells were transiently transfected with HA-Pat1b together with either YFP or YFP-Pat1b.
Cytoplasmic lysates (input) were prepared for IP with GFP-binder, and Western blot analysis was carried out to visualize interaction between
HA-Pat1b and YFP-Pat1b. The sizes of the molecular weight markers (in thousands) are indicated on the left.
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FIG. 3. Tethering of Pat1b accelerates mRNA decay. (A) Schematic representation of the reporter containing firefly luciferase fused to -globin
(FLB). Six copies of the PP7 binding site (bs) were inserted in the 3 UTR for the FLB-PP7bs reporter. An HA-tagged PP7 coat protein (cp) fused to
Pat1b specifically binds to the PP7bs RNA. (B) HeLa cells were transiently transfected with FLB or FLB-PP7bs reporter together with either HA-PP7cp,
HA-PP7cp-Pat1b, or HA-Pat1b. RNA and protein were extracted and analyzed by Northern (top two panels) and Western (bottom) blotting. The sizes
of the molecular weight markers (in thousands) are indicated on the left. Ribosomal protein S7 (RPS7) mRNA serves as RNA loading control. (C) HeLa
cells were transiently transfected with FLB or FLB-PP7bs reporter together with a Renilla luciferase (RL) reporter and either HA-PP7cp, HA-PP7cp-
Pat1a, HA-PP7cp-Pat1b, or HA-PP7cp fused to fragments of Pat1b. Cytoplasmic lysates were prepared after 24 h to measure FL/RL activity. FLB mRNA
levels were determined from the same lysates by Northern blot analysis, normalized to RPS7 mRNA, and quantified. Average values  SD from three
repeat experiments were plotted in the graph. (D) HeLa cells were transiently transfected with a T7-tagged -globin reporter containing 6 copies of PP7bs
(7B-PP7bs) together with either the HA tag alone, HA-PP7cp, HA-PP7cp-Pat1b, or HA-Pat1b. Total RNA was extracted at 1-h intervals after blocking
transcription with actinomycin D (5 g/ml). The reporter mRNA was detected by Northern blot analysis; nucleolin mRNA serves as loading control. In
the middle panels, deadenylation was visualized by quantifying the signal intensity (in arbitrary units [A.U.]) of 7B-PP7bs mRNA along the length of the
signal and plotting it as a function of mRNA size. In the bottom panel, the overall signal intensity of 7B-PP7bs mRNA was quantified and normalized
to nucleolin mRNA. Average values  standard errors (SE) were plotted as a percentage of the initial time point.
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measured, as a readout, both firefly luciferase activity and
reporter mRNA levels (Fig. 3C). The experiment showed that
the tethering of Pat1a had no significant effect compared to
PP7cp alone. The tethering of full-length Pat1b had the stron-
gest suppressive effect, reducing FL activity by about 3-fold and
mRNA levels by about 5-fold. The tethering of the AN frag-
ment, the dH deletion mutant, or the dA deletion mutant
resulted in strong inhibition of the FLB-PP7bs reporter,
though at the mRNA level the inhibition was less pronounced
than with full-length Pat1b. Since the tethering of the HC
fragment had a much weaker effect, the AN fragment of Pat1b
appears to be most important for the suppressive effect on
reporter mRNA expression. In general, there was good agree-
ment between the relative FL activities and mRNA abundance,
indicating that tethered Pat1b acts primarily at the level of
mRNA expression.
Next, we wanted to determine whether Pat1b would affect
the stability of the tethered mRNA. We expressed a -globin
reporter mRNA containing 6 copies of PP7bs (7B-PP7bs) to-
gether with the HA tag alone, HA-PP7cp, HA-PP7cp-Pat1b, or
HA-Pat1b in HeLa cells (Fig. 3D). Transcription was blocked
by the addition of actinomycin D in order to monitor degra-
dation of the reporter mRNA. The analysis showed that 7B-
PP7bs mRNA was stable in the presence of coexpressed HA or
HA-Pat1b or when HA-PP7cp alone was tethered to the
mRNA. In contrast, the tethering of HA-PP7cp-Pat1b caused
rapid degradation of the reporter mRNA. Overall signal in-
tensities were quantified to obtain mRNA half-lives (Fig. 3D,
bottom). Measurement of the signal intensity along the length
of the reporter mRNA shows that the mRNA was deadeny-
lated as a result of Pat1b tethering (Fig. 3D, middle).
Human Pat1b interacts with Rck, Hedls, Xrn1, and Lsm1.
To further explore the connection between human Pat1b and
mRNA degradation, we tested whether Pat1b interacts with
different mRNA decay factors that localize to P bodies. By
expressing HA-tagged Pat1b in HEK293 cells, we found that
Pat1b coimmunoprecipitates with the 5-3 exoribonuclease
Xrn1 and with the activators of decapping Rck, Hedls, Lsm1,
and Lsm4 (Fig. 4A, lane 5) as well as Edc3 (Fig. 4D). These
interactions were also observed with a YFP-tagged form of
Pat1b (HA-Pat1b-YFP) (Fig. 4B). eIF3B and eIF4G, transla-
tion initiation factors that do not localize in P bodies, did not
interact with Pat1b (Fig. 4A and B). As a negative control, the
HA tag alone did not co-IP with any of these proteins. Given
that mRNAs are also a component of P bodies, we next tested
whether the interaction of Pat1b with its partners is RNA
dependent. The addition of RNase A to the IP did not affect
the interaction of HA-Pat1b with any of its partners (Fig. 4B).
RNA extracted from the unbound fraction showed that RNase
A treatment had efficiently degraded rRNA (Fig. 4B, lanes 10
and 11). These results suggest that the association of Pat1b
with Rck, Hedls, Xrn1, and Lsm1 is based on protein-protein
interactions.
Since Pat1b contains an aggregation-prone domain (frag-
ment N) (Fig. 2F), we tested whether Pat1b may aggregate and
precipitate unspecifically in our co-IP experiments. From the
same HA-Pat1b-containing lysate (input), we carried out the
IP procedure with and without the HA antibody (Fig. 4C). In
the absence of HA antibody, neither HA-Pat1b nor associated
proteins were precipitated (Fig. 4C, lane 2). This shows that
precipitation by the antibody was specific.
To further characterize the binding of Pat1b to its partners,
we subjected the complexes to increasing salt concentrations
(Fig. 4D). Whereas the interaction with Hedls, Edc3, and Xrn1
was severely reduced at a NaCl concentration of 300 mM, the
interaction with Rck and Lsm4 was resistant to 300 mM NaCl.
Lsm1-Pat1b was the most stable of these interactions and
could not be separated by 500 mM NaCl. This indicates that
Lsm1/Lsm4 and Rck are more tightly associated with Pat1b
than Hedls, Edc3, and Xrn1. Since Xrn1 forms a stable com-
plex with Lsm1-7 in yeast (6), the interaction of human Xrn1
with Pat1b may occur through Lsm1-7. From these co-IP ex-
periments, however, it is not possible to tell whether Pat1b
directly binds to Rck and Lsm1.
Interestingly, Lsm1 co-IPs in similar amounts with Pat1a and
Pat1b, yet the association of Lsm4 and Xrn1 with Pat1a is
much weaker (Fig. 4A, lane 6). Thus, it is conceivable that
Pat1a may preferentially bind to “free” Lsm1 that is not asso-
ciated with the other Lsm proteins or Xrn1.
To obtain additional evidence for the observed interactions,
inverse IPs were carried out in HEK293 cells transiently trans-
fected with HA-Pat1b (Fig. 4E). The Xrn1 antibody was able
to co-IP HA-Pat1b and Lsm1 (Fig. 4E, lane 2), the Hedls
antibody could co-IP HA-Pat1b, Xrn1, and Lsm1 (lane 3), and
the Rck antibody could co-IP HA-Pat1b and Lsm1 (lane 4).
The Lsm1 antibody was not suitable for IP (Fig. 4E, lane 5),
and a 14-3-3 antibody served as a negative control (lane 6).
Taken together, these results confirmed the association of
Xrn1, Hedls, and Rck with both Pat1b and Lsm1 and provides
evidence for multiple interactions within this group of P-body
proteins.
Human Pat1b interacts with enhancers of decapping via
separate domains. Since the above analysis revealed that Rck
and Lsm1 are tightly associated with Pat1b, we determined
which domains of Pat1b are involved in these interactions. To
this end, we expressed different fragments of Pat1b as depicted
in Fig. 5A. Figure 5B shows that the AN fragment efficiently
co-IPs with Rck (lane 9), whereas the carboxy-terminal (HC)
fragment co-IPs Lsm1 (lane 11). Similar to Lsm1, the more
loosely associated proteins Hedls, Edc3, and Xrn1 were found
to be connected to Pat1b via the HC domain (see Fig. S7 in the
supplemental material). As shown in Fig. 4B for full-length
Pat1b, the interactions mediated by the AN and HC fragments
were resistant to RNase A treatment and are thus likely to be
RNA independent (Fig. 5B).
We further analyzed the association of Rck with the amino-
terminal half of Pat1b (Fig. 5C). Removal of the acidic domain
(dA) from full-length Pat1b was sufficient to abrogate the in-
teraction with Rck (Fig. 5C, lane 9). The same was observed
when the N fragment was expressed alone in comparison to the
AN fragment (Fig. 5C, lanes 10 and 11). Indeed, the HA-
tagged acidic domain alone, although not visible by Western
blot analysis due to its small size, efficiently co-IPs with Rck
(Fig. 5C, lane 12).
We then examined in more detail the association of HC with
Lsm1. Deletion of the conserved homology domain H from
full-length Pat1b (dH) abolished the interaction with Lsm1
(Fig. 5D, lanes 8 and 9). Similarly, comparison of the HC and
C fragments indicated that the H domain is required for asso-
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ciation with Lsm1 (Fig. 5D, lanes 10 and 11). The ANH frag-
ment, however, did not co-IP with Lsm1 (Fig. 5D, lane 12),
indicating that the H domain alone is not sufficient to mediate
this interaction. We concluded that Lsm1 binding requires
both the H and C fragment of Pat1b.
Human Pat1b interacts with the Dcp2-Dcp1a decapping en-
zyme. Since we found Pat1b to associate with a number of
decapping enhancers (Rck, Hedls, Edc3, and Lsm1), we
wanted to know if Pat1b would also interact with the decapping
enzyme Dcp2 and its closely associated activator Dcp1a. To
this end, we switched to YFP-tagged Pat1b proteins, since the
use of GFP-binder (33) overcomes detection problems related
to the presence of immunoglobulin in the IP. Full-length Pat1b
tagged with YFP was found to co-IP efficiently with Flag-Dcp2
and Flag-Dcp1a (Fig. 6A and B, lanes 8). Interestingly, the two
proteins associate with both the N and the HC region of Pat1b
(Fig. 6A and B, lanes 10 and 12). The association with Dcp2
and Dcp1a was found to be independent of RNA (see Fig. S8
in the supplemental material). Moreover, the two proteins did
not dissociate from Pat1b at 1 M NaCl (Fig. 6C), indicating
that Dcp2 and Dcp1a are tightly connected to Pat1b. Taken
together, the results show that Pat1b associates with all en-
hancers of decapping through at least three separate domains:
the A fragment associates with Rck, the N fragment with Dcp2
FIG. 4. Pat1b interacts with P-body proteins. (A) HEK293 cells were transiently transfected with vector alone, HA-tagged Pat1b, or HA-tagged
Pat1a. After 1 day, cytoplasmic lysates (input) were prepared for IP with anti-HA antibody. The HA-tagged proteins as well as endogenous Rck,
Hedls, Xrn1, Lsm1, Lsm4, and eIF3B were detected by Western blotting. The sizes of the molecular weight markers (in thousands) are indicated
on the right. (B) HEK293 cells transiently transfected with vector alone, HA-Pat1b, or HA-Pat1b-YFP were used for IP as described in the legend
for panel A. Where indicated, RNase A was added to the lysates during IP. Lanes 10 and 11 show RNA extracted from the unbound fraction and
stained with ethidium bromide. (C) HA-Pat1b was immunoprecipitated with HA antibody or without antibody as a control for unspecific
precipitation. (D) HA-Pat1b was immunoprecipitated and subjected to increasing NaCl concentrations prior to elution of the protein complexes.
*, immunoglobulin heavy chain. (E) Endogenous Xrn1, Hedls, Rck, Lsm1, and 14-3-3 were immunoprecipitated from the cytoplasmic lysate of
HEK293 cells transiently transfected with HA-Pat1b. The Western blot for Rck is not shown due to an overlapping signal from the immunoglobulin
heavy chain.
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and Dcp1a, and the HC fragment with Dcp2/Dcp1a, Lsm1/
Lsm4, Hedls, and Edc3.
Human Pat1b interacts with the Ccr4-Caf1-Not deadenyla-
tion complex. Since we found that the tethering of Pat1b
causes mRNA deadenylation (Fig. 3D), we tested for interac-
tions of Pat1b with the Ccr4-Caf1-Not deadenylation complex.
Notably, this complex is also concentrated in P bodies (27, 41,
47). Indeed, we found that YFP-Pat1b co-IPs efficiently with
Flag-Not1 (Fig. 7A) and myc-Ccr4 (Fig. 7B), as well as HA-
Caf1a and HA-Caf1b (Fig. 7C). In all cases, RNase A treat-
ment did not interfere with binding. We then confirmed the
interaction of YFP-Pat1b with endogenous Caf1a (Fig. 7D,
lane 8). Analysis of subdomains indicated that Caf1a can in-
teract with the N fragment of Pat1b alone (Fig. 7D, lane 10),
yet the acidic domain A enhances Caf1a binding (Fig. 7D, lane
11). Interestingly, the A domain was even more important for
association with Flag-Not1 and myc-Ccr4 since only the AN
fragment showed a robust interaction with these two proteins
(see Fig. S9A and B in the supplemental material). Although
Flag-Not1 and myc-Ccr4 also co-IP weakly with the HC do-
main (Fig. S9A and B), we concluded from these experiments
that the Ccr4-Caf1-Not complex associates primarily with the
AN domain.
By challenging these interactions with increasing salt con-
centrations, we found that Flag-Not1, myc-Ccr4, and HA-
Caf1a/b are very stably associated with YFP-Pat1b (Fig. 7E).
At a concentration of 1 M NaCl, these proteins remained in a
complex with YFP-Pat1b, whereas binding of Lsm1 was re-
duced and binding of Rck was lost. Thus, it appears that Pat1b
associates tightly with the Ccr4-Caf1-Not deadenylase complex
and may act as a physical bridge between deadenylases and
decapping enzymes.
To provide further evidence for such a bridging function, we
tested whether Pat1b would promote the association between
Caf1a and Dcp2. By IP of GFP-Caf1a, we found that the co-IP
of Flag-Dcp2 is strongly enhanced by coexpression of HA-
Pat1b (Fig. 7F, lane 3). This result shows that Pat1b can si-
multaneously interact with Caf1a and Dcp2 and thereby
promote the association between the deadenylation-and-de-
capping complex.
Tethering of Pat1b causes both deadenylation and mRNA
decapping. In order to test whether both deadenylation and
decapping activities were associated with Pat1b, we again
turned to the tethering assay. A dominant negative Caf1a-AA
(D40A/E42A) deadenylase similar to a mutant described by
Zheng et al. (47) was generated. In comparison to the vector
control, coexpression of Caf1a-wt slightly accelerated the deg-
radation rate of the reporter mRNA tethered to Pat1b (Fig. 8A
FIG. 5. Separate interaction domains within Pat1b. (A) Schematic representation of Pat1b fragments. A, acidic domain; N, amino-terminal
region; H, homology domain; C, carboxy-terminal region. (B) HEK293 cells were transiently transfected with vector alone, full-length HA-Pat1b,
HA-AN, or HA-HC. After 1 day, cytoplasmic lysates (input) were prepared for IP with anti-HA antibody. The HA-tagged proteins as well as
endogenous Rck, Lsm1, and eIF3B were detected by Western blotting. *, immunoglobulin heavy chain. The sizes of the molecular weight markers
(in thousands) are indicated on the right. (C) HEK293 cells transiently transfected with vector alone, HA-Pat1b, HA-dA, HA-AN, HA-N, or HA-A
were used for IP as described in the legend for panel B. The HA-tagged proteins and endogenous Rck were detected by Western blotting.
(D) HEK293 cells were transiently transfected with vector alone, HA-Pat1b, HA-dH, HA-HC, HA-C, or HA-ANH and used for IP as described
in the legend for panel B. The HA-tagged proteins and endogenous Lsm1 were detected by Western blotting.
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and B). Quantification of the mRNA decay rates is shown at
the bottom of Fig. 8 and summarized in Table S3 in the sup-
plemental material. In contrast to that of Caf1a-wt, coexpres-
sion of dominant negative Caf1a-AA prevented deadenylation
of the mRNA (Fig. 8C and G). The lack of the A mRNA
population is clearly visible in the middle panels of Fig. 8C and
G, in which the signal intensity was quantified along the length
of the mRNA. This result suggests that the tethering of Pat1b
causes Caf1-dependent mRNA deadenylation. Interestingly,
the A mRNA still underwent degradation without shortening
of its size, suggesting that tethered Pat1b could promote de-
capping of the A mRNA independently of deadenylation.
To test this possibility, we generated Dcp2-AA (E147A/
E148A) in analogy to a published mutation that inactivates the
decapping enzyme Dcp2 (44). Whereas coexpression of
Dcp2-wt did not have a significant effect on mRNA degrada-
tion (Fig. 8D), Dcp2-AA caused accumulation of the A
mRNA (Fig. 8E). Strong accumulation of A mRNA was also
visible when we cotransfected Caf1a-wt and Dcp2-AA (Fig.
8F). From this we concluded that the tethering of Pat1b also
leads to Dcp2-dependent mRNA decapping. Only by coex-
pressing both Caf1a-AA and Dcp2-AA did we achieve full
stabilization of the Pat1b-tethered mRNA (Fig. 8H). Taken
together, these experiments demonstrate that Pat1b is tightly
associated with both deadenylation and decapping activities in
the cell.
N is the primary effector domain of Pat1b. To determine
which domain of Pat1b mediates deadenylation and decapping,
we tested the effect of tethering Pat1b fragments to the re-
porter mRNA. The tethering of AN (Fig. 9C) or the N domain
alone (Fig. 9F) very efficiently caused mRNA deadenylation
and decapping, comparable to the effect of tethering full-
length Pat1b (Fig. 9B). The mRNA decay rates are quantified
in Fig. 9, bottom, and summarized in Table S4 in the supple-
mental material. In contrast to that of AN or N, the tethering
of the HC fragment (Fig. 9D) or the A domain (Fig. 9E) did
not induce mRNA decay and was similar to the tethering of
PP7cp alone (Fig. 9A). These data suggest that N is the most
potent fragment of Pat1b, and its tethering causes both dead-
enylation and decapping. This is in good agreement with our
observation that the N fragment interacts with both Caf1a (Fig.
7D) and Dcp2 (Fig. 6A). We finally tested the effect of remov-
ing the A and the H domain (Fig. 9G and H). Compared to
full-length Pat1b, the tethering of either the dA or dH mutant
led to a significantly reduced mRNA decay rate. Both mutants
caused mRNA deadenylation but resulted in the accumulation
of A mRNA. This suggests that the A domain, possibly by
interacting with Rck (Fig. 5C), and the H domain, possibly by
enhancing the binding of Lsm1 (Fig. 5D), activate decapping of
the tethered mRNA. These enhancing activities require the
presence of the N domain since the A and HC fragments on
their own were inactive in the tethering assay.
DISCUSSION
In this study we provide evidence that human Pat1b connects
two major steps in mRNA degradation: deadenylation and
decapping. In yeast, the major pathway by which mRNA is
degraded is deadenylation-dependent decapping followed by
5-3 exonucleolytic decay (15, 29). While this pathway has
been established through numerous genetic experiments, the
entity that physically connects the deadenylation with the de-
capping step has not been identified. Pat1 and the Lsm1-7
complex were likely suspects since both are activators of de-
capping and were found to be preferentially associated with
oligoadenylated mRNAs (5, 8, 18, 42). Our analysis reveals
that human Pat1b is tightly associated with both deadenylation
and decapping enzymes. By co-IP experiments, we found that
Pat1b interacts with the Ccr4-Caf1-Not deadenylase complex
(Fig. 7), with the decapping enzyme Dcp2 and its enhancers
Dcp1a, Rck, Lsm1, Lsm4, Hedls, and Edc3, and with the ex-
oribonuclease Xrn1 (Fig. 4 and 6). Thus, the entire deadeny-
lation–decapping–5-3 decay machinery appears to be con-
FIG. 6. Pat1b interacts with Dcp2 and Dcp1a. (A) HEK293 cells
were transiently transfected with YFP, YFP-Pat1b, YFP-A, YFP-N,
YFP-AN, or YFP-HC together with Flag-Dcp2. GFP-binder was used
for IP, and Western blot analysis was carried out with anti-GFP and
anti-Flag antibody. The sizes of the molecular weight markers (in
thousands) are indicated on the right. (B) Same analysis as described
in the legend for panel A, except that Flag-Dcp1a was cotransfected.
(C) HEK293 cells were transiently transfected with YFP-Pat1b to-
gether with either Flag-Dcp1a or Flag-Dcp2. IPs were carried out with
GFP-binder and subjected to increasing NaCl concentrations prior to
elution.
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nected to Pat1b. These interactions are functional within a cell
since tethering of Pat1b to a reporter mRNA caused both
rapid deadenylation and decapping (Fig. 8). By challenging
these interactions with increasing salt concentrations, we ob-
served that Pat1b binds most tightly to Ccr4-Caf1-Not1 and to
Dcp2/Dcp1a followed by Lsm1/Lsm4 and Rck. Although co-IP
experiments cannot provide conclusive evidence for direct
binding, our data suggest that Pat1b is in close proximity to the
Ccr4-Caf1-Not complex, Dcp2/Dcp1a, the Lsm1-7 heptamer
and to Rck. Association with Xrn1, Hedls, and Edc3 was much
weaker and is likely to be indirect.
Within this complex, Pat1b appears to have a scaffold func-
tion since it interacts with its partners through at least three
different domains (summarized in Fig. 10A). The first interac-
tion domain is the very amino-terminal A region of Pat1b that
mediates binding to Rck (Fig. 5C). Given that this domain has
an astonishing number of 32 acidic amino acids within its 84
residues and a net charge of 27.7 at pH 7.0, it will be inter-
esting to determine whether the Pat1b A domain has an influ-
ence on the nucleotide binding or helicase activity of Rck.
The N region that follows the acidic A domain mediates
interaction with Dcp2 and Dcp1a (Fig. 6) as well as Caf1a (Fig.
7). Interestingly, Ccr4 and Not1 do not interact with Pat1b
through the N region alone but also require the A domain (see
Fig. S9 in the supplemental material). Although binding of all
the deadenylation complex components appeared to be very
tight, as estimated by their resistance to salt, this difference
may suggest that Caf1a is positioned particularly close to the N
domain of Pat1b. Importantly, the N domain is also the frag-
ment that can potently induce deadenylation and decapping in
the tethering assay (Fig. 9F).
On the carboxy-terminal half of Pat1b, HC co-IPs efficiently
with Lsm1, Dcp2, and Dcp1a (Fig. 5 and 6), whereas the
interaction of HC with Not1, Ccr4, Xrn1, Hedls, and Edc3 is
weaker and possibly indirect (see Fig. S7 and S9 in the sup-
plemental material). The H domain that shows the highest
FIG. 7. Pat1b interacts with the Ccr4-Caf1-Not complex. (A) HEK293 cells were transiently transfected with YFP or YFP-Pat1b together with
Flag-Not1. GFP-binder was used for IP, and Western blot analysis was carried out with anti-GFP and anti-Flag antibody. The sizes of the molecular
weight markers (in thousands) are indicated on the right. Where indicated, RNase A was added during IP. (B) IP was carried out as described in
the legend for panel A using YFP or YFP-Pat1b together with myc-Ccr4; anti-myc was used for Western blot analysis. (C) IP was carried out as
described in the legend for panel A using YFP or YFP-Pat1b together with HA-Caf1a or HA-Caf1b; anti-HA was used for Western blot analysis.
On the right side, RNA was extracted from unbound fractions and stained with ethidium bromide. (D) HEK293 cells were transiently transfected
with YFP, YFP-Pat1b, YFP-A, YFP-N, YFP-AN, or YFP-HC and processed for IP with GFP-binder. The YFP-tagged proteins and endogenous
Caf1a were detected by Western blotting. (E) HEK293 cells were transiently cotransfected with YFP-Pat1b together with either Flag-Not1,
myc-Ccr4, HA-Caf1a, or HA-Caf1b. IPs were carried out with GFP-binder and subjected to increasing NaCl concentrations prior to elution.
(F) HEK293 cells were transiently transfected with Flag-Dcp2 together with either GFP alone, GFP-Caf1a alone, or GFP-Caf1a together with
HA-Pat1b. Cytoplasmic lysates were processed for IP with GFP-binder and then subjected to Western blot analysis. In the IP samples, the Flag
antibody cross-reacted with GFP-Caf1a.
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homology to the yeast Pat1 sequence appears to contribute in
particular to Lsm1 binding (Fig. 5D). This is in good agree-
ment with the interactions in S. cerevisiae, in which Pat1 occurs
in a stable complex with Lsm1-7 and Xrn1 (5, 6) and was found
to interact with Lsm1 via a middle domain that contains the H
region (30). Edc3 and Dcp1 were shown by two-hybrid analysis
to bind yeast Pat1 via its carboxy-terminal domain (30), which
we find to be true for human Pat1b as well. In addition, and
FIG. 8. Tethering of Pat1b causes mRNA deadenylation and decapping. HeLa cells were transiently transfected with the T7-tagged -globin reporter
containing 6 copies of the PP7bs (7B-PP7bs) together with HA-PP7cp-Pat1b and vector alone (A), Caf1a-wt (B), dominant negative Caf1a-AA
(D40A/E42A) (C), Dcp2-wt (D), dominant negative Dcp2-AA (E147A/E148A) (E), Caf1a-wt plus Dcp2-AA (F), Caf1a-AA plus Dcp2-wt (G), and
Caf1a-AA plus Dcp2-AA (H). Total RNA was extracted at 1-h intervals after blocking transcription with actinomycin D (5 g/ml). The reporter mRNA
was detected by Northern blot analysis; nucleolin mRNA served as a loading control. RNA samples marked dT were treated with oligo(dT) and RNase
H and served as a size marker for deadenylated (A) reporter mRNA. In the middle panels, deadenylation was visualized by quantifying the signal
intensity of 7B-PP7bs mRNA along the length of the signal and plotting it as a function of mRNA size. In the bottom panels, the overall signal intensity
of 7B-PP7bs mRNA was quantified and normalized to nucleolin mRNA. Average values SE were plotted as a percentage of the initial time point. An
asterisk indicates a significant difference in the mRNA half-life (t1/2) (P 	 0.05 by two-tailed Student’s t test) compared to the vector control depicted
in panel A. Statistical analysis of the mRNA t1/2 is summarized in Table S3 in the supplemental material.
FIG. 9. Tethering of Pat1b fragments. HeLa cells were transiently transfected with the 7B-PP7bs reporter and HA-tagged PP7cp (A),
PP7cp-Pat1b (B), PP7cp-AN (C), PP7cp-HC (D), PP7cp-A (E), PP7cp-N (F), PP7cp-dH (G), or PP7cp-dA (H). Degradation of the reporter
mRNA was analyzed and quantified as described in the legend to Fig. 8. Average values SE were plotted as a percentage of the initial time point.
An asterisk indicates a significant difference in the mRNA t1/2 (P 	 0.05 by two-tailed Student’s t test) compared to tethering of PP7cp-Pat1b
depicted in panel B. Statistical analysis of mRNA t1/2 is summarized in Table S4 in the supplemental material.
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different from the situation in yeast, human Pat1b also inter-
acts very efficiently with Dcp2 and Dcp1a through the N do-
main (Fig. 6). Moreover, Dcp2 in yeast was found to interact
with Pat1 and Lsm1 in an RNA-dependent manner by co-IP
experiments (42). This is not the case for human Pat1b, in
which the interaction with Dcp2 is RNA independent (see Fig.
S8 in the supplemental material). Thus, human Pat1b differs
substantially from its yeast counterpart: it makes very tight and
RNA-independent contacts with both the Ccr4-Caf1-Not
deadenylase and the Dcp2-Dcp1 decapping complexes and
thereby enhances the interaction between Caf1a and Dcp2
(Fig. 6 and 7). Based on our findings, a speculative model of
the human Pat1b complex is presented in Fig. 10B. While the
manuscript was in revision, Haas et al. published that the
homologous protein in Drosophila, HPat, also forms a tight
link between the Ccr4-Not complex and the Dcp2 decapping
enzyme (17).
It is interesting to note that the couplings of subsequent
steps in mRNA decay appear to be different in human and
yeast cells. While deletion of Xrn1 in yeast causes the accu-
mulation of mRNAs lacking both a cap and a poly(A) tail (20,
26), knockdown of Xrn1 in human cells causes the accumula-
tion of fully adenylated mRNAs (38). This indicates that cou-
pling of deadenylation, decapping, and 5-3 decay is more
tight in human cells than in yeast. It is tempting to speculate
that the close association of human Pat1b with the deadenylase
and decapping complexes may contribute to this tight coupling.
Analysis of Pat1b localization indicated that this protein
plays an important role in P-body assembly. First, Pat1b local-
izes to P bodies (34) (Fig. 1) similarly to Pat1 in yeast (40),
HPat in Drosophila (12), and PATR-1 in C. elegans (4). Sec-
ond, knocking down Pat1b strongly reduces the number of P
bodies in HeLa (34) and U2OS cells (Fig. 1; see also Fig. S5 in
the supplemental material). Third, overexpression of Pat1b
dramatically increases the number of P bodies in COS7 (Fig. 1)
and U2OS cells (see Fig. S3 in the supplemental material).
Many cells expressing YFP-Pat1b or HA-Pat1b had 50 or more
P bodies with a “salt”-like appearance. We noticed that some
of the small Pat1b foci did not contain other P-body proteins,
whereas larger Pat1b foci consistently colocalized with all P-
body proteins tested (Hedls, Lsm1, Lsm4, Xrn1, and Rck).
This observation suggests that Pat1b could serve as a seed for
P-body assembly. Pat1b may initially self-assemble into small
foci and subsequently serve as a scaffold for additional P-body
proteins as the aggregates grow in size. Other proteins, such as
Dcp1a, can increase the size of P bodies when overexpressed
(data not shown), yet the ability to serve as a “seed” and
augment P-body numbers has not been reported for any other
protein and thus appears to be a unique feature of Pat1b. Our
finding that Pat1b co-IPs with itself (Fig. 2H) supports the idea
of self-assembly. In addition, the ability of Pat1b-induced P
bodies to resist disassembly in the presence of CHX (see Fig.
S6 in the supplemental material) emphasizes that Pat1b plays
a role in stabilizing P bodies. The fact that Pat1b interacts with
other P-body proteins via at least three separate domains (Fig.
5 and 6) reflects its scaffolding function.
Our analysis of Pat1b subfragments suggests that the N re-
gion is critical for P-body assembly. By overexpression of
YFP-AN or YFP-N, we observed a strong tendency of these
fragments to form aggregates, many of which did not contain
other P-body proteins (Fig. 2E and F and data not shown).
Moreover, we observed that the AN and N fragments strongly
reduced the number of P bodies in transfected cells. This may
indicate that by forming autonomous aggregates, the N region
when expressed alone can compete with the aggregation pro-
cess within P bodies. This capacity is reminiscent of the C-
terminal aggregation-prone domain of TIA-1, which when ex-
pressed on its own antagonizes stress granule formation (22).
Similar to the C-terminal domain of TIA-1 that is strongly
enriched in glutamine residues (21.6%), the N region of Pat1b
contains a sequence of 120 aa (aa 261 to 380) with a high
proportion of glutamine and asparagine (17%) as well as pro-
line (17%) residues. This sequence is preceded by a stretch of
80 aa (aa 180 to 260) that is highly enriched in proline (28%).
Glutamine/asparagine- and proline-rich sequences are charac-
teristic of many aggregation-prone proteins, including yeast
prion proteins as well as RNA-binding proteins that promote
stress granule and P-body assembly (11, 16, 32, 36).
In addition to the N region, we found that the acidic domain
(A) at the very amino terminus of Pat1b (aa 1 to 84) influences
the size of P bodies. When mutant Pat1b lacking the A domain
(dA) was overexpressed, Pat1b foci became smaller and more
numerous, giving the protein a “pepper”-like distribution (Fig.
2D). These small foci still colocalized with P-body markers,
such as Hedls. Thus, the A domain seems to control the size of
FIG. 10. Role of Pat1b in P-body assembly and mRNA degrada-
tion. (A) Schematic representation human Pat1b subdomains, together
with interacting proteins and associated functions. All the interactions
depicted are RNA independent yet may be direct or indirect. (B) Hy-
pothetical model of the Pat1b-associated complex that connects dead-
enylation with mRNA decapping. The acidic region (A) associates with
Rck, the AN fragment with the Ccr4-Not complex, and the N fragment
with Caf1 and Dcp2-Dcp1a. The homology region (H) is required for
Lsm1 binding, and the HC fragment further associates with Dcp2-
Dcp1a. The HC fragment also shows weak association with Edc3,
Hedls, and Xrn1.
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P bodies, maybe by promoting the fusion of small aggregates
into larger P bodies. Since we found that the A domain inter-
acts with Rck (Fig. 5C), it is possible that Rck may be an
important driver of the aggregation process within P bodies.
Indeed, Rck was shown to be essential for P-body formation in
human cells (1).
In contrast to A and N, the H and C regions of Pat1b do not
appear to play an active role in P-body assembly. The H, C, and
HC fragments showed a mostly diffuse localization in the cell,
with a rather weak accumulation in P bodies (Fig. 2G; see also
Table S2 in the supplemental material). Localization of these
fragments in P bodies presumably occurs through interactions
with Lsm proteins, Xrn1, or decapping factors (Fig. 5 and 6).
Since the overexpression of the H, C, or HC fragments did not
affect the size or number of P bodies, it is likely that the HC
region is recruited passively to P bodies. This may be different
in yeast Pat1, in which the carboxy-terminal region (aa 422 to
797) was found to induce P bodies (30).
While Pat1b is clearly a central component of the RNA
decay machinery, its paralog Pat1a does not share any of its
functional characteristics: it does not localize to P bodies, does
not augment P-body number or size, and has no influence on
the expression level of a tethered reporter mRNA. In the cell
lines we have tested so far, Pat1a mRNA was expressed at very
low levels (data not shown). Rather, Pat1a seems to play an
important role in the germ line since the Xenopus ortholog of
Pat1a was recently shown to suppress translation during oocyte
maturation (28).
In S. cerevisiae, Pat1 is a regulator of both mRNA decay and
translation. Besides its role in decapping, yeast Pat1, together
with the helicase Dhh1, is required for suppression of transla-
tion upon glucose starvation (9). This second function is prob-
ably linked to the finding that yeast Pat1 interacts with Pab1,
eIF4E, and eIF4G in an RNA-dependent manner (30, 42). In
our tethering experiments, human Pat1b did not have a strong
effect on translation since luciferase activity and mRNA levels
were reduced to similar degrees (Fig. 3C). We also measured
global translation rates by [35S]methionine-cysteine incorpora-
tion and polysome profile analysis but could not see changes
after knocking down or overexpressing human Pat1b (data not
shown). Finally, we did not observe an interaction of human
Pat1b with either eIF4G (Fig. 4B) or eIF4E (data not shown).
Thus, the role of human Pat1b appears to be restricted to
mRNA degradation. One might speculate that the two func-
tions of yeast Pat1 have segregated into two gene products in
the course of vertebrate evolution: Pat1a as a regulator of
translation and Pat1b as a scaffold of the mRNA decay ma-
chinery. During this process, human Pat1b seems to have ac-
quired a much closer association with both the Ccr4-Caf1-Not
deadenylase and the Dcp2-Dcp1 decapping complexes,
thereby providing a tight physical link between deadenylation
and decapping.
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FIG. S1. Conservation among Pat1 Proteins. (A) Two domains are conserved at the level of the primary 
amino acid sequence between Pat1 proteins in fungi and metazoa: an acidc region "A" at the amino-
terminus of the protein (medium grey) and a small region in the middle of the protein with highest 
sequence similarity termed the homology "H" domain (dark grey). Mammals have two Pat1b homologs 
that were designated Pat1a and Pat1b. Sc, Saccharomyces cerevisiae; Ce, Caenorhabdidis elegans; 
Dm, Drosophila melanogaster; Dr, Danio rerio; Xl, Xenopus laevis; Hs, Homo sapiens. (B) Sequences 
of the homology domain were aligned using Clustal W. *, identical amino acids; :, similar amino acids. 
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hPat1a          ---------------MNCLEGPGK-----------TCGPLASEEELVSACQLEKEEENEG 
hPat1b          MFRYESLEDCPLDEDEDAFQGLGEEDEEIDQFNDDTFGSGAVDDDWQEAHERLAELEEKL 
                                :.::* *:           * *. * :::  .* :   * *::  
 
hPat1a          ------EEEEEEEDEEDLDPDLDPDLEE------EENDLGDPAVLGAVHN---------- 
hPat1b          PVAVNEQTGNGERDEMDLLGDHEENLAERLSKMVIENELEDPAIMRAVQTRPVLQPQPGS 
                      :  : *.** **  * : :* *       **:* ***:: **:.           
 
hPat1a          ------------------------------------------------------------ 
hPat1b          LNSSIWDGSEVLRRIRGPLLAQEMPTVSVLEYALPQRPPQGPEDDRDLSERALPRRSTSP 
                                                                             
 
hPat1a          ------------------------------------------------------------ 
hPat1b          IIGSPPVRAVPIGTPPKQMAVPSFTQQILCPKPVHVRPPMPPRYPAPYGERMSPNQLCSV 
                                                                             
 
hPat1a           --------------------TQRALLS------------SPGVKAPGMLGMSLASLH--- 
hPat1b          PNSSLLGHPFPPSVPPVLSPLQRAQLLGGAQLQPGRMSPSQFARVPGFVGSPLAAMNPKL 
                                     *** *             *  .:.**::* .**:::    
 
hPat1a          FLWQTLDYLSPIPFWPTFPSTSSPAQHFGPRLPSPDPTLFCSLLTSWPPRFSHLTQLHPR 
hPat1b          LQGRVGQMLPPAPGFRAFFSAPPSATPPPQQHPPGPGPHLQNLRSQAPMFRPDTTHLHPQ 
                :  :. : *.* * : :* *:...*     : *.   . : .* :. *   .. *:***: 
 
hPat1a          HQRILQQQQHSQTP------------SPPAKKPWSQQPDPYANLMTRKEKDWVIKVQMVQ 
hPat1b          HRRLLHQRQQQNRSQHRNLNGAGDRGSHRSSHQDHLRKDPYANLMLQREKDWVSKIQMMQ 
                *:*:*:*:*:.: .            *  :.:    : ******* ::***** *:**:* 
 
hPat1a          LQSAKPRLDDYYYQEYYQKLEKKQADEELLGRRNRVESLKLVTPYIPKAEAYESVVRIEG 
hPat1b          LQSTDPYLDDFYYQNYFEKLEKLSAAEEIQGDGPKKERTKLITPQVAKLEHAYKPVQFEG 
                ***:.* ***:***:*::**** .* **: *   : *  **:** :.* *   . *::** 
 
hPat1a          SLGQVAVSTCFSPRRAIDAVPHGTQEQD---IEAASSQRLRVLYRIEKMFLQLLEIEEGW 
hPat1b          SLGKLTVSSVNNPRKMIDAVVTSRSEDDETKEKQVRDKRRKTLVIIEKTYSLLLDVEDYE 
                ***:::**:  .**: ****  . .*:*    : . .:* :.*  *** :  **::*:   
 
hPat1a          K-----YRPPPPCFSEQQSNQVEKLFQTLKTQEQNNLEEAADGFLQVLSVRKGKALVARL 
hPat1b          RRYLLSLEEERPALMDDRKHKICSMYDNLRGKLPGQERPSDDHFVQIMCIRKGKRMVARI 
                :      .   *.: :::.::: .:::.*: :  .: . : * *:*::.:**** :***: 
 
hPat1a          LPFLPQDQAVTILLAITHHLPLLVRRDVADQALQMLFKPLGKCISHLTLHELLQGLQGLT 
hPat1b          LPFLSTEQAADILMTTARNLPFLIKKDAQDEVLPCLLSPFSLLLYHLPSVSITSLLRQLM 
                ****. :**. **:: :::**:*:::*. *:.*  *:.*:.  : **.  .: . *: *  
 
hPat1a          LLP-----PGSSERPVTVVLQNQFGISLLYALLSHGEQLVSLHSSLEEPNSDHTAWTDMV 
hPat1b          NLPQSAATPALSNPHLTAVLQNKFGLSLLLILLSRGEDLQSSDPATES--TQNNQWTEVM 
                 **     *. *:  :*.****:**:***  ***:**:* * ..: *.  :::. **::: 
 
hPat1a          VLIAWEIAQMPTASLAEPLAFPSNLLPLFCHHVDKQLVQQLEARMEFAWIY- 
hPat1b          FMATRELLRIPQAALARPISIPTNLVSLFSRYVDRQKLNLLETKLQLVQGIR 
                .: : *: ::* *:**.*:::*:**:.**.::**:* :: **:::::. 
 
 
FIG. S2. Alignment of human Pat1a and Pat1b. The sequences of human Pat1b (PATL1, NP_689929) 
and human Pat1a (PATL2, NP_001138584) were aligned using Clustal W software. The amino-
terminal acidic domain (A) is highlighted in blue, the central homology domain (H) is highlighted in 
yellow. 
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FIG. S3. Intracellular localization of 
human Pat1a and Pat1b in U2OS cells. 
(A-E) U2OS cells were transiently 
transfected with (A) YFP, (B) YFP-Pat1a 
or (C-E) YFP-Pat1b. Cells were then 
processed for immunofluorescence 
microscopy, and cytoplasmic P-bodies 
were counterstained in red using an 
antibody against (A-C) Hedls, (D) Rck or 
(E) Lsm1. Cells in panels A-E were also 
stained with Hoechst 33342 in blue to 
visualize nuclei. Images were acquired 
by spinning disc confocal microscopy, 
maximum projections of z-stacks are 
depicted. (F-G) Untransfected U2OS 
cells were stained in red for endogenous 
Pat1b with antibody 387, and in green for 
P-bodies using antibodies against (F) 
Hedls or (G) Lsm1. Arrows point 
towards P-bodies; bar, 10 µm. 
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FIG. S4. Human Pat1b antibody. Cytoplasmic protein lysates were made from HEK293 cells that were 
either untransfected or transiently transfected with HA-Pat1b, HA-Pat1b-YFP or YFP-Pat1a. (A) 
Western blot analysis was carried out with Ab387, a polyclonal rabbit antibody raised against human 
Pat1b (upper panel). This antibody recognizes overexpressed Pat1b, but not endogenous Pat1b. The 
predicted size of human Pat1b is 87 kDa. Separate blots of the same lysates were probed with an HA 
antibody (HA.11, Covance, middle panel) and a GFP antibody (ab 293, Abcam, lower panel) that also 
recognizes YFP. (B) Cytoplasmic lysates of untransfected (–) or HA-Pat1b (+) transfected HEK293 
cells were used for IP with rabbit α-HA, rabbit α-Pat1b (Ab387) or mouse α-HA antibody. Ab387 can 
weakly precipitate overexpressed HA-Pat1b, but not endogenous Pat1b. 
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FIG. S5. Pat1b is required for P-body formation. The expression of Pat1b was knocked down in U2OS 
cells by transfection of two different siRNAs (T2 and T3) at a concentration of 100 nM. An unspecific 
siRNA (D0) was transfected as a negative control. (A) Endogenous Pat1b mRNA levels were 
quantified by real-time PCR, normalized to nucleolin (Ncl) mRNA levels and represented as % of the 
value in the control transfection. (B) P-bodies were visualized by immunofluorescence microscopy in 
U2OS cells after transfection of siRNAs against Pat1b (T2 and T3), control siRNA (D0) or water alone. 
Cells were fixed and stained for P-bodies using an antibody against Hedls. Yellow arrowheads point to 
individual P-bodies. 
Ozgur et al. 2010
Appendix of Sevim Özgür’s dissertation - Page 133
OZGUR ET AL. SUPPLEMENTAL MATERIAL      6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. S6. Localization of Pat1b in 
presence of cycloheximide (CHX). 
COS7 cells were transiently 
transfected with (A, C-F) YFP-
Pat1b or (B) YFP-AN and, where 
indicated, treated with 5µg/ml 
CHX for 2 hours prior to fixation. 
By immunofluorescence micro-
scopy, P-bodies in the cytoplasm 
were counterstained using 
antibodies against (A and B) Hedls 
and Rck, (C and D) Xrn1 and (E 
and F) Lsm4. Images were 
acquired by spinning disc confocal 
microscopy, maximum projections 
of z-stacks are depicted. Merged 
pictures are shown in the panel on 
the right side; size bar, 10 µm. 
Hedls, Rck, Xrn1 and Lsm4 show 
focal colocalization with YFP-
Pat1b in the presence of CHX. In 
contrast to cells transfected with 
YFP-Pat1b, CHX abolishes focal 
staining of Xrn1 and Lsm4 in 
untransfected cells. 
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FIG. S7. Hedls, Edc3 and Xrn1 interact with the HC fragment of Pat1b. HEK293 cells were transiently 
transfected with vector alone, full length HA-Pat1b, HA-AN or HA-HC. After one day, cytoplasmic 
lysates (input) were prepared for IP with an anti-HA antibody. The HA-tagged proteins as well as 
endogenous Rck, Hedls, Edc3, Xrn1, Lsm1 and eIF3B were detected by Western blotting. Where 
indicated, RNase A was added to the lysates during IP. Rck interacts with the AN fragment of Pat1b, 
whereas Hedls, Edc3, Xrn1 and Lsm1 interact with the HC fragment. All interactions are RNA-
independent. 
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FIG. S8. Interaction of Dcp1a / Dcp2 with Pat1b is RNA-independent. HEK293 cells were transiently 
transfected with YFP or YFP-Pat1b together with either Flag-Dcp1a or Flag-Dcp2. GFP-binder was 
used for IP, and Western blots were carried out with anti-GFP and anti-Flag antibodies. Where 
indicated, RNase A was added to the lysates during IP. 
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FIG. S9. Pat1b fragments interacting with Not1 and Ccr4. (A) HEK293 cells were transiently 
transfected with YFP, YFP-Pat1b, YFP-A, YFP-N, YFP-AN or YFP-HC together with Flag-Not1.  
After IP with GFP-binder, the YFP-tagged proteins and Flag-Not1 were detected by Western blotting. 
(B) YFP-Pat1b fragments were transfected together with myc-Ccr4 and processed for IP as in panel A. 
Both Flag-Not1 and myc-Ccr4 primarily interact with the AN fragment of Pat1b. 
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TABLE S1. Primer Sequences 
G18 5'-ACATTCGGCCGGGTCGACCACTG-3' 
G19 5'-AATTGATATCCACCATGGCCAGCATGACCGGCGGCCAGCAGATGGGCGTGCATCTGTCCAG-3' 
G78 5'-GGTGGTCGGAAAGCTATC-3' 
G83 5'-TTACAAAGTCACTCAGGATG-3' 
G85 5'-AGCTTACCACCATGTACCCATACGATGTTCCAGATTACGCTGGTACCGGATCCG-3' 
G86 5'-AATTCGGATCCGGTACCAGCGTAATCTGGAACATCGTATGGGTACATGGTGGTA-3' 
G243 5'-ATATAAGCTTCCACCATGGTGAG-3' 
G244 5'-ATATGGTACCCTTGTACAGCTCG-3' 
G1000 5'-GTGCATCTGTCCAGTG-3' 
G1001 5'-GCCGATTTAGGTGACACTATAGAATACCCTGAAGTTCTC-3' 
G1008 5'-GCCGATTTAGGTGACACTATAGAATACTATAGACACCAG-3' 
G1009 5'-GCCGATTTAGGTGACACTATAGAATACTTAGCGTCTTCG-3' 
G1122 5'-ATATGGATCCGCCACCATGCCAGCGGCAACTGTAG-3' 
G1123 5'-TATACTCGAGTGACTGCTTGTTGGCTTCC-3' 
G1198 5'-TTAATCTAGATCAGTAAATCCAGGCAAACTCC-3' 
G1219 5'-GCCAAGATGAATTGCCTTGAAG-3' 
G1221 5'-ACTGCTTGCAGCTTCTATATCC-3' 
G1222 5'-GTCTGATGATTCAACTTCC-3' 
G1225 5'-ATATGGTACCATGTTCCGCTACGAG-3' 
G1226 5'-TATACTCGAGTTAGTGACTTCCTCTATCTCC-3' 
G1227 5'-ATATGGTACCCGGAGCAGTCATCAAG-3' 
G1228 5'-TATACTCGAGTTATTCTTCAGCAGCTGAC-3' 
G1229 5'-ATATGGTACCATACAAGGTGATGGC-3' 
G1230 5'-TATACTCGAGTTATCGTATCCCCTGAAC-3' 
G1253 5’-ATATCTCGAGTTAACCCTTGTACAGC-3’ 
G1256 5’-ATATAAGCTTCCACCATGGAAGACGCC-3’ 
G1257 5’-ATATGGTACCCACGGCGATCTTTC-3’ 
G1295 5'-CTCCAGTTTTTCAAACTTTCGGAGATG-3' 
G1296 5’-CATCTCCGAAAGTTTGAAAAACTGGAG-3’ 
G1315 5'-CTTCTGAGGAGGAGCTGGTGTCTG-3' 
G1332 5'-CTCGCCGAGCTATTGATGC-3' 
G1340 5'-CAAGGAGGCAAGTGACATTC-3' 
G1353 5'-ATATGGATCCGAATTCATGAATTGCCTTGAAGGGC-3' 
 
Ozgur et al. 2010
Appendix of Sevim Özgür’s dissertation - Page 138
OZGUR ET AL. SUPPLEMENTAL MATERIAL      11 
 
 
 
 
TABLE S1. Primer Sequences (continued) 
G1408 5'-ATATGGTACCAATCTGGCAGAAAGG-3' 
G1425 5'-TATACTCGAGTTACTCCTCATGGTCACC-3' 
G1501 5’-ATATGGTACCATGTCCAAAACCATC-3’ 
G1502 5’-ATATGGTACCACGGCCCAGCGGCAC-3’ 
G1730 5’-AGCGTTTAAACTTAAGCTTGG-3’ 
G1731 5’-CCTGAATTCTCCAATGGGTCTTGCAACCACACCTGGAAACGCGGTGGCCATAGCAAC-3’ 
G1883 5’-CAGGGGTACCTAGCAAAATCAGG-3’ 
G1884 5’-CTTTGATATCAAAACCAGTTGCTGCAAAGACCTCTC-3’ 
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TABLE S2. Intracellular Localization of Pat1b Fragments 
 Diffuse Aggregates or P-bodies Effect on P-bodies 
YFP ++++ 
nucl > cyto 
– no obvious effect 
YFP-Pat1b – ++++ 
small to medium size round foci 
containing P-body markers 
"salt":  
strong increase in P-body 
numbers 
YFP-dH – ++++ 
small to medium size round foci 
containing P-body markers 
"salt":  
strong increase in P-body 
numbers 
YFP-dA – ++++ 
very small size round foci containing 
P-body markers 
"pepper": 
stronger increase in P-body 
numbers 
YFP-AN ++ 
nucl < cyto 
++ 
large round foci and irregular 
patches, only some containing P-
body markers 
suppression of P-bodies 
YFP-N + 
nucl < cyto 
+++ 
medium size round foci and irregular 
patches, only some containing P-
body markers 
suppression of P-bodies 
YFP-A ++++ 
nucl > cyto 
– no obvious effect 
YFP-HC +++ 
nucl = cyto 
+ 
medium size round foci containing P-
body markers 
no obvious effect 
nucl, nuclear localization; cyto, cytoplasmic localization 
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TABLE S3. Statistical Analysis of PP7cp-Pat1b tethered 7B-PP7bs mRNA Decay Rates (Figure 8) 
 Average 
mRNA t½ (hrs) 
SD SE n P * 
vector 1.25 0.070 0.041 3  
Caf1a-wt 0.96 0.154 0.089 3 0.044 
Caf1a-AA 1.63 0.397 0.229 3 0.177 
Dcp2-wt 2.40 1.546 0.892 3 0.266 
Dcp2-AA 2.53 0.765 0.442 3 0.045 
Caf1a-wt + Dcp2-AA 3.74 1.282 0.740 3 0.028 
Caf1a-AA + Dcp2-wt 1.60 0.483 0.279 3 0.281 
Caf1a-AA + Dcp2-AA 15.03 # 4.401 2.541 3 0.006 
* P-value (two-tailed) was calculated in comparison to "vector"  
# mRNA t ½ is too long for reliable extrapolation from 3 hour time course experiments 
 
 
 
 
 
TABLE S4. Statistical Analysis of 7B-PP7bs mRNA Decay Rates (Figure 9) 
 Average 
mRNA t½ (hrs) 
SD SE n P * 
PP7cp 16.53 # 14.997 5.302 8 0.027 
PP7cp-Pat1b 1.74 0.841 0.266 10  
PP7cp-AN 0.87 0.345 0.141 6 0.032 
PP7cp-HC 9.16 # 5.353 2.185 6 0.001 
PP7cp-A 37.66 # 48.526 28.017 3 0.023 
PP7cp-N 1.08 0.193 0.112 3 0.218 
PP7cp-dH 3.45 1.256 0.562 5 0.008 
PP7cp-dA 3.48 1.972 0.882 5 0.030 
* P-value (two-tailed) was calculated in comparison to "PP7cp-Pat1b"  
# mRNA t ½ is too long for reliable extrapolation from 3 hour time course experiments 
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